





Investigating the role of the RNA binding protein TDP-43 in Amyotrophic 
Lateral Sclerosis using animal and cell-based models of disease 
 
 









Submitted in partial fulfillment of the  
requirements for the degree of Doctor of Philosophy 
under the Executive Committee 
of the Graduate School of Arts and Sciences 
 
 























Helaina Jessica Skop Lehrer 
All rights reserved  
ABSTRACT 
Investigating the role of the RNA binding protein TDP-43 in ALS using animal 
and cell-based models of disease 
 
Helaina Jessica Skop Lehrer 
 
TDP43 is an RNA and DNA binding protein that has been shown to play an integral role 
in disease mechanisms that underlie ALS. In fact, a common feature of the vast majority of ALS 
cases is the presence of TDP-43 aggregates in postmortem tissue from the brain and spinal cord. 
This finding has spurred research to understand the physiological roles of TDP-43 in the absence 
of disease, and how these roles are affected by disease. Current TDP-43 mouse models fail to 
faithfully and reproducibly recapitulate key aspects of ALS, possibly due to the transgenic 
approaches used. To address these concerns, we generated a targeted, conditional mouse model, 
and embryonic stem cell lines expressing either human WT or M337V mutant TDP-43 at 
equivalent levels. We show that expression of mutant hTDP-43 in mice with a mixed genetic 
background leads to selective motor neuron loss, muscle weakness and premature death. 
However this disease phenotype is not observed with the same TDP43 mutation in a pure Bl6 
background. We next sought to identify alterations in the biochemistry of the mutant protein that 
may underlie its toxicity, such as its interactions with RNA and protein. By creating a library of 
RNAs bound by TDP-43 in the mouse spinal cord, we found that the M337V mutation does not 
compromise the ability of TDP43 to bind to target mRNA transcripts, although the mutation does 
lead to changes in expression of genes known to be involved in inflammation. In addition, we 
identified 22 proteins that bind to TDP43 in an RNA-dependent manner, and found that the 
M337V mutation does not alter these interactions. This work establishes novel mouse and 
cellular models that provide insights into the functions of normal and ALS-causing mutant 
TDP43 protein.   
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PREFACE 
The primary objective of the work described in this thesis was to assess the effects of an 
ALS-causing mutation in human TDP-43 on protein-RNA interactions, and protein-protein 
interactions. My initial attempts to assess protein-RNA interactions in human induced pluripotent 
stem cells (iPSCs) met with technical difficulties both from an experimental and bioinformatics 
perspective, although the data from those experiments is presented briefly in the Appendix. At 
the time I was experiencing these difficulties, Dr. Aarti Sharma, a postdoctoral fellow in Dr. Neil 
Shneider’s lab, found that mice which she had generated expressing human, mutant TDP-43 
displayed progressive motor neuron (MN) loss, muscle denervation, late paralysis and death at 
18 months of age. These initial findings occurred in mice on a mixed genetic background, 
although all subsequent breeding was maintained on a pure C57BL/6 (Bl6) genetic background. 
The pure Bl6 background is commonly used for maximal expression of mutant alleles (Champy 
et al. 2008), and a pure background eliminates the possibility of genetic modifiers differentially 
affecting mutant and WT mice. 
 This TDP43 mouse model presented an opportunity to study the interactions between 
TDP-43 and its target molecules in the context of an ALS-like phenotype, with control animals 
expressing hTDP-43WT on the same genetic background as the mutant mice. In addition, I 
derived embryonic stem cell lines from these mice, which provided an alternative source of 
material for biochemical experiments, and a rapid system for assessing MN viability. I conducted 
all viability assays. 
 Having learned the HiTS-CLIP technique from Dr. Yuan Yuan, a postdoctoral fellow in 
the Darnell Laboratory, I collected and processed mouse spinal cords and submitted cDNA 
libraries derived from RNAs bound to TDP-43 for high-throughput sequencing. In collaboration 
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with Aarti Sharma, we additionally submitted whole spinal cord and whole brain samples for 
RNA-Seq. With the help of Sean O’Keeffe, I analyzed the CLIP and RNA-Seq datasets. I 
worked with Paolo Guarnieri to perform comparative analyses of my CLIP and RNASeq datasets 
to published data.  
 Because the CLIP data did not show genotype-dependent changes in binding, I sought to 
determine whether the M337V mutation alters interactions between TDP-43 and other proteins. 
For this experiment, I used the embryonic stem cell system to prepare myc co-
immunoprecipitates, which I submitted for mass spectrometry. Upon receiving the mass 
spectrometry data, I performed validation experiments and compared the interacting proteins in 
my dataset to published datasets. 
 While conducting the above analyses, I had also found that, in mice where hTDP-43 
expression was restricted to predominantly MNs, there was no MN loss or muscle denervation. It 
then became apparent that the hTDP-43M337V mice (expressing the mutant protein in all Tau-
positive cells) we had been aging to further assess the late stage phenotype were not getting sick 
at 18 months, or at 22 months. Even at 30 months, I saw no evidence of MN loss or muscle 
denervation compared to controls, and no overt motor phenotype. We therefore concluded that, 
in backcrossing to the Bl6 genetic background, we had likely lost a genetic modifier that was 
permissive to a τONhTDP-43M337V dependent phenotype. This finding was especially unfortunate 
in light of all of the efforts described above. While the above findings of protein-RNA and 
protein-protein interactions cannot be interpreted in the context of an ALS-like phenotype, they 
still provide information about functions of hTDP-43, as well as evidence that the M337V 
mutation alone does not alter these functions. If the phenotype can be recovered, this will be a 
very useful model in the ALS field. 
	  





The discovery that the RNA and DNA binding protein, TDP-43, is a major component of 
aggregates in neurons and glia of ALS patients, and identification of mutations in TDP-43 
responsible for a small percentage of familial ALS cases, has established a strong relationship 
between TDP-43 and ALS. This connection has spurred research to understand both the 
physiological role of TDP-43 in RNA processing and how this role may be perturbed in disease. 
Such studies require controlled model systems that, ideally, recapitulate features of motor neuron 
disease. To establish a framework for assessing the utility of, and deriving meaningful insights 
from, TDP-43 model systems, I will first discuss the characteristics of human ALS, and the 
widely used SOD1 ALS mouse model. I will then survey the current state of ALS genetics, with 
particular attention to ALS genes functionally related to TDP-43. In order to evaluate TDP-43 
dysfunction, I will present the previous investigations into the physiological functions of TDP-
43. Finally, I will describe published cellular and animal models of TDP-43 dysfunction and 
discuss clues they offer regarding the mechanism of TDP-43-mediated neurodegeneration. 
Together, this review of TDP-43 and related ALS literature will reveal the complexity of the 
TDP-43 proteinopathy field, the plethora of TDP-43 functions necessitating further careful and 
detailed study, and the need for more accurate TDP-43 models of neurodegeneration. 
 
1.1 ALS in Patients: Symptoms, Pathology, Epidemiology, and Treatment 
The term amyotrophic lateral sclerosis (ALS) first appeared in a paper by Jean-Martin 
Charcot in 1874. His description of the disease course has remained relevant and accurate in the 
ensuing years (Rowland 2001a): 
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1) Paralysis without loss of sensation of the upper limbs, accompanied by rapid 
emaciation of the muscles . . . At a certain time, spasmodic rigidity always takes 
over with the paralyzed and atrophic muscles, resulting in permanent deformation 
by contracture.  
 
2) The legs are affected in turn. Shortly, standing and walking are impossible. 
Spasms of rigidity are first intermittent, then permanent… The muscles of the 
paralyzed limb do not atrophy to the same degree as the arms and hands. The 
bladder and rectum are not affected… 
 
3) In the third period, the preceding symptoms worsen and bulbar symptoms 
appear. These three phases happen in rapid succession—6 months to a year after 
the onset, all the symptoms have appeared and become worse. Death follows in 2 
or 3 years, on average, from the onset of bulbar symptoms.  
 
This is the rule but there are a few anomalies. Symptoms may start in the legs or 
be limited to one side of the body, a form of hemiplegia. In two cases, it started 
with bulbar symptoms.  
At present, the prognosis is grave. As far I know, there is no case in which all the 
symptoms occurred and a cure followed… 
 
Charcot not only carefully described the clinical symptoms of his patients; he also correlated 
these symptoms with pathological and histological findings at autopsy. He concluded that 
amyotrophy, or muscular atrophy, resulted from atrophied nerve fibers in the anterior spinal 
nerve roots and deformed and atrophied cells in what was likely the anterior horn of the spinal 
cord. Likewise, he connected spastic symptoms with disease in the lateral columns of the spinal 
cord that transmit upper motor neuron tracts to their synaptic partners in the anterior horn 
(Rowland 2001b). 
 In 1990, the El Escorial Criteria provided a basis for the clinical diagnosis of ALS, 
although a definitive diagnosis is only possible upon autopsy (Brooks et al. 2000).  At autopsy, 
the following features confirm the ALS diagnosis: degeneration of corticospinal tracts with 
extensive loss of lower motor neurons or anterior horn cells, degeneration and loss of Betz cells 
	  
	   3	  
and other pyramidal cells in the motor cortex, and ubiquitin-positive motor neuron cytoplasmic 
inclusions (Geser et al. 2010). 
More detailed post-mortem studies of ALS patient spinal cords have revealed additional 
disease-related findings (reviewed in Hirano 1996). Decreased synaptophysin, a presynaptic 
marker, in the anterior horn correlates with loss of presynaptic terminals. Phosphorylated 
neurofilaments, specifically of high and medium molecular weight, aggregate in the soma and 
proximal axons of anterior horn cells. Golgi apparatus fragmentation also appears more often in 
ALS patients than in control individuals with other neurological diseases. Bunina bodies, small 
eosinophilic granules consisting of tubules and vesicular structures, were seen as the only 
specific pathological hallmark of ALS. Ubiquitin-positive skein-like inclusions in anterior horn 
cells are characteristic of ALS, but not entirely specific for it (Hirano 1996). The more recent 
identification of TDP-43 as a major component of these ubiquitin-positive inclusions provided an 
additional potential method for distinguishing ALS-specific pathology, although these inclusions 
present in other neurodegenerative diseases as well (Geser et al. 2010). 
 ALS has an estimated prevalence in the United States of 1-2 cases per 100,000. Most 
patients receive their diagnosis between the ages of 55-75 years, with a male to female ratio of 
approximately 1.75:1. As described above, most patients die within 5 years of diagnosis, 
although 8-22% survive for at least 10 years. A family history of ALS is obtained in ~10% of 
cases (fALS), while the remaining 90% of patients present with sporadic disease (sALS). 
The only FDA-approved treatment for ALS is riluzole (Rilutek), a glutamate antagonist. 
Therapeutic trials determined that riluzole extends life by slowing disease progression by only 3-
6 months, although patients notice little difference in their symptoms (Rowland & Shneider 
2001). 
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1.2 Heredity and Genetics of ALS 
Despite slow progress in developing therapeutics to treat ALS, significant achievements 
have been made in identifying the genetic causes of ALS. The first ALS-causing mutation was 
discovered in the superoxide dismutase 1 (SOD1) gene in 1993, accounting for ~12% of fALS, 
and was quickly followed by the development of mouse models that phenotypically recapitulate 
major aspects of ALS (Renton et al. 2014, discussed in Section 1.3). 
A subsequent lull in ALS genetic discoveries ended in 2007, at which point the list of 
ALS-associated genes began to expand. Table 1.1 depicts the complexity of the ALS genetic 
landscape. Mutations in over 40 genes have been linked to ALS, some as ALS-causative, and 
others as risk or modifier variants (Table 1.1). To date, known mutations account for the genetic 
etiology of roughly 66% of fALS and 11% of sALS cases (Renton et al. 2014). Almost all 
mutations are inherited in an autosomal dominant manner, although some are incompletely 
penetrant (Marangi et al. 2015). The variety of genes in which mutations are known to cause 
ALS, and the distribution of those mutations throughout each gene, make it quite difficult to 
deduce common mechanisms of neurodegeneration. The culmination in aggregate formation, 
however, offers a clue to these mechanisms. 
 The discovery of TDP-43 as a major component of aggregates in ALS patient tissue 
(Neumann et al. 2006) was quickly followed by the identification of ALS-causing mutations in 
the TARDBP gene that codes for TDP-43, accounting for ~4% of fALS (Sreedharan et al. 2008). 
Importantly, TDP-43 was simultaneously identified as a major component of the aggregates 
found in a subset of frontotemporal dementia (FTD) cases (Neumann et al. 2006), and FTD-
causing mutations in TARDBP have since been identified (Borroni et al. 2009). FTD is a group 
of heterogeneous disorders that present with presenile dementia and primarily affect the frontal 
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and temporal lobes of the brain (Ng et al. 2015). These findings have strengthened previously 
reported connections between ALS and FTD, and provide evidence that ALS and FTD may 
represent a spectrum of TDP-43 proteinopathies, rather than distinct clinical entities (Renton et 
al. 2014). While the work presented here focuses primarily on understanding the role of TDP-43 
in ALS, the reagents described may also offer insight into pathological mechanisms of FTD, and 
genetic modifiers that influence various disease phenotypes on the spectrum of TDP-43 
proteinopathies. 
 Because of the known physiological involvement of TDP-43 in RNA processing, the 
discovery of its role in ALS led to an interest in connections between ALS mechanisms and 
RNA biology. The discovery of ALS-causing mutations in FUS, another RNA binding protein, 
in 2009 strengthened this connection. Interestingly, FUS-immunoreactive neuronal inclusions in 
FUS-ALS spinal cords do not display TDP-43 immunoreactivity (Kwiatkowski et al. 2009, 
Vance et al. 2009). This may imply a role for FUS, likely in an RNA processing pathway, 
downstream of TDP-43, a finding supported by genetic interaction assays in Drosophila (Wang 
et al. 2011). Alternatively, the same downstream protein degradation pathways may be 
compromised in both TDP-43 and FUS ALS (Lee et al. 2011), despite different proteins 
triggering initial aggregation events. 
 Further support for aberrant RNA processing as a pathogenic mechanism of ALS came 
with the landmark discovery of a hexanucleotide repeat expansion in the C9orf72 gene. This 
repeat expansion explained the long known chromosome 9p21–linked cases of ALS and FTD, 
accounting for ~40% of fALS, ~25% of familial FTD, and ~7% sALS cases of Europeans 
ancestry (Renton et al. 2014). RNA foci that may act as RNA binding protein sinks have been 
noted in fibroblasts of C9ORF72 patients (DeJesus-Hernandez et al. 2011). In addition, the CG-
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rich hexanucleotide repeat forms highly stable RNA G-quadruplexes, which can interfere with 
RNA processing (Fratta et al. 2012). An alternative mechanism of ALS pathogenesis resulting 
from the repeat expansion lies in the identification of repeat-associated non-ATG (RAN) protein 
translation generating aggregation-prone peptides (Cleary&Ranum 2013). In addition, studies 
that are in review provide compelling evidence for a role of defective nuclear/cytoplasmic 
transport in C9ORF72 ALS. The actual pathogenic mechanism may result from a combination of 
aberrant RNA processing, the generation of RAN translation products, and compromised 
transport between the nucleus and cytoplasm. The latter defect is thought to result in the 
formation of cytoplasmic protein aggregates. 
 Increased aggregate formation, decreased aggregate clearance by the ubiquitin-
proteasome and autophagy pathways, and activation of neuroinflammation, has emerged as a 
common theme among genes containing ALS-causing mutations. Strong evidence indicates that 
some aggregates may originate from ribonucleoprotein granules. A recent massive exome 
sequencing study identified how various genes containing ALS-causing mutations, including 
newly ALS-associated tank-binding kinase (TBK1), fit together in neuroinflammatory and 
protein degradation pathways (Figure 1.2). Aggregation-prone proteins, such as TDP-43 and 
FUS, become ubiquitinated activating the ubiquitin-proteasome pathway, which contains 
UBQLN2 (also part of autophagy pathways). Protein or protein/RNA aggregates additionally 
lead to neuroinflammation, a TBK-1 containing pathway, and activate autophagy, in which 
optineurin (OPTN), sequestosome-1 (SQSTM1/p62), and VCP all play a role (Cirulli et al. 
2015). Because disparate genes involved in a variety of pathways have been linked to ALS, this 
model presents a promising method for linking these genes to common pathways. 
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This model additionally suggests that an understanding of the normal functions of TDP-
43 that are potentially lost when TDP-43 localizes to aggregates, as well as an understanding of 
how mutations in TDP-43 lead to aggregation, may be important in gaining further insight into 
ALS disease mechanisms. As a framework for developing this understanding in the context of 
TDP-43-ALS, we will first review how parallel questions have been addressed in the well-
established and broadly used SOD1-ALS mouse model. 
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1.3 ALS Mechanisms derived from SOD1 Mouse and Cell Culture Models 
SOD1 Mouse Models  
Shortly after the identification of ALS-causing mutations in SOD1, a transgenic mouse 
model expressing mutant SOD1 was found to recapitulate many aspects of ALS. In high 
expressor SOD1G93A mice, neuromuscular junction (NMJ) denervation occurs early in the 
disease process, prior to motor neuron (MN) loss. Overt paralytic symptoms appear by postnatal 
day 100 (P100), with a 70% loss of fast motor units, which are preferentially susceptible in ALS 
patients. Complete hindlimb paralysis occurs at age ~P125 with subsequent forelimb paralysis 
and euthanasia only 10 days later (Kanning et al. 2010).  
Mouse models have revealed that SOD1 pathogenesis relates to a toxic gain of function 
of the mutant protein rather than the loss of superoxide dismutase function. This gain of function 
almost certainly relates to the misfolding of many ALS-associated SOD1 mutants, which form 
ubiquitinated cytoplasmic inclusions (Ilieva et al. 2009). Despite decades of research, the exact 
nature of this toxic gain of function is still unclear, although a multitude of mechanisms have 
been proposed (Figure 1.1, reviewed in Ilieva et al. 2009).  
1. Glutamate excitotoxicity characterized by neuronal overstimulation and 
failure of the EAAT2 glutamate transporter to effectively clear glutamate from 
the synapse. 
2. Mutant SOD1 triggers ER stress by accumulating in ER fractions, inhibiting 
the ER-associated degradation pathway, and potentially blocking proper 
processing of other proteins within the ER lumen. 
3. Proteasome inhibition results from mutant SOD1 expression in vivo and in 
cell culture. In a proposed positive feedback mechanism SOD1 misfolding 
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decreases activity of the proteasomal components that clear it leading to 
aggregate accumulation. 
4. Mitochondrial damage may result from the presymptomatic association of 
mutant, but not WT, SOD1 with the outer mitochondrial membrane. Different 
models show different mitochondrial abnormalities. 
5. Secretion of SOD1 into the extracellular space results from association with 
neurosecretory vesicles, which activates microglia. Proteasome inhibition may 
enhance extracellular secretion of SOD1. 
6. Mutant SOD1 may generate excess superoxides through a higher affinity for 
Rac1 than SOD1WT and resultant activation of Nox2, which produces 
superoxides to fight infection in microglia. 
7. Axonal disorganization results from mutant SOD1 disrupting both anterograde 
and retrograde transport, concomitant with synaptic vesicle stalling. 
8. Microhemorrhages of spinal capillaries are seen in all SOD1 mutant models, 
and decreased mRNA levels of endothelial cell tight junction proteins are 
decreased in patients. 
These proposed mechanisms highlight the interplay between various nervous system cell 
types in motor neuron disease. Genetic experiments have revealed that mutant SOD1 expression 
in motor neurons mediates disease onset while mutant expression in microglia and astrocytes 
affects disease progression. Paradoxically, Cre-mediated excision of a dismutase active SOD1 
mutant in Schwann cells accelerated the late phase of disease, arguing that dismutase activity in 
Schwann cells slows disease progression (Ilieva et al. 2009). Selective removal of mutant SOD1 
from oligodendrocyte precursors, however, causes delayed disease onset with no effect on 
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disease progression (Nonneman et al. 2014). A role for various cell types in ALS onset and 
progression is supported by patient data, and further experiments are needed to reveal the exact 
nature of the interplay between different cell types, particularly in non SOD1-ALS.  
 
SOD1 Cell Culture Models 
While genetic approaches in the mouse SOD1G93A mouse model has provided insight into 
the role of various cell types in ALS, the biochemical dissection of these contributions is quite 
difficult because of the complexity of the in vivo nervous system. Advances in cell culture 
techniques have allowed for the development of model systems for studying the effects of 
various neuronal support cells on neurons (Wichterle et al. 2002). Remarkably, these culture 
systems reveal both cell autonomous and non-cell autonomous hallmarks of ALS. For example, 
SOD1 mutant embryonic stem cell (ESC) derived motor neurons (ES-MNs) show decreased 
viability and ubiquitinated SOD1 aggregates compared to control ES-MNs (Di Giorgio et al. 
2007). Furthermore, these culture systems reveal the toxic effect of SOD1G93A astrocytes on both 
primary MNs and ES-MNs (Di Giorgio et al. 2007, Nagai et al. 2007). Motor neuron-specific 
expression of green fluorescent protein (GFP) has been used to obtain enriched populations of 
motor neurons. Culturing these neurons on glass coverslips allows for the physical isolation of 
MNs and astrocytes while permitting exchange of secreted factors. This approach revealed high 
concordance between expression profiles of SOD1 mutant astrocytes and ES-MNs, and SOD1 
mutant mouse spinal cords (Phatnani et al. 2013). Advances in post-mortem tissue isolation has 
also revealed that astrocyte-like cells derived from neural precursor cells from human spinal 
cords of fALS and sALS patients have a toxic, SOD1-dependent, effect on motor neurons 
(Haidet-Phillips et al. 2011). This exciting new field not only allows for in depth biochemical 
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study of large populations of ALS-relevant cell types, but it has also provided a transition point 
for incorporating induced pluripotent stem cell technologies into the study, and potentially 
treatment, of ALS (Dimos et al. 2008, further discussion in Appendix 1). 
 
Applicability of SOD1 Models to Human ALS 
 Figure 1.1 summarizes proposed pathomechanisms involved in ALS, primarily deduced 
from the SOD1G93A mouse model. Therapeutics targeting aspects of all of these proposed 
mechanisms have failed in clinical trials, despite promising results primarily in the SOD1G93A 
mouse model (McGoldrick et al. 2013). We can understand these failures in a few ways. Perhaps 
most importantly, therapeutic trials in mice often begin pre-symptomatically, and are therefore 
able to exert their effects at an earlier, and potentially more reversible stage of disease. With the 
current absence of effective early stage biomarkers, patients diagnosed with ALS are already far 
along in the progression of the disease. Thus, pre-symptomatic treatment is not yet possible. 
Additionally, since ALS is a multifactorial disease, treatments may require combination therapy, 
as in cancer treatment, to yield appreciable results in patients. However, designing combination 
therapy will be quite difficult in the absence of any data supporting the efficacy of individual 
therapies (McGoldrick et al. 2013). 
 Additional explanations may lie with the SOD1G93A model itself. First, mice express high 
levels of mutant SOD1 leading to an early onset and rapidly progressing disease phenotype that 
might not faithfully represent the onset and course of human ALS. More importantly, mutations 
in SOD1 account for only 2% of all ALS cases, and SOD1 pathology is largely absent from 
patients lacking an SOD1 mutation. It is also possible that mechanisms of SOD1-mediated 
neurodegeneration differ from the majority of ALS cases that show TDP-43 pathology. 
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However, it is important to note that the clinical presentation of ALS is indistinguishable 
between SOD1 patients and other forms of familial or sporadic ALS.  It is likely that there are 
both common and unique sources of pathology that culminate in the same outcome: motor 
neuron disease. Thus, the failure of tested therapeutics, and potential differences between TDP-
43-related and SOD1-related motor neuron degeneration, highlight the absolute necessity for 
strong alternative ALS models. These models will both provide an understanding of underlying 
disease mechanisms and provide reagents for testing potential, and hopefully successful, 
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1.4 TDP-43 Structure and Function 
While SOD1 models can provide a framework for assessing how well TDP-43 models 
recapitulate ALS, an understanding of the normal functions of TDP-43 is also essential in 
assessing abberant functions or interactions that may occur with mutation. The TAR DNA 
binding protein (TARDBP) gene that encodes TDP-43 contains six exons, five of which are 
coding exons, and is located on human chromosome 1 and on mouse chromosome 4. Through 
alternative splicing in mammalian cells and tissue, the TARDBP gene locus encodes at least 10 
additional mRNAs aside from the TDP-43 mRNA, although the function of these alternative 
splice variants is not known (Wang et al. 2004). An intron within the 3’UTR of TARDBP 
determines whether the mRNA is translated or targeted for degradation (Bembich et al. 2014). 
TDP-43 is a 43 kDa, 414 amino acid, heterogenous nuclear ribonucleoprotein (hnRNP) 
that contains two N-terminal RNA recognitions motifs (RRMs), nuclear localization and export 
signals, and a low complexity, glycine rich, prion-like C-terminal domain (Figure 1.3). It mirrors 
other hnRNPs both in its amino acid sequence and domain structure, as well as its ubiquitous 
expression and primarily nuclear localization  (Buratti et al. 2008). It is highly conserved across 
metazoans, particularly through RRM1 and half of RRM2 in human, mouse, drosophila and C. 
elegans (Figure 1.4). Excluding worm TDP-43, the mammalian and fly proteins share 70% 
similarity. This similarity drops to 30% within the C-terminal glycine rich domain, which is 
completely absent in the worm (Wang et al. 2004). These likely reflect species-specific 
functional differences.  
The TDP-43 N-terminal RRMs, one of the most common protein domains composed of a 
hexameric RNP2 and an octameric RNP1 motif (Maris et al. 2005), mediate binding to RNA and 
DNA. Initial in vitro studies of tagged TDP-43 revealed that RRM1, particularly RNP2 amino 
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acids 106-111 and two RNP1 phenylalanine residues F147 and F149, is necessary and sufficient 
for nucleotide binding (Buratti et al. 2001). Subsequent studies revealed that RRM2 alone also 
possesses nucleotide binding activity, albeit at a lower affinity than RRM1 in the case of binding 
to DNA, and with inverse affinity to RRM1 when binding UG rich RNA of varying repeat 
lengths (Kuo et al. 2009). The crystal structure of RRM2 revealed homodimerization, 
implicating this domain in the formation of full length TDP-43 dimers (Kuo et al. 2009). The 
RRMs of TDP-43 preferentially bind UG or TG rich sequences, with a minimum of six repeats 
necessary for significant binding (Buratti et al. 2001). Crystal structures reveal more extensive 
interactions of RRM1 with DNA compared to RRM2 (Kuo et al. 2014). We discuss the function 
and effects of TDP-43 binding to DNA and RNA below. 
In order for TDP-43 to interact with DNA, it must enter the nucleus. In fact, TDP-43 
localizes primarily to the nucleus, although it is also detected in the cytoplasm under low 
detergent conditions (Winton et al. 2008a). An N-terminal, bipartite nuclear localization signal 
(NLS) at amino acids 82-98 contains two clusters of basic residues, which cause mislocalization 
to the cytoplasm when mutated, separated by a stretch of ten amino acids (Winton et al. 2008a). 
A leucine-rich nuclear export signal (NES) at amino acids 239-250, mutation of which leads to 
the formation of intranuclear inclusions, permits TDP-43 transport into the cytoplasm (Winton et 
al. 2008a). Heterokaryon assays demonstrate that wild-type TDP-43 efficiently shuttles between 
the nucleus and the cytoplasm (Ayala et al. 2008a). Nucleocytoplasmic shuttling likely 
represents an important aspect of the multi-faceted role TDP-43 plays in RNA processing. 
The role of the C-terminal, glycine-rich domain of TDP-43 is less clear. This domain, 
through an interaction with hnRNP A2, is essential for splicing inhibition in an in vitro splicing 
assay (Buratti et al. 2005, D’Ambrogio et al. 2009). A bioinformatics approach to predicting 
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naturally disordered regions indicates that 80% of this domain, from amino acids 287-414, is 
structurally disordered (Chen et al. 2010). An algorithm developed from yeast prion proteins 
identifies TDP-43 as the 69th most prion-like protein among almost 30,000 human proteins, with 
the prion-like domain contained within the C-terminal region (Cushman et al. 2010). 
Furthermore, in vitro assays show that the C-terminal domain is essential for aggregation (Chen 
et al. 2010, Johnson et al. 2009). Thus, while the C-terminal domain may mediate protein-protein 
interactions essential to various functions of TDP-43, its disordered nature and prion-like 
properties make it a prime suspect in aggregation-dominated TDP-43 proteinopathies. 
The domain structure of TDP-43 suggests its cellular functions, ranging from 
transcription to mRNA turnover, and sequestration in stress granules (summarized in Figure 1.6). 
Many of the experiments that have identified the various functions of TDP-43 utilize 
overexpression systems, which must always be interpreted with caution, but especially so in the 
case of aggregation-prone TDP-43. We discuss these experiments, but include caveats as some 
results may derive from TDP-43 aggregation rather than revealing functions of TDP-43 
expressed at physiological levels. 
 
Embryonic Development  
 The fact that TDP-43 is an essential protein complicates our ability to studying its role in 
an organ and cell-type specific disease. Three independent knockout mouse models reveal the 
requirement of TDP-43 for normal prenatal development and viability. TARDBP-/- embryos 
show early embryonic lethality, resulting from defective expansion of the inner cell mass 
(Warraich et al. 2010). TDP-43 knockdown in one cell culture system caused genomic 
instability, increased apoptotic cell death, and cell cycle disruption, with concomitant observed 
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nuclear deformation (Ayala et al. 2008b). TDP-43 knockdown in mouse embryonic stem cells 
(mESCs) similarly lead to cell death and reduced expression of cell cycle regulatory genes, in 
addition to reduced expression of genes involved in RNA metabolism and neuronal pathways 
(Chiang et al. 2010).  
Additionally, TDP-43 gene expression is upregulated during developmental stages in 
Drosophila and C. elegans (Warraich et al. 2010). In the blastocyst stage of mouse embryos, 
TDP-43 expression occurs in every cell nucleus, including within the inner cell mass. As 
development progresses, expression persists in all cells but becomes more prominent in neural 
stem cells. By embryonic day (E)10-12, TDP-43 is expressed in differentiated neurons and 
neural progenitors (Sephton et al. 2012). Thus, the role of TDP-43 in early embryonic, and 
specifically nervous system, development is clearly established. It may carry out this role, and 




 Because of its role in RNA processing, and ability to bind DNA, it is not surprising that 
full length TDP-43 consistently localizes to the nucleus in either a diffuse, or fine, punctate 
pattern. Transfection of a naturally occurring short TDP-43 isoform (mTDP-S) resulted in 
speckle-like nuclear staining, and colocalization with known nuclear bodies including SMN-
mediated GEM association, PML gene product oncogene domains (PODs), and extensive 
overlap with SC35 splicing speckles. The relevance of these mTDP-S TB nuclear bodies in 
cellular physiology is not clear (Wang et al. 2002). Non-overexpression based support for TDP-
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43 interacting with GEMs, however, comes from TDP-43 deficiency preventing nuclear GEM 
formation (Shan et al. 2010).  
Neurons in vivo reveal a concentration of TDP-43 in euchromatin domains, perichromatin 
fibrils, and sites of transcription and co-transcriptional splicing. Weak TDP-43 staining 
colocalizes with splicing factor nuclear speckles. It is absent, however, from the nucleolus, 
heterochromatin and transcription-free Cajal bodies (Casafont et al. 2009). The association of 
TDP-43 with euchromatin may be RRM2-dependent (Lagier-Tourenne et al. 2010). Thus, TDP-
43 localizes to nuclear sites of active transcription and RNA processing, although its association 
with particular nuclear bodies may be isoform-specific. 
 
Transcription 
The localization of TDP-43 to sites of transcription is consistent with its role as a 
transcriptional regulator. TDP-43 was first identified as a transcriptional repressor that binds to 
the single-stranded, polypyrimidine-rich TAR DNA sequence of HIV-1 (Ou et al. 1995). TDP-43 
also acts as a transcriptional repressor in regulating expression of the SP-10 gene during 
spermatogenesis (Acharya et al. 2006). Multiple studies, particularly those demonstrating 
interactions between FUS, RNA Polymerase II, and other transcription factors, have more firmly 
established a primary role for FUS in transcription, and potentially in coupling transcription to 
splicing (Schwartz et al. 2012, Schwartz et al. 2014, unpublished data). Further studies are 
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RNA and RNP Binding 
Although TDP-43 was first identified as a transcriptional regulator, subsequent research 
has primarily focused on understanding its role in RNA regulation. In neurons, TDP-43 is found 
in high molecular weight, RNA-dependent complexes. In both neurons and cell culture, TDP-43 
co-immunoprecipitates with RNA binding proteins, many of which have also been linked to ALS 
(Freibaum et al. 2010, Kim et al. 2010, Sephton et al. 2011). Most notable among these binding 
partners is FUS, mutations in which account for a small percentage of fALS cases, and which 
possesses a very similar domain structure and functional profile to that of TDP-43. RNA 
immunoprecipitation experiments, as well as high and low throughput sequencing of UV cross-
linked TDP-43 immunoprecipitates reveals extensive interactions between TDP-43 and at least 
20% of the mammalian transcriptome (Polymenidou et al. 2011, Sephton et al. 2011, Tollervey 
et al. 2011, Xiao et al. 2011, extensively analyzed in Chapter 3).  
 
Splicing: Direct or Indirect? 
Both high and low throughput studies of TDP-43 binding to RNA have focused on its 
involvement in pre-mRNA splicing. Perhaps the most deeply studied example is of TDP-43 
binding to an intronic UG-tract in the mRNA of the cystic fibrosis transmembrane regulator 
(CFTR) gene. This binding promotes skipping of CFTR exon 9, which yields an mRNA that 
cannot be translated into a functional protein (Lagier-Tourenne et al. 2010). TDP-43 also 
promotes skipping of exon 3 in apolipoprotein A-II mRNA splicing. In these first two cases, 
CFTR and apoA-II splicing regulation by TDP-43 depends upon its interactions with other 
hnRNPs. TDP-43 binding directly to exon 7 promotes its inclusion in survival motor neuron 
(SMN) mRNA splicing, however the authors acknowledge that this result may be an artifact of 
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TDP-43 overexpression, and that it depends on hnRNPA1 (Bose et al. 2008). TDP-43, as well as 
hnRNP H, binding to an exonic regulatory sequence in the 3’UTR of the splicing factor SC35 
mRNA represses a splicing event that mediates the autoregulatory control by SC35 of its own 
mRNA levels (Dreumont et al. 2009). In these two examples, overexpression but not knockdown 
of TDP-43 affects splicing. The caveats associated with each experiment call into question the 
physiological relevance of TDP-43 in splicing the identified transcripts. The role of TDP-43 in 
splicing may rely heavily on its incorporation into multi-protein complexes, and potentially on its 
regulation of splicing factor transcripts. 
Transcriptome-wide analyses of TDP-43 binding support the hypothesis that TDP-43 
plays an indirect role in splicing by regulation of the mRNAs that code for splicing factors. 
Knockdown of TDP-43 in the mouse striatum revealed over 500 TDP-43-regulated cassette 
exons, however, the majority of altered splicing events did not contain TDP-43 binding within 
2kb of the splice site (Polymenidou et al. 2011). In the human brain, the number of TDP-43-
regulated cassette exons that fit a proposed pattern of TDP-43 splicing regulation was relatively 
small, although 19% of RNABPs encoding RNAs are bound by TDP-43 (Tollervey et al. 2011). 
Taken together, these data indicate that TDP-43 likely plays an indirect role in splicing, either 
through interactions with direct splicing factors, or through regulation of the transcription or 
stability of RNAs encoding splicing factors. 
 
Involvement in miRNA Biogenesis 
While TDP-43 does appear to play a role in splicing, albeit indirect, its role in miRNA 
biogenesis is less clear. The strongest support for this role comes from knockdown of TDP-43 in 
differentiating neurons, which downregulates microprocessor subunits Drosha and DGCR8 (Di 
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Carlo et al. 2013). Less direct support comes from experiments in which TDP-43 down-
regulation in various systems alters the expression levels of subsets of miRNAs (Gascon & Gao 
2014). Less conclusively, overexpression experiments reveal that TDP-43 interacts with 
components of the miRNA microprocessor complex in non-neuronal cells (Gregory et al. 2004, 
Polymenidou et al. 2011). Interactions between overexpressed TDP-43 and Drosha, as well as 
TDP-43 and Dicer facilitate processing of a subset of pre-miRNAs in cell culture (Kawahara & 
Meida-Sato 2012). In Drosophila, TDP-43 regulates miR-9a levels by promoting the stability of 
pri-miR-9a (Li et al. 2013).  
As in splicing experiments, however, the issue of TDP-43 overexpression may lead to 
non-physiological interactions with miRNA processor components. Knockdown experiments 
likely reveal more biologically relevant findings, and suggest that TDP-43 regulates 
microprocessor component expression, potentially through interactions with the mRNA coding 
for these subunits. Likewise, regulation of miRNAs may result more through TDP-43-RNA, than 
TDP-43-protein interactions. These data suggest TDP-43 involvement in multiple aspects of 
miRNA biogenesis, but the details of this involvement require further study. 
 
mRNA Turnover 
 Aside from its role in splicing, and potential role in miRNA biogenesis, increasing 
evidence indicates a role for TDP-43 in mRNA stability and turnover. TDP-43 negatively 
regulates levels of Cdk6 through binding to GT repeats within its mRNA (Ayala et al. 2008). 
Alternatively, TDP-43 positively regulates Hdac6 mRNA levels through binding to FUS (Fiesel 
et al. 2010). Positive regulation of the microtubule-associated protein Futsch/MAP1B in 
Drosophila by TDP-43 maintains neuronal morphology and NMJ structure (Godena et al. 2011). 
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TDP-43 additionally stabilizes human NFL mRNA through binding to its 3’UTR in spinal cord 
tissue (Strong et al. 2007). Finally, TDP-43 destabilizes VEGF and PGRN mRNAs through 
binding to their 3’UTRs (Colombrita et al. 2012). Thus, depending on the target, TDP-43 binding 
can exert either a positive or negative regulatory effect on specific mRNA.  
 
RNA Autoregulation and Protein Turnover 
One of the most important RNAs to which TDP-43 binds is its own, as this mediates an 
autoregulatory feedback loop that maintains TDP-43 levels within a narrow physiological range 
(Figure 1.5, reviewed in Sephton et al. 2012). Support for this conclusion comes from TDP-43 
knockout experiments in which heterozygous mice express TDP-43 protein at the same levels as 
WT mice. Furthermore, transgene expression without the regulatory 3’UTR leads to decreased 
levels of endogenous mRNA and protein (Sephton et al. 2012). Similar to autoregulatory 
mechanisms reported for other RNA binding proteins, TDP-43 binding within the 3’UTR of its 
own mRNA causes excision of an alternatively spliced intron containing the optimal TDP-43 
polyadenylation site. This spliced mRNA is a predicted target for nonsense-mediated RNA decay 
(NMD) through the persistence of non-productive spliceosomal complexes bound to the mRNA 
(Ayala et al. 2011, Polymenidou et al. 2011). Alternatively, high TDP-43 levels may induce 
splicing to suboptimal poly-adenylation sites, which leads to mRNA degradation. Regardless of 
the detailed mechanism, higher TDP-43 protein levels lead to greater production of TDP-43 
mRNA that is targeted for degradation, while lower TDP-43 levels result in a successfully 
translated transcript.  
Maintenance of physiological TDP-43 protein levels depends on both the ubiquitin 
proteasome system and the autophagy lysosomal pathway. Inhibition of either of these pathways 
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causes TDP-43 cytoplasmic accumulation in cell culture (Wang et al. 2010). As additional 
evidence for TDP-43 degradation by both pathways, TDP-43 associates with both the ubiquitin-
like protein Ubiquilin-1, and the autophagosomal protein HDAC6 (Warraich et al. 2010). 
Therefore, perturbations in either of these pathways might lead to aberrant TDP-43 
accumulation. 
 
Cellular Stress Response 
 Protein degradation pathways may play a greater role in TDP-43 processing under 
conditions of cellular stress. TDP-43 localizes to cytoplasmic granules (stress granules, or SGs), 
sites of translation inhibition, in response to a variety of cellular stresses, including heat shock, 
oxidative stress, osmotic stress, serum deprivation, ubiquitin-proteasome inhibition, and 
endoplasmic reticulum (ER) stress (Dewey et al. 2012). Localization to these foci requires the 
RRM1 and C-terminal domains of TDP-43 (Colombrita et al. 2009). Overexpression of TDP-43 
with a defective NLS, but not WT TDP-43, triggers the formation of cytoplasmic aggregates that 
co-stain for SG markers (Dewey et al. 2012). TDP-43, however, is not necessary for stress 
granule formation nor does it alter cell viability following oxidative stress induction (Colombrita 
et al. 2009). In fact, certain stressors, such as the ER stressor thapsigargin, induce TDP-43 
localization to SGs in some cell lines, such as HeLa, but not others, such as Neuro2a and SH-
SY5Y (Dewey et al. 2012). Thus, while published data establishes the RNA-binding dependent 
TDP-43 localization to SGs in response to certain stressors, the molecular mediators, cell-type 
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Neuronal Localization and Function 
Aside from responding to specific stressors, TDP-43 may also possess cell-type specific 
functions. TDP-43 shows ubiquitous expression in the adult mouse, with prominent expression 
through the central nervous system (CNS), including in the cortex and grey and white matter of 
the spinal cord (Sephton et al. 2012). In a neuronal cell culture system, normal neurite outgrowth 
requires TDP-43 expression (Kawahara & Mieda-Sato 2012). In in vivo model systems, normal 
locomotion, dendritic outgrowth, accurate bouton numbers at neuromuscular junctions (NMJs), 
and appropriate axon length and branching require endogenous TDP-43 expression levels 
(Sephton et al. 2012). The mouse nervous system development and function shows a similar 
requirement for endogenous TDP-43 expression levels (Sephton et al. 2012). 
 In addition to its localization to stress granules, TDP-43 localizes to other RNP granules 
in neurons. TDP-43 associates with multiple proteins that compose neuronal transport mRNP 
granules, e.g. Staufen, FMRP, SMN, and HuD (Freibaum et al. 2010). Depolarization of primary 
cultured neurons induces increased colocalization of TDP-43 with Staufen and FMRP, as well as 
with post-synaptic density marker PSD-95. These dendritic RNP granules contain β-actin and 
CaMKII mRNA (Wang et al. 2008). Sciatic axotomy also induces TDP-43 colocalization with 
Staufen, as well as with the SG marker TIA-1, in cytosolic granules. These granules resolve by 
28 days after injury (Moisse et al. 2009). In addition, TDP-43 forms cytoplasmic RNP granules 
that transport RNA cargo along neuronal processes in a microtubule-dependent manner (Alami et 
al. 2014). Thus, despite its primary nuclear localization, TDP-43 plays important roles in 
particular cytoplasmic compartments of neurons.  
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We can conclude from the many experiments described in this section that published data 
supports a diversity of roles for TDP-43 in RNA processing, from transcription to translation and 
delivery of RNA to particular cellular compartments. Because many of the described 
experiments were conducted through overexpression of TDP-43, non-physiological findings may 
result from the intrinsic propensity of TDP-43 to aggregates, especially when expressed at higher 
than physiological levels. Thus, additional experiments of TDP-43 expressed at or near 
endogenous levels will aid in confirming, or refuting, the various identified roles of TDP-43.  
In this section, I have included a discussion of knockdown or over-expression 
experiments where these reveal functions of WT TDP-43. A more extensive analysis of these, 
and other, disease-relevant experiments follow below, with a particular focus on rodent models 
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1.5 The role of TDP-43 in Neurodegeneration and ALS 
Two important discoveries definitively established a causative role for TDP-43 in ALS: 
the identification of TDP-43 as a major component of ubiquinated inclusions in ALS, and the 
discovery of heritable, ALS-causing mutations in TDP-43. The simultaneous detection of TDP-
43 in a subset of Frontotemporal Dementia (FTD), a common cause of pre-senile dementia, cases 
prompted the designation of these disorders as TDP-43 proteinopathies. As mentioned above, we 
will focus here on the role of TDP-43 in ALS, but will mention some evidence from FTD 
patients when it correlates with data from ALS cases. 
 
TDP-43 Mutations and Prion-like Properties 
 As described above, algorithms developed from yeast prion proteins identify the C-
terminal glycine-rich region of TDP-43 (amino acids 277-414) as a prion-like domain, which 
mediates the protein’s intrinsic propensity to aggregate. In C. elegans and cellular models, 
deletion of the entire prion-like domain prevents TDP-43 misfolding and toxicity (Ash et al. 
2010, Johnson et al. 2008). In fact, deletion of just amino acids 311-320 can prevent aggregation 
in vitro (King et al. 2012). Notably, of over 40 ALS-linked mutations identified in TDP-43, all 
but three fall within the prion-like domain (Figure 1.3). Some mutations, including M337V and 
Q331K, accelerate TDP-43 misfolding in vitro and enhance toxicity in yeast, while others do not 
(Johnson et al. 2009).  
 In vivo and in vitro experiments indicate that the prion-like C-terminal domain of TDP-
43, as well as that of FUS and other hnRNPs, might play a role in the normal function of these 
proteins by allowing them to assemble into higher-order complexes. In ALS, these aggregation-
prone domains become a liability as usually reversible RNP granule formation becomes 
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irreversible through conversion to amyloid structures, and ultimately to pathogenic inclusions 
(Ramaswami et al. 2013). Intact protein degradation pathways, however, may successfully clear 
these inclusions. Evidence for this comes from studies of VCP, an autophagy related protein, 
finding that stress granule clearance is impaired by depletion or pathogenic mutations in VCP 
(Buchan et al. 2013). In patients, mutations in VCP cause ALS and FTD with pathological 
accumulation of TDP-43, hnRNPA1, hnRNPA2/B1, and other stress granule markers (Dewey et 
al. 2013). These findings fit within a model of altered ribostasis, or regulation of the cellular 
transcriptome, whereby irreversible pathogenic inclusions sequester RNA binding proteins, their 
target RNAs, and potentially altering signaling pathways (Ramaswami et al. 2013). In the 
following sections, we will discuss aspects of TDP-43 pathology consistent with the involvement 
of its aggregation-prone prion-like domain in ALS. 
 
TDP-43 Pathology 
Abnormal TDP-43 inclusions define TDP-43 proteinopathies. While some TDP-43 
pathology has been identified in other neurodegenerative diseases, including Alzheimer’s 
disease, and Lewy body disorders, the amount and distribution of this pathology in ALS and 
FTD far exceeds that seen in other disorders (Lee et al. 2011). Aside from labeling previously 
identified ubiquitin-positive inclusions, antibodies against TDP-43 also reveal novel glial 
cytoplasmic inclusions, and the diffuse granular staining of “pre-inclusions.” Loss of 
physiological nuclear TDP-43 immunoreactivity frequently accompanies TDP-43 pathology (Lee 
et al. 2011). 
The neuropathology of sporadic ALS cases consists of abnormal cytoplasmic 
accumulation of TDP-43 in multiple brain regions and cell types including neurons and glia of 
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the primary motor cortex, brainstem motor nuclei, spinal cord, and white matter tracts. These 
inclusions present with varying morphologies including small granules, compact Lewy-body-like 
inclusions, and filamentous skeins (Mackenzie et al. 2007). The distribution of TDP-43 
pathology in the brain and spinal cord has not been found to correlate with the site of disease 
onset, although TDP-43 accumulations in the extramotor neocortex and hippocampus often 
present in ALS with dementia (Brettschneider et al. 2013, Mackenzie et al. 2010). Pathological 
TDP-43 in a variety of subcortical regions may correlate with additional symptoms such as 
parkinsonism. TDP-43 aggregates presents less consistently with non-ALS motor neuron disease 
phenotypes (Mackenzie et al. 2010). In addition, TDP-43 inclusions do not display 
immunoreactivity for FUS or SOD1 (Mackenzie et al. 2010). 
Biochemically and ultrastructurally, pathological TDP-43 differs from physiological 
TDP-43. In ALS patient tissue, TDP-43 is often hyperphosphorylated and ubiquitinated (Lee et 
al. 2011). Dual phosphorylation at TDP-43 residues S409/S410 presents as a consistent feature 
of both ALS and FTD. Fractionation of ALS patient nervous system tissue reveals novel, 
sarkosyl-insoluble, TDP-43 species including predominantly brain-specific phosphorylated C-
terminal TDP-43 fragments (CTFs) of 20-25 kDa, a more spinal cord-specific phosphorylated 45 
kDa species, and high molecular weight ubiquitinated species (Lee et al. 2011). Ultrastructural 
studies of TDP-43 aggregates reveal granular material with variably abundant, TDP-43 
immunoreactive, ~15nm filaments. The amyloid nature of TDP-43 inclusions remains 
controversial, with recent data suggesting that TDP-43 forms amyloid oligomers, perhaps in the 
absence of further polymerization into amyloid fibrils (Geser et al. 2010, Fang et al. 2014).  
 These pathological studies provide a variety of assays, aside from neuronal dysfunction 
and death, with which to assess potential models of TDP-43-ALS. In the context of these assays, 
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I will now describe a representative subset of published models of TDP-43 (rodent models 
summarized in Table 1.2), assess their biological relevance to the study of motor neuron 
degeneration and ALS, and describe what we can learn from them about TDP-43 physiology and 
pathology.  
 
Animal Models of TDP-43 
Non-mammalian TDP-43 Models  
 Because of the ease of generating invertebrate genetic disease models, and the presence 
of TDP-43 homologues in both Drosophila (TBPH) and C. elegans, multiple models in both 
systems provide insight into TDP-43-mediated neurodegeneration. As in mice, loss of TDP-43 
function by deletion of TBPH yields a lethal or semi-lethal phenotype in Drosophila. The 
phenotype of surviving TBPH null flies, which is partially rescued by TDP-43 expression in 
MNs, consists of motor deficits, neuronal loss, abnormal neuromuscular junctions (NMJs), and 
early mortality (Wegorzwska & Baloh 2011). Paradoxically, deletion of the C. elegans TDP-43 
homologue, tdp-1, results in a longer lifespan, although with increased sensitivity to oxidative 
and osmotic stress. TDP-1 mutants, however, show varied phenotypes including slow 
development and locomotion defects (Therrien & Parker 2014). 
 Neuronal promoter driven overexpression of human TDP-43 in both flies and worms 
causes neurodegeneration. Flies reveal a dose-dependent phenotype ranging from death during 
the larval stage in high expressing lines to movement defects, paralysis, and mortality of adult 
flies in lower expressing lines. Mutant hTDP-43M337V expression causes a more severe 
degenerative phenotype in the fly eye than WT expression. Fly TDP-43 overexpression models 
variably present with molecular TDP-43 pathology. For instance, biochemical analysis of three 
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different models with TDP-43 toxicity revealed insoluble full-length TDP-43, soluble CTFs, and 
neither of these, respectively (Wegorzwska & Baloh 2011). Worms overexpressing human full 
length, human C-terminal fragmented, and C. elegans TDP-43 from a pan-neuronal driver show 
motility defects and neurodegeneration, promisingly correlated with TDP-43 phosphorylation. 
Notably, overexpression of the human CTF did not lead to MN loss. Restricted overexpression of 
mutant, but not WT, hTDP-43 specifically in GABAergic neurons caused adult-onset, 
progressive paralysis with GABAergic neurodegeneration (Therrien & Parker 2014).  
 As in mice, results in invertebrates remain unclear regarding the subcellular location of 
TDP-43 toxicity. Mislocalization of TDP-43 to the cytoplasm by NLS mutation causes a 
degenerative phenotype similar to WT in flies, however the same NLS mutant expressed in 
worms was not toxic (Wegorzwska & Baloh 2011). The latter case suggests that TDP-43 toxicity 
occurs in the nucleus whereas the former supports the hypothesis of toxicity in the cytoplasm. 
Future experiments will hopefully clarify this inconsistency. 
 The primary utility of invertebrate models lies in the ease of identifying genetic modifiers 
and interactors, such as UBQLN and ataxin-2, results that can then translate to clinical findings 
(Wegorzwska & Baloh 2011). In addition, experiments in flies revealed genetic and biochemical 
interactions between TDP-43 and FUS, placing these two ALS-associated RNABPs in the same 
pathway (Wang et al. 2011). 
 Experiments in zebrafish reveal that mutant TDP-43 expression causes shorter motor 
axons, excessive axonal branching, and swimming deficits to a greater extent than WT. Implying 
a loss of function toxic mechanism, TDP-43 knockout leads to a similar phenotype, rescued by 
TDP-43WT but not mutant expression (Kabashi et al. 2010). Thus, non-mammalian models of 
TDP-43 are generally consistent with mammalian findings, which will be discussed next. 
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TDP-43 Constitutive and Conditional Knockout Mouse Models 
 As mentioned above, complete loss of mouse TDP-43 results in early embryonic lethality 
at embryonic day 3.5-8.5, thereby defining an essential role for TDP-43 in development 
(McGoldrick et al. 2013, Table 1.2). In hemizygous knockout mice, however, with disruption of 
only one TARDBP allele, protein and mRNA levels remained the same as in WT mice, 
supporting the hypothesis of an autoregulatory mechanism for maintaining TDP-43 protein 
levels. Hemizygous mice, ranging in age from 342-840 days, displayed age-related deficits in 
two test of grip strength, but no histological evidence of motor neuron degeneration or TDP-43 
pathology, compared to their WT littermates (Kraemer et al. 2010). Thus, while TDP-43 is 
essential for development, loss of one allele has very few consequences. 
 A conditional knockout strategy overcomes the essential role of TDP-43 in embryonic 
development and allows investigators to study TDP-43 deficiency in adult mice or in particular 
cell types. Heterozygous deletion of Tardbp does not alter protein or mRNA levels, while 
ubiquitous deletion of both alleles in adult mice causes rapid body fat loss and death within nine 
days, precluding any study of a potential motor phenotype (Chiang et al. 2010). Targeted 
depletion of TDP-43 in Hb9+ motor neurons revealed a progressive motor phenotype beginning 
with weight loss at 56 days, progressing to abnormal hindlimb clasping and kyphosis at 100 
days, and death at 10 months. In these mice, a significant and progressive loss of ChAT+ spinal 
cord MNs occurred alongside gliosis and cytoplasmic ubiquitin accumulation in neurons lacking 
TDP-43 (Wu et al. 2012). A similar experiment depleting TDP-43 in VAChT+ somatomotor 
neurons, with roughly 50% efficiency, found a minor but progressive motor phenotype along 
with denervation, gliosis, and motor neuron atrophy, but not survival deficit at 700 days (Iguchi 
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et al. 2013). Exacerbation and ALS-relevance of these phenotypes might be enhanced by TDP-
43 depletion in additional nervous system cell types. As cited, these findings support at least a 
partial loss of function mechanism of TDP-43-mediated motor neuron degeneration. 
Confusingly, overexpression of TDP-43WT also leads to motor deficits and ALS-like pathology.  
  
Transgenic Models: TDP-43 expression by the mouse prion promoter 
 The mouse prion promoter allows expression of transgenes in the mouse central nervous 
system (CNS). Conflicting reports find only mild gliosis and increased ubiquitin staining with 
expression of human TDP-43WT from the mPrp promoter at 3-fold endogenous levels (Stallings 
et al. 2010), compared to neurodegeneration and reduced lifespan with transgene expression at 
less than 3-fold endogenous levels (Xu et al. 2010, Xu et al. 2011). Both groups report that 
expression of mutant hTDP-43 (A315T in the former and M337V in the latter) at levels 
comparable to hTDP-43WT, resulted in molecular TDP-43 abnormalities, motor deficits, and 
early death (Stallings et al. 2010, Xu et al. 2011).  
 In the first published TDP-43 model, hTDP-43A315T expression at 3-fold endogenous 
levels lead to a motor phenotype by 13 weeks and death at 22 weeks of age, accompanied by 
UMN loss with cortical ubiquitinated aggregates and brain and spinal cord CTFs (Wegorzewska 
et al. 2009).  Subsequent analysis found that death in this model resulted from intestinal 
obstruction which, when alleviated with a diet of jellied food, permitted the development of late 
onset motor neuron disease (Herdewyn et al. 2014). 
The most promising published TDP-43 transgenic model finds a mutation-dependent 
motor phenotype compared with an appropriate hTDP-43WT control. In this model, mice express 
hTDP-43WT, M337V, and Q331K, from the mPrP promoter at, according to the authors, roughly 
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the same level as endogenous mTDP-43 (Arnold et al. 2013). Independent examination of the 
published results, however, suggests that the Q331K mutant is actually expressed at higher levels 
than the WT, or M337V mutant protein. This is consistent with the reported onset of a motor 
phenotype by 3 months with hTDP-43Q331K expression, but not until 10 months of age with 
hTDP-43M337V expression. Strikingly, despite motor neuron loss and denervation in hTDP-
43Q331K expressing mice, the authors found no evidence of molecular TDP-43 abnormalities. 
Additionally, the motor phenotype plateaued at 10 months of age without additional 
degeneration or progression of motor deficits. Thus, while this model might continue to provide 
information about mutant TDP-43-mediated motor dysfunction, its relevance to ALS requires 
further investigation. 
 
Transgenic Models: TDP-43 expression by the Thy1.2 promoter  
 The Thy1.2 drives transgene expression in neuronal cells from one week of age, thereby 
avoiding any developmental effects. Expression of hTDP-43WT in one such transgenic 
mousseline revealed significant sexual dimorphism, with hTDP-43 expressed at 1.9x endogenous 
levels in females and 3.6x endogenous levels in males. Males developed an altered gait at P14 
and began losing weight by P28. IHC revealed some nuclear aggregation of TDP-43, diffuse 
cytoplasmic ubiquitin staining, abnormal mitochondria distribution, and increased GEM 
formation. The authors do not, however, describe a survival phenotype in this mouse line (Shan 
et al. 2010).  
 Wils and colleagues found a dose-dependent effect of hTDP-43WT expression driven by 
the Thy1.2 promoter. Low expression resulted in only minor motor dysfunction at 15 months 
with no effect on lifespan. Intermediate and high expression resulted in motor dysfunction at 4 
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months and 18 days, and death at 6.7 months and 30 days, respectively. Loss of both upper and 
lower motor neurons, as well as TDP-43 ubiquitination, phosphorylation, aggregation, and 
fragmentation, accompanied the motor deficits and early mortality (Wils et al. 2010). Subsequent 
comparison to expression of hTDP-43M337V by the Thy1.2 promoter revealed a similar dose-
dependent phenotype, slightly exacerbated by the mutation with respect to motor dysfunction, 
neurodegeneration, phosphorylated TDP-43 pathology, and lethality. CTFs and TDP-43 or 
ubiquitin-containing aggregate accumulation seem, however, not to correlate with disease 
progression (Janssens et al. 2013). Tsao and colleagues have developed mice expressing hTDP-
43 under Thy1.2 promoter at levels slightly higher than endogenous. They develop robust MN 
disease with flaccid paralysis around 2 years of age. The phenotype does not differ between mice 
expressing hTDP-43WT and hTDP-43G298S (unpublished data). 
 Interestingly, an additional model expresses the 25 kDa C-terminal fragment of TDP-43 
under the control of the Thy1.2 promoter and reveals no phenotype other than an age-dependent 
increase in CTFs detected by Western Blot, and cognitive decline detected by behavioral testing 
(Caccamo et al. 2012).  
 
Transgenic Models: TDP-43 expression by the CaMKII promoter 
 Using the CamKII promoter, which limits transgene expression to the forebrain, to 
express WT mTDP-43 at 2-fold greater than endogenous levels, yields motor deficits and UMN 
loss by P180. At the molecular level, TDP-43 mislocalizes, aggregates, fragments, and becomes 
ubiquitinated (Tsai et al. 2010). Interestingly, rapamycin alleviates the motor phenotype in these 
mice, potentially through increased autophagy (Wang et al. 2013).  
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Conditional expression of hTDP-43WT and hTDP-43ΔNLS under control of the CamKII 
promoter resulted in 0.8-fold and 7.9-fold, respectively, higher expression of hTDP-43 compared 
to endogenous mTDP-43. Not unexpectedly, the high expression of hTDP-43ΔNLS lead to rapid 
development of a limb clasping defect by seven days after induction, 50% neuronal loss in the 
dentate gyrus by four weeks post-induction, and death by six months. Rare ubiquitinated and 
phosphorylated TDP-43 aggregates with frequent cytoplasmic mislocalization of TDP-43 
accompanied the motor phenotype. Mice expressing hTDP-43WT showed a similar phenotype but 
with a later onset, slower progression, and no survival defect (Igaz et al. 2011). Another group 
identified dose-dependent cortical atrophy, hippocampal neuron loss, and mortality with 
increased conditional expression of hTDP-43WT by the CaMKII promoter. Neuronal pathology 
included cytoplasmic aggregation of mitochondria and phosphorylated TDP-43, and cytoplasmic 
ubiquitin immunoreactivity. Delaying expression of hTDP-43WT to P21 ameliorated the mortality 
and mitochondrial phenotypes, although cortical atrophy and pathology were still evident 
(Cannon et al. 2012). 
 
Transgenic Models: TDP-43 using a bacterial artificial chromosome 
 In bacterial artificial chromosomes (BAC) transgenesis, a gene’s own endogenous 
promoter drives its expression. Mice expressing hTDP-43WT, A315T, and G348S from a BAC 
transgene at 3-fold endogenous levels display motor dysfunction between P250 and P300, with 
slightly earlier onset with mutant compared to WT expression. In all genotypes, the number of 
large caliber axons decrease with a seemingly compensatory increase in the number of small 
caliber axons. Interestingly, expression of mutant hTDP-43 in these mice resulted in greater 
TDP-43 pathology, including TDP-43 aggregation and mislocalization (Swarup et al. 2011). 
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TDP-43 Knock-in Model: Endogenous mouse promoter 
 Recombinase-mediated cassette exchange (RCME) introduced ALS patient cDNA 
harboring the TDP-43 A315T mutation into the mouse TDP-43 locus. Despite expression of the 
mutant protein at 3-fold endogenous levels, and concomitant downregulation of mouse TDP-43, 
mutant mice displayed only a mild “predisease” phenotype characterized by 10% reduction in 
body weight and motor neuron number but only slight motor impairment. Insoluble TDP-43 
accumulated beginning at 3 months of age, and electron microscopy revealed abnormal neuronal 
mitochondria (Stribl et al. 2014).  
 
Transgenic Rat Model: Conditional expression by CMV promoter 
 Constitutive expression of hTDP-43M337V, but not WT, by BAC transgenesis resulted in 
early mortality and inability to maintain the transgenic line. Therefore, the authors chose to 
constitutively express hTDP-43M337V from tetracycline responsive miniCMV construct. Induction 
of mutant hTDP-43 expression at P4 lead to motor deficits by P35, paralysis around P50, 
significant loss of LMNs, large caliber axon degeneration, and muscle denervation and atrophy. 
Neurons exhibited diffuse TDP-43 mislocalization and pathology, with aggregates identified 
only infrequently, and only in the cortex (Zhou et al. 2010). 
 The same group investigated the effect of conditional expression of hTDP-43M337V in 
specific cell types. Using the same TetOFF system, rats deprived of doxycycline, expressed 
mutant TDP-43 either in neurons and skeletal muscle (neurofilament heavy chain (NEF) 
promoter), or almost exclusively in motor neurons (choline acetyltransferase (ChAT) promoter). 
Interestingly, restricted expression of hTDP-43M337V in ChAT-positive cells resulted in a more 
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rapidly progressive motor phenotype, and 40% greater MN loss, with lethality at least one week 
earlier than in rats more broadly expressing the mutant protein, indicating that mutant TDP-43 
may exert protective effects in a non-cell autonomous manner. The authors note a lack of TDP-
43 pathology, particularly TDP-43-positive aggregates, although surviving MNs in the spinal 
cord do contain cytoplasmic, ubiquitinated inclusions (Huang et al. 2012). 
 
Non-human Primate TDP-43 Model 
 Researchers injected an adeno-associated virus (AAV1) vector containing flag-tagged 
human TDP-43WT into the cervical spinal cord of adult cynomolgus monkeys, leading to hTDP-
43 expression exclusively in neurons at 20-fold higher transcript levels than endogenous TDP-
43. Monkeys developed unilateral progressive muscle weakness, atrophy, and paralysis on the 
injected side, with some contralateral involvement, accompanied by significant (50%) motor 
neuron and large axon loss. TDP-43 pathology included early cytoplasmic mislocalization that 
then decreased with disease progression, and occasional aggregates with nuclear clearing. The 
authors did not detect C-terminal fragments, however, they did detect phosphorylated 
neurofilament and peripherin accumulations, a feature seen in human patients. Rats injected with 
the same AAV1 virus displayed a similar motor phenotype, without cytoplasmic mislocalization 
of TDP-43 (Uchida et al. 2012). 
 
Summary of Animal Models of TDP-43  
  Animal models expressing TDP-43 mutations have yet to simultaneously recapitulate all 
of the pathologic signs reported from ALS patients, such as progressive upper or lower motor 
neuron loss, skeletal muscle atrophy and paralysis, respiratory muscle failure, and the presence 
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of ubiquitinated and phosphorylated TDP-43 and C-terminal fragments. In these models, mutant 
forms of TDP-43 are not particularly aggregation-prone. When overexpressed, the wild type 
form of TDP-43 sometimes causes an even more severe phenotype than the mutant protein or 
CTFs. ALS-like phenotypes observed in transgenic animals manifest in younger mutants and, 
unlike the human condition, often resulted in early death (Stribl et al. 2014).  
 
Human induced pluripotent stem cell TDP-43 Models 
 While mammalian model systems provide opportunities to study disease in the context of 
full organs and tissues, the genetic background of these systems differs from that of human 
patients. Induced pluripotent stem cell technology has provided a cell culture system in which 
patient cells can be studied in the context of the human genetic background in which disease 
developed. Application of motor neuron differentiation techniques to induced pluripotent stem 
cells (iPSCs) from ALS patients harboring TDP-43 mutations has revealed the recapitulation of 
ALS hallmarks in a directly disease relevant cellular context. MNs derived from TDP-43M337V 
iPSCs (iMNs) had increased levels of soluble and insoluble TDP-43 protein, impaired survival 
and increased sensitivity to PI3K kinase inhibition (Bilican et al. 2012). Astrocytes (i-astrocytes) 
produced from the same iPSCs also showed increased TDP-43 protein levels with cytoplasmic 
aggregates and impaired survival. Mutant i-astrocytes did not, however, affect the viability of co-
cultured MNs (Serio et al. 2013). An independent study found that iMNs harboring three 
different mutations in TDP-43 all contained increased amounts of insoluble TDP-43 bound to the 
spliceosomal protein SNRPB2. Furthermore, these cells displayed upregulation of genes 
involved in RNA metabolism and downregulation of genes encoding cytoskeletal proteins. 
Anacardic acid seemed to improve cell survival, increase MN neurite length, and decrease 
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insoluble TDP-43 (Egawa et al. 2012). Thus, human patient iPSCs can serve both as a model for 
studying motor neuron disease and as a substrate for screening potential therapeutics. 
Additionally, iPSC models might corroborate findings in mouse models and vice versa. 
 
TDP-43 Pathological Mechanism: Loss of Function or Gain of Toxic Properties 
 It is difficult to construct a mechanistic framework for understanding how TDP-43, either 
by mutation in fALS cases, or other mechanisms in the vast majority of sALS cases, leads to the 
development of neurodegeneration. Biologists often understand the effects of a mutation either 
by causing a loss of a proteins normal function, or gain of a novel function not attributed to the 
WT protein. Attempts to fit current data into this dichotomous framework fail to fully capture the 
complexity of the field (Lee et al. 2011, Vanden Broeck et al. 2014), potentially because we have 
little information about the natural course of TDP-43 dysfunction in human disease. I discuss 
here a two-step framework that considers primary and secondary effects of TDP-43 dysfunction. 
For instance, a primary gain of toxic function in the cytoplasm might result in the downstream 
loss of TDP-43 function in the nucleus. This framework relates somewhat to the “two-hit” 
hypothesis for TDP-43 toxicity in which an underlying predisposition exists toward pathology, 
but an additional stressor, or “hit,” is required to actually initiate degeneration. 
A primary loss of function hypothesis is difficult to test because of the obvious 
developmental requirement for TDP-43, i.e. constitutive TDP-43 null mice display early 
embryonic lethality. Conditional, ubiquitous, TDP-43 knockout in mice also leads to sudden 
death within nine days of induction (Chiang et al. 2010). In cell culture systems, TDP-43 
knockdown impairs cell viability and activates apoptotic pathways. Data from non-mammalian 
models reveals that knockdown of TDP-43 homologues can lead to motor phenotypes and 
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neuronal morphological abnormalities (Lee et al. 2011). Conditional, primarily MN-restricted, 
TDP-43 knockdown produced behavioral motor deficits as well as MN loss and denervation, 
with a variable effect on survival potentially related to the efficiency of knockdown. Further 
support for a loss of function hypothesis comes from the inability of ALS-linked mutant TDP-43 
to rescue knockdown phenotypes in flies and worms (Vanden Broeck et al. 2014). As mentioned 
above, a relatively early finding in ALS patients is of TDP-43 clearance from neuronal nuclei 
(Lee et al. 2011). These results argue in favor of at least a partial primary loss of TDP-43 
function contributing to motor neuron degeneration (Wu et al. 2012, Iguchi et al. 2013). 
 Multiple aspects of TDP-43 pathology in ALS patients potentially support a primary gain 
of toxic properties, including phosphorylation, ubiquitination, mislocalization to the cytoplasm, 
and accumulation of CTFs. While over-expression of full length TDP-43 certainly results in 
dose-dependent motor phenotypes in multiple systems, arguing for a gain of toxic properties, the 
frequent lack of molecular markers of ALS pathology argues against the disease relevance of 
these models. Whether protein aggregates themselves exert toxic effects within the cell, or 
represent a cellular attempt to ameliorate toxicity, remains unresolved in the field of 
neurodegenerative diseases. In the case of TDP-43, aggregation is not essential for the 
neurodegeneration observed in various models, but it may play a role in disease pathways, either 
by sequestration of TDP-43 from performing its physiological functions, or novel toxicity of the 
aggregate, responses to which may lead to a toxic positive feedback loop (Lee et al. 2011). 
Animal models overexpressing full-length TDP-43 and C-terminal fragments reveal aggregation 
of phosphorylated TDP-43 species, reminiscent of those seen in patients. Mutation of 
pathologically phosphorylated residues S409/410 eliminates the neurotoxicity of ALS-mutant, 
but not WT, TDP-43 in a C. elegans model (Liachko et al. 2010). While this suggests that 
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phosphorylation might alter TDP-43 function, cellular models show that phosphorylation is not 
necessary for TDP-43 aggregation, toxicity, or cleavage (Lee et al. 2011).  
Attempts to assess novel toxicity of TDP-43 C-terminal fragments have yielded mixed 
results. First, overexpression of CTFs in various systems leads to the formation of ubiquitinated 
and phosphorylated cytoplasmic aggregates, potentially implicating fragment accumulation as an 
early pathological event. Inducing cleavage of TDP-43 by introduction of an exogenous cleavage 
site, however, does not lead to CTF accumulation, implying that a second “hit” may be necessary 
to reveal the toxicity of CTFs (Pesiridis et al. 2011). The extent to which pathological CTFs 
detected in mouse models reflect those in patient samples is questionable, based on solubility and 
fractionation experiments (Lee et al. 2011). CTFs harm cultured rodent neurons by a dominant 
negative mechanism rescued by full length TDP-43, arguing for a primary gain of toxicity 
leading to loss of function of TDP-43. In other systems, however, CTFs do not exhibit toxicity 
(Lee et al. 2011). Furthermore, studies in multiple models show that TDP-43 neurotoxicity 
depends on maintenance of its RNA binding ability, arguing against a primary toxicity of CTFs, 
and indicating that toxicity relates to the normal function of TDP-43 in RNA binding. These 
finding do not clarify, however, whether this binding is lost, enhanced, or toxically altered 
(Vanden Broeck et al. 2014). 
Because TDP-43 mislocalizes to the cytoplasm in response to cellular stressors, its 
presence in the cytoplasm of ALS neurons may represent an exacerbated or prolonged stress 
response, leading to a toxic enhancement of normal cytoplasmic function. In primary rat neurons 
expressing fluorescently tagged TDP-43, mislocalization of the fluorescent signal into the 
cytoplasm correlates with neuorotoxicity, worsened by TDP-43A315T expression (Barmada et al. 
2010). NLS TDP-43 mutation in animal models can lead to neurodegeneration, however this 
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phenotype does not differ strongly from overexpression of WT TDP-43 (Lee et al. 2011). 
Cytoplasmic protein, then, may play a role in TDP-43 toxicity but the causality of 
mislocalization, and relation to nuclear clearing, remains uncertain. All of the potentially primary 
gain of function mechanisms described can occur in association with, or lead to, a secondary loss 
of function of TDP-43, either in a particular cellular compartment, or in the entire cell.  
The complexity of subdividing TDP-43 pathogenic mechanisms by their support for a 
loss or gain of function of pathogenic TDP-43 highlights the need for improved systems to study 
TDP-43 pathology. Furthermore, a major obstacle to modeling TDP-43 mediated 
neurodegeneration lies in the toxicity of WT overexpression, rendering detection of mutation-
specific pathology quite difficult. We address this obstacle, and attempt to learn more about the 
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1.6 Summary and Description of Thesis Chapters 
Although ALS was first described over 100 years ago, until recently, study of the disease 
focused mostly on observation of patients and post-mortem tissue. Discovery of the first ALS-
causing mutations in the SOD1 gene permitted a shift in ALS research toward experimentation 
and animal modeling. Despite accurately recapitulating the patient ALS phenotype, and 
providing extensive information about the underlying mechanisms of disease, SOD1-based 
models have not yet yielded effective and clinically translatable treatments. 
Recent advances in ALS genetics, and new findings in ALS patient pathology, have made 
possible novel animal and cellular models of disease that can build on the insights gained from 
the study of SOD1 mutant models. Notably, the identification of ALS-causing mutations in the 
RNA binding protein TDP-43 suggested that aberrant RNA processing may underlie common 
mechanisms of neurodegeneration in ALS and focused attention on the physiological functions 
of TDP-43 that might contribute to disease.  
In this thesis I will present my work in a novel TDP-43 mouse and cellular model that 
aims to further elucidate physiological functions of TDP-43 and understand how a mutation in 
TDP-43 might alter these functions, and assess potential dysfunction in motor neurons 
expressing mutant TDP-43: 
- Chapter 2: I will describe the generation of novel models expressing hTDP-43 from the 
MAPT locus and characterize the effects of TDP-43 mutation on aspects of TDP-43 
function and motor neuron viability. 
- Chapter 3: I will characterize the RNA targets of both mutant and WT hTDP-43 and 
describe mutation-dependent changes in gene expression. In addition, I will compare 
TDP-43 bound and regulated transcripts to those contained within published datasets. 
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- Chapter 4: I will assess mutation and RNA-dependent changes in the protein-binding 
partners of hTDP-43, and compare identified partners to published datasets. 
- Chapter 5: I will draw conclusions from the findings presented in this thesis. 
- Chapter 6: I will describe experimental methods used in this work. 
- Appendix 1: I will characterize the RNA targets of both mutant and WT hTDP-43 in iPS-
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Figure 1.1: ALS pathomechanisms and targets tested in recent preclinical trials 
(McGoldrick et al. 2013) 
 
a range of aberrant cellular dysfunctions caused by mutant TDP-43,
including abnormal neuronal function and synaptic defects [51,52],
deleterious effects on m tochondria [53,54] and proteasome dysfunc-
tion [55]. Although it remains unclear how mutations in TARBP cause
ALS, both loss and gain of function mechanisms have been proposed
[56].
Several groups have attempted to model TDP-43-ALS in rodents
and results have shown varied phenotypes, with no TDP-43-ALS
model currently replicating an ALS-like phenotype. Similar to SOD1
rodent models, development of disease phenotypes in TDP-43-ALS
transgenic rodents is highly dependent upon the promoter used and
the level of transgene expression; however these models display
mostly axonal phenotypes with relatively mild motor neuron cell
death. In marked contrast to SOD1 transgenic mice, overexpression
of human wildtype TDP-43 has been shown to cause significant
neurodegeneration. Moreover, unlike SOD1 transgenic mice, transgene
expression levels of TDP-43 are typically low and founder lines
which have the highest levels of overexpression show early mortality
preventing the generation of transgenic lines with high levels of
overexpression. The TDP-43 transgenic rodent models generated to
date are summarised in Table 2.
3.1. Knock-out of mouse Tardbp to model ALS
Following the identification of ALS causative mutations in TARDBP
[4,5], knock-out mice were developed to determine the effects of
TDP-43 deficiency and to establish whether mutations in TARDBP














































































































Fig. 1. ALS pathomechanisms and targets tested in recent preclinical trials in rodents.
1423P. McGoldrick et al. / Biochimica et Biophysica Acta 1832 (2013) 1421–1436
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Figure 1.2: Genes and pathways implicated in ALS disease progression. 
Genes known to have sequence variants that cause or are associated with ALS are indicated in 
red. These mutations can lead to the formation of protein or protein-RNA aggregates, which 
activate the ubiquitin-proteasome and autophagy pathways, as well as leading activating TBK-1 
containing neuroinflammatory pathways (Cirulli et al. 2015). 
 
 
Figure 1.3: TDP-43 Domain Structure 
RRM1 and RRM2 - RNA-recognition motifs, NLS - bipartite nuclear localization signal, NES – 
nuclear export signal. Vertical lines indicate ALS/FTLD mutations. The arrow indicates the 
putative TDP-43 cleavage site. Known TDP43 phosphorylation sites (S379, S403/S404, and 
S409/S410) are indicated by asterisks. 
 
protein LC3, thereby facilitating the autopha-
gic turnover of infectious bacteria coated with
ubiquitinated proteins, a specific cargo of the
OPTN adaptor (33). Considering that TBK1 colo-
calizes with OPTN and SQSTM1 in autophago-
somes, it is possible that all three proteins
associate with protein aggregates in ALS (33).
Indeed, TBK1 appears to play a role in the deg-
radation of protein aggregates by autophagy
(34). Additionally, OPTN also functions in the
autophagic turnover of damaged mitochondria
via the Parkin ubiquitin ligase pathway (35). Fi-
nally, VCP, encoded by another gene with muta-
tions that cause ALS, also binds to ubiquitinated
protein aggregates. VCP and autophagy are re-
quired for the removal of stress granules (dense
cytoplasmic protein-RNA aggregates), which are
a common feature of ALS pathology (36). Thus,
OPTN, SQSTM1, VCP, and TBK1 may be critical
components of the aggresome pathway required
for the removal of pathological ribonucleoprotein
inclusions (37). It appears that defects in this path-
way can be selective for motor neuron death, in
some cases apparently sparing other neuronal
cell types.
In addition to their roles in autophagy, OPTN,
SQSTM1, and TBK1 all function in the NF-kB
pathway (Fig. 3) (27, 38). For example, IkB ki-
nases (IKKa and IKKb) phosphorylate the IKK-
related kinase TBK1, which in turn phosphorylates
the IkB kinases, suppressing their activity in a
negative autoregulatory feedback loop (39). TBK1
also phosphorylates and activates the transcrip-
tion factor IRF3 (40–42) and the critical innate
immunity signaling componentsMAVSandSTING
(43). The coordinate activation ofNF-kB and IRF3
turns on the transcription of many inflammato-
ry genes, including interferon-b (44). The innate
immune pathway and neuroinflammation in
general are thought to be important aspects
of neurodegenerative disease progression (45).
Thus, pathogenic variants in OPTN, SQSTM1, or
TBK1 would be expected to lead to defects in
autophagy and in key innate immunity signaling
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Fig. 2. Variants in TARDBP and VCP. Dominant coding variants are shown in TARDBP and VCP (dis-
covery data set). Case variants are enriched at the 3′ end of the gene in TARDBP and near the cell division
protein 48 domain 2 region in VCP. LoF variants are filled in red, and nonsynonymous variants are filled in
blue. Case variants are shown with red lines, control variants are shown with blue lines, and variants found
in both cases and controls are shown with dashed lines.
Fig. 3. Genes and path-
ways implicated in ALS
disease progression.
Genes known to have
sequence variants that
cause or are associated with
ALS are indicated in red.
These mutations can lead to
the formation of protein or
protein-RNA aggregates
that appear as inclusion
bodies in post mortem
samples from both familial
and sporadic ALS patients.
Some of the mutant pro-
teins adopt “prion-like”
structures (see text for
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Figure 1.4: Amino acid sequence alignment of the eukaryotic TDP-43 proteins.  
The amino acid sequences of TDP-43 proteins of human (hTDP-43), mouse (mTDP-43), D. 
melanogaster (dTDP-43), and C. elegans (cTDP-43) are aligned, with identical and similar 
amino acids indicated in the black and gray boxes, respectively. The two RRM domains and the 
RNP motifs are underlined with gray and black lines, respectively. The glycine-rich regions of 
the mammalian and fly TDP-43 proteins are boxed. The positions of the introns in each TDP-43 
are indicated with dotted boxes uniting two codons (phase 0) or containing one codon (phase 1 or 
2; Wang et al. 2004). 
symbol TARDBP). During a search for genes expressed in
specific regions of the mouse brain, we have cloned two
isoforms of TDP: mTDP-L, hic encodes the mouse
ortholog of human TDP-43, and mTDP-S [10]. Of the
two, mTDP-S protein is located in a class of nuclear
subs ructure termed TB, or TDP-nuclear body. The TBs
appear to link several other types of nuclear bodies,
including POD, CB, GEM, and speckles [10], all of which
have been implicated in the regulation of transcription and/
or splicing, among other nuclear activities [11]. mTDP-S
also appears to interact in vivo with the spinal motor
neuron (SMN) [10], a protein required for the general
assembly of the spliceosomes [12]. These cellular and
biochemical findings again tie well with the known dual
functions of TDP-43, i.e., transcription repression and exon
skipping.
In the following, we report the structure and evolution
analysis of the mammalia TDP genes, in compariso to the
TDP genes of Caenorhabditis elegans and Drosophila
melanogaster. The mammalian TDP genes turned out to
belong to a gene family. We also show that in addition to
TDP-43, there are at least 10 other alternatively spliced
isoforms of TDP expressed in mammalian cells. Finally, we
present evidence that the glycine-rich domain is essential for
Fig. 1. Amino acid sequence alignment of the eukaryotic TDP-43 proteins. The amino acid sequences of TDP-43 proteins of human (hTDP-43), mouse
(mTDP-43), D. melanogaster (dTDP-43), and C. elegans (cTDP-43) are aligned, with identical and similar amino acids indicated in the black and gray boxes,
respectively. The two RRM domains and the RNP motifs are underlined with gray and black lines, respectively. The glycine-rich regions of the mammalian and
fly TDP-43 proteins are boxed. The positions of the introns in each TDP-43 are indicated with dotted boxes uniting two codons (phase 0) or containing one
codon (phase 1 or 2).
H.-Y. Wang et al. / Genomics 83 (2004) 130–139 131
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Figure 1.5: TDP-43 Autoregulation 
TDP-43 binds to the 3ʹUTR of its own mRNA to promote degradation, at least partly through the 
exosome. There are conflicting reports about the mechanism of autoregulation, in particular 
whether alternative splicing leading to nonsense-mediated decay (NMD) is the mechanism of 
TDP43 autoregulation (Lee et al. 2011). 
 
 
Figure 1.6: RNA processing pathways controlled by TDP-43.  
The major nuclear and cytoplasmic processes in which TDP-43 has been shown to play a role 
under physiological conditions are shown. Key protein–protein interactions with hnRNPs and 
FUS/TLS are shown together with the pathways that are most affected by these interactions. 
Ovals represent TDP-43 (green), FUS-TLS (yellow), hnRNP of the A/B family (orange), other 
hnRNPs proteins or factors (grey). The red line represents RNA and the continuous black line 
represents DNA (Buratti&Baralle 2010). 
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Gene Symbol Pathway/Process 
Mendelian/High Risk Genes 
GRN Autophagy; lysosomal pathway; inflammation 





SOD1 Toxic aggregation 
C9orf72 Toxic RNA or dipeptide aggregation  
FUS DNA/RNA metabolism  
TARDBP DNA/RNA metabolism  
SPG11 DNA damage repair 
SETX DNA/RNA processing 
MATR3 DNA/RNA metabolism 
TAF15 RNA metabolism 
HNRNPA1 RNA metabolism  
HNRNPA2B1 RNA metabolism 
GLE1 RNA metabolism  
VAPB Vesicle trafficking  
DCTN1 Vesicle trafficking  
SIGMAR1 Endoplasmic reticulum lipid rafts 
ERLIN2 Endoplasmic reticulum lipid rafts 
TBK1 Neuroinflammation 
PFN1 Cytoskeleton 
ERBB4 Dysregulation of the neuregulin-ErbB4 pathway 
ARHGEF28 Interaction with NEFL 
PNPLA6 Neurite outgrowth and process elongation 
PRKAR1B metabolism; ion transport; transcription 
ANG Blood vessel formation 
CHCHD10 Mitochondrial function 
ALS2 Modulator for endosomal dynamics  
DAO Excitotoxicity? 
Low Risk/Susceptibility Genes 
TMEM106B  lysosomal pathway; progranulin pathways  
NEFH Cytoskeleton 
PRPH Cytoskeleton 
ELP3 RNA metabolism 
SMN1 RNA metabolism 
ATXN2 Modifier of TDP-43 toxicity 
KCNN1  Neurotransmitter release/neuronal excitability  
FIG4 Polyphosphoinositide phosphatase 
DPP6 peptidase 
VEGF growth factor 
PON1,2,3 organophosphate hydrolysis 
HFE iron absorption 
KIFAP3 small G protein 
 
Table 1.1: ALS Disease Genes (adapted from Guerreiro et al. 2015, Leblond et al. 2014) 
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Table 1.2: TDP-43 Rodent Models 
Levels are expressed as fold change compared to endogenous mouse TDP-43 expression levels. 
“TDP-43 protein” refers to the human protein unless otherwise noted (ms = the mouse protein). 
ND – not described, Y – yes, dashes indicates absence, (i) – inducible TetOff system, rating 
system ranges from + (rarely seen) to +++ (frequently seen). A indicates presence of the 





























































































mPrp A315T 3 ++ + A ND Y 0 20% Y 90 154 gait Wegorzewska,@2009
mPrp A315T 3 + + ND ND NA 20% 0 Y ND ND ++ Herdewyn@et@al.@2014
mPrp WT 3 ND ND D ND Y 0 ND Y ND >330 ++ Stallings@et@al.@2010
mPrp A315T 4 + ++ A ++ Y 0 ND Y ND 75 weakness,@gait Stallings@et@al.@2010
mPrp WT 2.5 + ++ D ++ Y ND 0 Y 21 45 clasp,@tremors,@gait Xu,@2010
mPrp M337V 2.7 + ++ D +++ Y ND 0 Y 21 30 clasp,@tremors,@gait Xu,@2011
Thy1.2 WT 2 ++ ++ D + Y ND 25% Y 20 <30 paralysis,@clasp Wils@et@al.@2010
Thy1.2 M337V 1.8 ++ ++ D ++ Y ND Y Y 12 17 clasp,@tremors,@gait Janssens@et@al.@2013
Thy1.2 WT 3.6 + ++ D ND + No ND Y 16 ++ clasp,@tremors,@gait Shan@et@al.@2010
Thy1.2 25@kDa@CTF 4.7 + + + + Y ND ND ND NA ++ ++ Caccamo@et@al.@2012
CamKII@(i) WT 3 ND ++ D ++ Y ND Y Y ND 60 ND Cannon@et@al.@2012
CamKII@(i,@P21) WT 3 ND ++ A ++ Y ND Y Y ND >360 ND Cannon@et@al.@2012
CaMKII ms@WT@cDNA 2 ++ ++ A + Y ND 24 Y 180 495 clasp,@rotarod Tsai@et@al.@2010
CamKII@(i) WT 0.8 + + No + + ND 20 Y 75 ND clasp Igaz@et@al.@2011
CamKII@(i) ΔNLS 7.9 +++ + A + + ND 50 Y 7 180 clasp Igaz@et@al.@2011
BAC WT 3 ++ ++ A ND + 5% 0 Y 294 ND rotarod Swarup@et@al.@2011
BAC A315T 3 +++ +++ A ND Y ND 0 Y 266 ND rotarod Swarup@et@al.@2011
BAC G348C 3 +++ +++ A ND Y 10% 0 Y 252 ND rotarod Swarup@et@al.@2011
mPrp WT 1 + + + + + 0 0 Y NA ++ ++ Arnold@et@al.@2013
mPrp M337V 1 + + + + + 0% 0 Y 300 ++ rotarod Arnold@et@al.@2013
mPrp Q331K 1.5 + + + + + 30% 35% Y 90 ++ tremors,@weakness Arnold@et@al.@2013
endogenous A315T 3 ++ ++ A + + ND 10% ND 90 ++ gait Stribl@et@al.@2014
NA constitutive@KO ND ND ND ND ++ ++ Wu@et@al.@2009
NA constitutive@KO ND ND ND ND E6.5 ++ Sephton@et@al.@2010
NA constitutive@KO ND ND ND ND E7.5 ++ Kraemer@et@al.@2010
NA conditional@KO ND ND ND ND 9 ++ Chiang@et@al.@2010
Hb9+Cre conditional@KO ND 46 Y 100 300 rotarod,@kyphosis Wu@et@al.@2012
VaChT+Cre conditional@KO 40% Y Y 350 ++ tremor,@weakness Iguchi@et@al.@2013
BAC WT ND ++ + D D Y ND 0 N NA >200 ++ Zhou@et@al.@2010
BAC M337V ND Y ND 15 20 weakness,@paralysis Zhou@et@al.@2010
CMV@(i) M337V ND ++ + D D Y 40% 12 Y 40 55 weakness,@paralysis Zhou@et@al.@2010
NEF@(i) M337V 2 ND + A ND ND 0% 20% ND 14 ND weakness,@paralysis Huang@et@al.@2012
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Chapter 2 
Generation and Characterization of novel models expressing hTDP-43 
from the MAPT locus  
 
 
2.1 Introduction  
As discussed in Chapter 1, the identification of mutations in TDP-43, as well as FUS and 
an increasing number of other genes (Table 1.1), have focused the attention of ALS researchers 
on understanding the normal function of these proteins and how mutation may affect those 
functions. The ubiquity of TDP-43 pathology in ALS patients suggests that an understanding of 
how TDP-43 mutations cause ALS might be broadly applicable to the ALS patient population. 
The discovery of these connections between TDP-43 and ALS has provided a foundation for the 
development of new animal models to complement the existing SOD1 model in identifying 
broadly relevant disease mechanisms and therapeutic targets.  
Table 1.2 shows the tremendous efforts made to produce reliable rodent models of TDP-
43-mediated neurodegeneration, as well as the, thus far, unpromising outcomes. The greatest 
weakness of these models lies in their inability to recapitulate at once the phenotypic, cellular, 
and molecular aspects of human disease. In addition, the toxicity of overexpressed WT TDP-43 
has hindered studies that attempt to identify mutation-dependent neurodegenerative changes. 
They highlight the necessity for additional, controlled model systems that more faithfully mimic 
ALS. 
To address this necessity, we chose a knock-in approach in which we generated targeted, 
conditional mice in which a single copy of a wild type, or ALS-associated mutant, cDNA 
transgene of human TDP-43 (hTDP-43) is conditionally expressed from the MAPT (τ) locus. 
This approach overcomes the disadvantages of transgenic and bacterial artificial chromosome 
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(BAC) genetic manipulation techniques.  The reproducible transgene expression in these models 
makes them well-suited for direct comparison of wild type and mutant hTDP-43, and a myc-tag 
provides a useful biochemical and immunohistochemical tool to study hTDP-43 function.  
 In this Chapter, we investigate whether τ model systems exhibit hallmarks of ALS. We 
determine genotype and species-specific effects on the subcellular localization of TDP-43, as 
well as assessing genotype and genetic background-dependent effects on MN function and 
survival, both in vivo and in cell culture. Despite a lack of ALS-like features in the context of a 
pure Bl6 genetic background, we report promising initial data from τON mice bred on a mixed 
genetic background.  
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2.2 Results 
Generation of novel mouse line expressing hTDP-43 from the MAPT promoter 
To further investigate the physiological functions of hTDP-43, and assess the effects of 
an ALS-causing mutation in TDP-43 on protein function and motor neuron survival, we 
generated mouse lines expressing wild type (WT), or the ALS-associated M337V mutant, human 
TDP-43. We avoided the limitations of standard transgenic mouse model derivation by targeting 
the mouse MAPT (tau (τ)) gene (Hippenmeyer et al. 2005) to introduce a cDNA encoding wild 
type (hTDP-43WT) or ALS mutant (hTDP43M337V), human TDP-43. The cDNA additionally 
encodes an N-terminal myc tag to label the exogenous hTDP-43 protein. Homologous 
recombination in Ola/129 murine embryonic stem cells (ESCs), followed by outcrossing to the 
murine C57BL/6J generated two conditional mouse lines referred to as τOFFhTDP-43WT, and 
τOFFhTDP-43M337V.  
A neomycin (NEO) selection cassette flanked by loxP sites precedes the hTDP-43 cDNA 
in the τOFF allele. The loxP sites function as a transcriptional stop to silence the recombinant tau 
allele. However, upon expression of Cre recombinase, the stop is removed and hTDP-43 is 
expressed from the mouse τ locus (Figure 2.1A). To compare the effects of WT mutant hTDP-43 
expression in vivo, we first crossed the τOFFhTDP-43WT and τOFFhTDP-43M337V conditional 
mouse lines to the germline CRE deleter line Prmt1-Cre (O’Gorman et al. 1997) to generate the 
τONhTDP-43WT and τONhTDP-43M337V lines in which myc-tagged hTDP-43 is expressed 
constitutively in all τ-expressing cells, including neurons, as well as some oligodendrocytes and 
astrocytes (Migheli et al. 1988). All mutants analyzed were heterozygous for the τONhTDP-43 
allele in order to faithfully mimic the ALS patient condition of dominantly inherited mutations in 
TDP-43, and Sanger sequencing of the hTDP-43 cDNA revealed the presence or absence of the 
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M337V (1009A>G) point mutation (Figure 2.1B). Immunohistochemical analysis of the 
τONhTDP-43M337V demonstrated expression of myc-hTDP-43 in neurons and non-neuronal cells 
(Figure 2.1C) in a pattern consistent with the known pattern of MAPT expression in the spinal 
cord (Bloom et al. 1984). 
Both cell autonomous and non-autonomous mechanisms contribute to MN degeneration 
in the SOD1G93A mouse model of ALS (Ilieva et al. 2009). To determine the cell autonomous 
nature of hTDP-43 function or dysfunction, we used a ChAT-Cre deleter strain (Rossi et al. 
2011) crossed to the conditional τOFFhTDP-43WT and τOFFhTDP-43M337V lines. We refer to this 
series of mice as the τMN mouse lines, expressing myc-hTDP-43 exclusively in ChAT-positive 
cells. In each case, τ-myc-hTDP43 protein expression is restricted almost exclusively to MNs in 
the vental horn, with additional expression in the limited number of ChAT+ cells elsewhere in 
the spinal cord (Figure 2.1D). 
 
Mutant hTDP-43 causes MN degeneration in the mixed τON mouse model 
(Mixed C57BL/6 and Ola129 genetic background, collaboration with Dr. Aarti Sharma) 
We were first interested in whether hTDP-43M337V expression might result in motor 
neuron dysfunction or death. Strikingly, in our initial breeding of a small cohort of τONhTDP-
43M337V mice on a mixed C57BL/6 and Ola129 genetic background, mutant mice exhibited clear 
evidence of MN degeneration.  
To determine the extent of motor neuron loss resulting from hTDP-43M337V expression, 
we encircled and counted MNs at lumbar spinal level 5 (L5), visualized with an antibody against 
choline acetyl transferase (ChAT, Figure 2.4A). Already at P30, mice in this group showed 
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modest but significant loss of ~5.2% of ChAT immunoreactive (ChAT-IR) L5 MNs, increasing 
to 8% by P90 (Figure 2.2A), and preferentially affecting large caliber α-MNs.  
To determine whether MN loss was accompanied by skeletal muscle denervation, motor 
axon terminals were visualized with an antibody against either vesicular acetylcholine 
transporter (VAChT) or synaptophysin, and the post-synaptic surface of the neuromuscular 
junction (NMJ) was identified using a fluorescent conjugate of α-bungarotoxin (α-BTX, Figure 
2.4B). Denervation of NMJs in the TA muscle also reaches significance at P30 and progresses to 
10% by P90 (Figure 2.2A), without any denervation of the slow twitch soleus muscle, which is 
preferentially spared in ALS (Hegedus, Putman, and Gordon 2007).  
At ~16 months of age these mice developed selective, distal, hindlimb weakness and an 
obvious, associated gait disturbance, as captured in two images (Figure 2.2B) from the following 
video: Ton hTDP43 M337V gait. This was followed by premature death at 18 months of age. At 
the time of death, greater than 45% of all L5 MNs are lost (n=1, Figure 2.2D) in this cohort of 
τONhTDP-43M337V mice, and as γ-MNs are spared, this corresponds to a loss of over 60% of the 
large diameter α-MNs. Moreover, there is a selective loss of dorsiflexors in the dorsolateral 
region of the L5 spinal cord (Figure 2.2C), consistent with a loss of vulnerable fast-twitch MNs. 
This is promising evidence of ALS-related hTDP-43M337V toxicity in this mouse model. 
 
Encouraged by the results from the mixed background breeding, we devoted our efforts 
to the generation of mutant animals on a pure Bl6 genetic background, as this is commonly used 
for maximal expression of mutant alleles (Champy et al. 2008), and a pure background 
eliminates the possibility of genetic modifiers differentially affecting mutant and WT mice. This 
purity is particularly desirable for the biochemical experiments conducted in Chapter 3 and 4 of 
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this thesis. For this reason, analyses conducted in the rest of the thesis, including the generation 
of embryonic stem cell lines, utilized τONhTDP-43 mice bred on a pure C57BL/6 (Bl6) genetic 
background. Because the behavioral motor phenotype, coupled with MN loss and denervation, 
did not occur on the mixed background until 18 months of age, we did not become aware of the 
lack of this phenotype on the pure Bl6 background until after completion of many of the 
described experiments. Despite this unfortunate occurrence, the data described here does 
evaluate whether the M337V mutation alters normal functions of TDP-43, and therefore 
contributes to an understanding of ALS disease mechanisms, albeit in the context of published 
accounts of TDP-43 toxicity, and the toxicity seen on the mixed genetic background. 
  
Comparable levels of wild type and mutant hTDP-43 expression in τON mice  
A difference in the level of expression of mutant compared to WT TDP-43 is a prominent 
shortcoming of existing transgenic TDP-43 mouse models (Table 1.2). We hypothesized that, by 
targeting the Tau locus and therefore utilizing the same promoter to express a single copy of 
hTDP-43 cDNA, we might overcome this shortcoming in our model.  
To address this hypothesis, we quantified mRNA levels of human TDP-43 (Figure 2.3A-
B1, primers 3 and 4) in the mouse spinal cord, and found no significant difference in expression 
levels of hTDP-43M337V compared to hTDP-43WT. Consistent with this result, Western blotting of 
mouse spinal cords revealed that hTDP-43M337V protein levels did not differ significantly from 
hTDP-43WT (Figure 2.3C, myc panel). Importantly, the equal RNA and protein levels detected 
here will enable meaningful comparisons in the phenotypic characterization of τON mice.  
Although we found the comparable expression levels of hTDP-43 promising, we 
questioned what effect exogenous TDP-43 expression might have on endogenous mouse TDP-
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43, and how levels of the mouse and human proteins might compare. This was of particular 
concern because of known TDP-43 autoregulatory mechanisms (Bembich et al. 2014), and the 
fact that mouse models overexpressing human TDP-43 detect downregulation of mouse TDP-43. 
Our first concern was with the levels of endogenous mouse TDP-43 (mTDP-43). If hTDP-43 
downregulates mTDP-43, we would expect to see lower levels of mTDP-43 transcript in control 
mice not expressing hTDP-43 (Ctrl), compared to τON mice expressing hTDP-43. We find, 
however, equivalent mTDP-43 expression in control and τON mouse spinal cords, by amplifying 
a region in the 3’UTR of the TDP-43 transcript that is absent from the hTDP-43 mRNA (Figure 
2.3B1, left panel). We were additionally interested in what effect hTDP-43 expression has on 
total TDP-43 RNA levels and found, from our RNA-Seq data (dataset described in Chapter 3), 
that total TDP-43 RNA did not change in mice expressing hTDP-43 compared to controls 
(Figure B2). From these experiments, we could not determine the ratio of hTDP-43 to mTDP-43 
mRNA.  
Western blotting, however, revealed a human to mouse TDP-43 ratio of approximately 
0.24 in mice expressing hTDP-43 (Figure 2.2C2). Because we detected no significant difference 
in mTDP-43 protein levels between the three genotypes, this corresponds to a 20% increase of 
total TDP-43 in τON mice. Thus, TDP-43 protein levels are slightly higher in τONhTDP-43 
expressing mice, although RNA levels are equivalent.  
 
Increased cytoplasmic distribution of hTDP-43 protein in τON mice  
Having determined the relative levels of endogenous mouse and human TDP43 RNA and 
protein, we were next interested in determining whether hTDP-43 exhibits a different subcellular 
localization compared to that of mTDP-43, and whether the disease-causing mutation affects this 
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localization. To address this question, we performed a subcellular fractionation experiment in the 
mouse spinal cord. We find that endogenous mTDP-43 segregates predominantly in the nuclear 
fraction although we detect the protein in the cytoplasm as well (Figure 2.3D). The percentage of 
mTDP-43 localizing to the nucleus is ~89% regardless of genotype (Figure 2.3D, percentage of 
~45 kDa signal in nuclear fraction compared to total signal in both fractions). In the case of myc-
hTDP-43, however, the percentage localized to the nucleus is ~60% of the total myc signal in the 
nucleus and cytoplasm, almost 30% lower than mTDP-43 (Figure 2.3D, myc-probed panel). We 
used RNA Pol II as a nuclear marker because, unlike histones, it is less likely to precipitate with 
chromatin, and GAPDH as the cytoplasmic marker. These results indicate that myc-hTDP-43 
localizes to the nucleus to a lesser extent than endogenous mouse TDP-43, and therefore a 
greater percentage of the myc-tagged protein resides in the cytoplasmic compartment. We do not 
see mutation-dependent effects on fractionation. We conclude that in our mouse model the ALS 
causing mutation in human TDP43 does not significantly affect the nuclear/cytoplasmic 
distribution of the protein. 
  
Effects of mutant hTDP-43 expression on motor neuron survival in vivo 
(C57BL/6 (Bl6) genetic background) 
Mutant hTDP-43 does not cause cell autonomous MN degeneration in the τMN mouse model 
Based on the motor phenotype and MN loss in mice generated on a mixed genetic 
background, we were interested in whether mutant hTDP-43 mediates MN degeneration in a cell 
autonomous manner. To determine whether the selective expression of hTDP-43M337V primarily 
in MNs caused cell autonomous degeneration in vivo, we counted ChAT-IR MNs in the L5 
spinal cord (ChAT, Figure 2.4A). At 12 months of age, there was no significant difference in the 
	  
	   58	  
number of ChAT immunoreactive (ChAT-IR) MNs in the τMNhTDP-43M337V (98% of control 
MN number) compared to the τMNhTDP-43WT (100% of control MN number) and non-τMN, WT, 
littermate controls (Figure 2.4C). This indicates the absence of a cell autonomous effect of 
mutant TDP-43 expression on MN survival in vivo, however it does not rule out MN 
dysfunction. 
To determine whether, as with broad expression on the mixed background, expression of 
mutant hTDP-43 selectively in ChAT-expressing cells resulted in the withdrawal of motor axons 
from muscles innervated by FF motor units, we looked for denervation in the tibialis anterior 
(TA) muscle (Figure 2.4A). Concordant with no MN loss in the τMNhTDP-43M337V mice, we also 
did not detect any significant denervation of the TA muscle at P360 in τMNhTDP-43M337V (98% 
of NMJs innervated) or τMN TDP-43WT (98% of NMJs innervated) mice (Figure 2.4C). These 
data indicate no cell autonomous effect on MN function or survival with mutant hTDP-43 
expressed almost exclusively in MNs on a pure Bl6 background. 
 
Genetic background effect on MN degeneration in the τON mouse model 
To determine whether the motor phenotype seen on the mixed genetic background 
persists in mice bred on the pure C57BL/6 genetic background, we counted ChAT-IR MNs in the 
L5 spinal cord of τON mice and their littermate controls bred on a pure Bl6 background. Even at 
the late age of 30 months, in τONhTDP-43M337V mice there was no significant difference in the 
number of ChAT-IR MNs compared to controls (Figure 2.4D), Similarly, we did not appreciate 
any significant denervation of NMJs in τONhTDP-43M337V (98% of NMJs innervated) or 
τONhTDP-43WT (99% of NMJs innervated) mice compared to WT littermate controls (Figure 
2.4D). These results demonstrate that, on the Bl6 background, even expanded expression of 
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hTDP-43M337V in all Tau-positive cells does not affect MN survival in the lumbar region of the 
spinal cord.  
 
Generation and characterization of an embryonic stem cell model expressing hTDP-43  
Despite the absence of an ALS phenotype in mice on a pure Bl6 background, the mixed 
background cohort had demonstrated the ability of the τONhTDP-43M337V allele to affect MN 
survival. Therefore, we elected to develop a cell culture system in which to study those effects. 
Recent advances in cell culture and ES cell differentiation techniques have revealed the facility 
of ESC-derived MNs (ES-MNs) in studying MN function and dysfunction, particularly related to 
ALS (DiGiorgio et al. 2007, Phatnani et al. 2013). To capitalize on these advances, which allow 
for the rapid generation and isolation of large numbers of purified MNs that can be characterized 
by automated tools, we crossed the τONhTDP-43WT and τONhTDP-43M337V hemizygous mice to 
Hb9::GFP transgenic mice (Wichterle et al. 2002). The Hb9 gene encodes a homeodomain 
transcription factor expressed in all post-mitotic motor neurons, providing both a means of 
monitoring differentiation, and a marker for separating motor neurons from other cell types 
(Arber et al. 1999, Thaler et al. 1999, Wichterle et al. 2002). I isolated blastocyst-stage embryos 
from the above crosses and generated two ESC lines per genotype containing either one of the 
τON alleles and the Hb9::GFP transgene, or exclusively the Hb9::GFP transgene as controls (Ctrl) 
(Figure 2.6A and C).  
We differentiate these ESCs toward a motor neuron lineage by exposure to retinoic acid 
and a sonic hedgehog agonist (Wichterle et al. 2002), and use fluorescence activated cell sorting 
to isolate highly green fluorescing cells (Figure 2.6A). By FACS, we found no statistically 
significant genotype-specific difference in the percentage of differentiating ESCs that expressed 
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GFP (Figure 2.6D). GFP-positive ES-MNs exhibit a neuronal morphology with primarily nuclear 
myc immunoreactivity. Although we detect TDP-43 immunoreactivity primarily in the nuclei of 
all cells in a mixed culture of ES-MNs, myc expression is restricted to a subset of cells, which 
includes the GFP-positive MNs (Figure 2.5A). 
Similar to the τON mice, τON ES-MNs express hTDP-43 transcript and protein at the same 
level, regardless of genotype. We detect higher (30% of endogenous) hTDP-43 protein levels in 
ES-MNs (Figure 2.5B-C) compared to spinal cord lysates (20% of endogenous). This higher 
percentage of hTDP-43 in ES-MNs likely results from the greater percentage of cells in purified 
samples that express the myc-tagged protein compared to in heterogenous spinal cord samples. 
As in the spinal cord, hTDP-43 does not significantly downregulate endogenous mTDP-43 
(Figure 2.5C). Likewise, the equivalent expression levels between WT and mutant hTDP-43 ES-
MNs allows for the assessment of mutation-dependent, and therefore ALS-relevant, phenotypic 
and biochemical changes, uncomplicated by expression level differences.  
To assess the effect of hTDP-43 expression on MN survival, we conducted cell viability 
assays under different culture conditions by plating ES-MNs in 96 well plates, live imaging each 
well at various time points, and using the Metamorph software neurite outgrowth algorithm 
(Molecular Devices) to calculate the number of GFP+ neurons per well (Figure 2.7A). Although 
hTDP-43M337V unsorted ES-MNs (uES-MNs) initially showed a trend toward decreased viability 
compared to hTDP-43WT uES-MNs, averaging results from multiple differentiations and 
replicate ESC lines ultimately rendered this difference insignificant (Figure 2.7D). Similarly, 
hTDP-43M337V sorted ES-MNs (sES-MNs) co-cultured with non-transgenic glia conditioned 
media, showed no viability deficits compared to WT (Figure 2.7C).  
Because normal culture conditions did not reveal a viability phenotype, we were 
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interested in assessing the effect of SOD1G93A on τON ES-MNs. Mutant SOD1 glia are toxic to 
cultured motor neurons, and preferentially affect the survival of mutant (Di Giorgio et al. 2007, 
Nagai et al. 2007). Additionally, SOD1G93A glia have a greater negative effect on the survival of 
iMNs expressing mutant hTDP-43 than WT glia (Carrasco, personal communication). While 
sES-MNs from both τON lines showed decreased viability when cultured over SOD1G93A glia 
compared to SOD1WT glia, the viability was affected to the same extent for hTDP-43M337V and 
WT expressing cells (Figure 2.7B). Thus, consistent with in vivo experiments described above, 
τONhTDP-43M337V expression does not alter the viability of ES-MNs grown in cell culture during 
the time frame of our experiments. Also consistent with in vivo experiments, ES-MN viability 
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2.3 Discussion 
In this chapter, we characterize a novel TDP-43 model expressing human, myc-tagged, 
WT or M337V mutant, TDP-43 cDNA from the MAPT locus. We chose to introduce the M337V 
mutation into our mouse model because it was among the first ALS-causing mutations in TDP-
43 identified in human patients (Rutherford et al. 2008), and one of the mutations frequently 
studied in other mouse models (Table 1.2), allowing for more direct comparisons to published 
data. We targeted hTDP-43 cDNA to the MAPT locus because it is efficiently targeted, has a 
predominantly neuronal expression pattern, and an efficient promoter which proved to express 
both mutant and WT hTDP-43 at the same transcript and protein levels. This is a very promising 
result as it allows for direct comparison of mutant and WT τ mice without the confounding factor 
of differing expression levels found in many published transgenic models (Table 1.2). The 
relatively low expression levels of hTDP-43 compared to mTDP-43, however, represent a 
drawback of this model as they likely contribute to a lack of phenotype on the Bl6 background 
and the lengthy timecourse of the mixed background phenotype. 
Interestingly, our data indicate that hTDP-43 does not downregulate endogenous mTDP-
43. It is well established that TDP-43 autoregulates its transcript levels via a negative feedback 
loop in which it binds to the 3’UTR of its own mRNA (Bembich et al. 2014). The hTDP-43 
cDNA lacks the autoregulatory 3’UTR of endogenous TDP-43. We might expect, therefore, that 
hTDP-43 might be expressed at relatively high levels in the τON spinal cord and ES-MNs, and 
that this would then lead to downregulation of mTDP-43. Pooled expression data in the BioGPS 
gene portal (Wu et al. 2009) reveals that levels of TDP-43 expression in the mouse spinal cord 
are roughly 4-fold greater than Tau expression levels. Therefore, our results are consistent with 
differences in promoter strength between TARDBP and MAPT.   
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Because hTDP-43 composes only a fraction of total cellular TDP-43, increased 
cytoplasmic localization of hTDP-43 is a rather surprising result. Table 1.2 seems to show a 
loose correlation between expression level and mislocalization. A difference in the nuclear 
localization signal (NLS) between the mouse and human protein could account for such a 
localization difference, however the bipartite NLS is identical between the two species (Ayala et 
al. 2008, Wang et al. 2004). Differential interactions with RNA or protein binding partners, then, 
is more likely to account for the difference in subcellular distribution. Mouse TDP-43 may form 
higher affinity interactions with its binding partners in the nucleus, leaving hTDP-43 unbound, 
potentially leading to cytoplasmic shuttling. We expected that increased hTDP-43 levels in the 
cytoplasm might lead to aggregation, but were not surprised that our τON lack ALS-like 
aggregates. Perhaps because of the lifespan of mouse model systems, or a difference between 
mouse and human nervous system physiology, aggregates have not been found to correlate with 
toxicity in mouse TDP-43 models. This may also reflect a lack of ability, thus far, to accurately 
model TDP-43-mediated neurodegeneration. 
Strikingly, the mutant hTDP-43 transgenic line shows MN degeneration when expressed 
on a mixed genetic background, however, this phenotype is lost after breeding transgenic animal 
to pure Bl6 backgound. Phenotypic variability on different mouse genetic backgrounds is well 
documented (Davisson et al. 2012). Such findings mimic results in humans where the same 
mutation might present with variable penetrance depending on the individual. Genetic modifiers 
likely cause this variability, and might account for the presence of a motor phenotype in 
τONhTDP-43M337V mice on a mixed genetic background but the complete absence of this 
phenotype on the pure C57Bl/6 background. The pure background does, however, increase the 
signal-to-noise ratio in transcriptomic and proteomic experiments such as those described in 
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previous chapters. For phenotypic analysis, however, the pure background severely hinders 
disease modeling, despite it being generally permissive to expression of mutant alleles.  
 This chapter presents important information in understanding how mutant TDP-43 leads 
to ALS, and strongly implicates additional genetic factors in the neurodegenerative process. 
Because of the equivalent expression of mutant and WT hTDP-43, as well as the knock-in 
approach used in its generation, this is an ideal system in which to evaluate genotype-dependent 
contributions to MN degeneration. The major direction of future efforts in pursuing this model is 
toward recovering the ALS phenotype by crossing pure C57Bl/6 mice to mixed backgrounds. 
That situation would permit comparison of the phenotype-permissive and prohibitive genetic 
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Figure 2.1 Generation of τ  hTDP-43 Mouse Lines 
(A) The MAPT(τ) locus (upper panel), the τ locus with knock-in of myc-hTDP-43 cDNA 
preceded by a floxed NEO cassette (middle panel, τOFF), and the τ locus after crossing to a Cre-
deleter mouse line with the NEO cassette removed permitting expression of myc-hTDP-43 
(lower panel, τON). (B) Sanger sequencing of amplified myc-hTDP-43 cDNA showing the 
M337V, or 1009A>G mutation in the mutant but not the WT mouse line. (C and D) Myc 
expression in the L5 spinal cord of τON, showing broad expression throughout the ventral horn, 
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Figure 2.2: τONhTDP-43M337V lead to MN loss and muscle denervation (mixed background) 
(A) Significant loss of MNs (p-value = 0.02) and denervation of NMJs (p-value = 0.01)  with 
mutant hTDP-43 expression compared to control mice starting at P90. (B) Overt motor 
phenotype evidenced by (left) difficulty grasping the wire cage lid with hindlimbs and (right) 
dragging of hindlimbs with impaired gait. (C) Immunohistochemical evidence of loss of 
dorsiflexor MNs in the upper region of the ventral horn. (D) MN loss reaches 45% of WT levels 
and TA denervation reaches 60% in 18 month-old mouse depicted in D. 
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Figure 2.3 Expression levels and subcellular localization of myc-hTDP-43 in τON mice 
(A) Primers used to specifically amplify mouse (1 and 2), and human (3 and 4) TDP-43. (B1) 
RT-qPCR analysis of mouse and human TDP-43 transcripts in total spinal cord (top panel).  
The bottom panel shows the specificity of primers 1 and 2 amplifying a 178bp band from the 
3’UTR of mTDP-43 (left) and primers 3 and 4 amplifying a 217bp band from the myc-hTDP-43 
allele that is only found in τON animals (right). (B2) Levels of total TDP-43 RNA, as determined 
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spinal cord extracts from control and τON animals revealed that human TDP-43 migrates at 
higher molecular weight (70 kDa band, upper and middle panels) compared to mouse TDP-43 
(45 kDa band, middle panel). Quantification of mouse and human TDP-43 is expressed as a 
fraction of total TDP-43 protein (C2). (D) Western blot analysis of human and mouse TDP-43 
from total spinal cord extracts. Spinal cords were subjected to subcellular fractionation and 
proteins are shown from the cytoplasmic and nuclear fractions. Pol II was used as a nuclear 
marker (upper panel), and GAPDH was used as a cytoplasmic marker (lower panel). As in C1, 
hTDP-43 (70 kDa) was detected with both anti-myc and anti-TDP-43 antibodies, while mTDP-
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Figure 2.4: τhTDP-43M337V does not lead to MN loss or muscle denervation (pure) 
(A) Schematic of the mouse spinal cord. The box indicates a ventral horn, shown on the right 
with ChAT+ MNs circled in red for quantification (Dulin & Lu 2014). (B) Depiction of the 
mouse tibialis anterior muscle (Tripodi et al. 2011). The box zooms in to three neuromuscular 
junctions (NMJs) with the pre-synaptic marker synaptophysin in green and the post-synaptic 
marker α-bungarotoxin in red. Yellow in the bottom panel represents innervated NMJs . (C) At 
P360, τMN mice show no significant loss (p-value > 0.05) of ChAT-IR motor neurons in the L5 
ventral horn or denervation of NMJs in the TA muscle, regardless of phenotype.  (D) At P900, 
τON mice show no significant loss (p-value > 0.05) of ChAT-IR motor neurons in the L5 ventral 
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Figure 2.5 Characterization of τONhTDP-43 mESC Lines 
(A) τONhTDP-43 mESC lines express myc-hTDP-43 in GFP+ cells as well as a subset of non-
GFP+ cells.  TDP-43 immunoreactivity, however, is found in all cells in a mixed culture of 
differentiated mESCs (scale bar = 50um). (B) RT-qPCR analysis of mouse and human TDP-43 
transcripts (p-value > 0.05) in τONhTDP-43 ES-MNs, using the primers depicted and validated in 
Figure 2.3. (C) Representative Western Blot of τONhTDP-43 ES-MN protein lysates, in which 
hTDP-43 (70kDa) is detected by both anti-myc (upper panel) and anti-TDP-43 (middle panel) 
antibodies. Mouse TDP-43 (45 kDa) is detected only by an anti-TDP-43 antibody (middle 
panel). Quantification of mouse and human TDP-43 (p-value > 0.05) is expressed as a fraction of 
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Figure 2.6 Generation and Differentiation of τONhTDP-43 mESC Lines 
(A) The uterus was dissected from pregnant females mice (1), blastocysts were isolated (2) and 
cultured to form outgrowths (3), which were then passaged and cultured as established ES cell 
colonies (4). (B) Differentiation protocol for generation of motor neurons from mESCs. The 
colored bars represent transcription factors activated during each stage of differentiation. 
Retinoic acid (RA) and Sonic hedgehog (Shh) bias cells toward the motor neuron lineage, and 
the neurotrophic factor, GDNF, facilitates maintenance of motor neuronal identity (Wichterle 
and Peltjo 2008). (C) Two mESC lines were generated for each genotype. (D) No significant 
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Figure 2.7: Viability of τONhTDP-43 ES-MNs 
(A) Representative image of the upper half of one well from a 96 well plate used to culture and 
live image ES-MNs over the analysis time period (5-6 days). The lower image in gray shows a 
Metamorph outline of GFP+ cells with neurite tracing allowing for counting of only cells with 
neuronal morphology and quantitation of neurite length. (B) τON ES-MNs show decreased 
viability when co-cultured with SOD1G93A glia compared to SOD1WT glia, however there is no 
cell autonomous, genotype-specific alteration in viability. Note: SOD1WT and non-transgenic glia 
yield the same survival curve. (C) Sorted ES-MNs cultured with glia-conditioned medium and 

























hTDP43 ES-MNs in Mixed Culture
hTDP43WT
hTDP43M337V
























































	   73	  
Chapter 3: 





In Chapter 2, I introduced a novel TDP-43 model in which we promisingly found 
equivalent levels of mutant and WT hTDP-43 expressed from the MAPT locus, and a genetic 
background-dependent motor phenotype. We hypothesized that, because hTDP-43M337V is 
capable of causing motor neuron degeneration, the mutation might lead to alterations in 
biochemical properties of the protein, such as in its binding to RNA or regulation of gene 
expression. Using sensitive deep sequencing technologies, such alterations should present a 
detectable signal.  
HiTS-CLIP technology provides such a sensitive detection method. This method requires 
UV cross-linking to capture close-range interactions between, in this case, TDP-43 and bound 
RNAs, immunoprecipition of TDP-43-RNA complexes, and sequencing of isolated TDP-43 
bound RNAs following cDNA library preparation (Darnell 2010). This technique, in conjunction 
with expression profiling following depletion of the protein of interest, has provided a method 
for assessing the global effects of RNABP binding on gene expression and mRNA splicing 
(Licatolosi et al. 2008). Variations on HiTS-CLIP technology, as well as less specific RIP-Seq 
and RIP-ChIP experiments, have been used to investigate the binding of TDP-43 to RNA in 
mouse, human, and rat brains, as well as in human and mouse neuronal cell lines (Figure 3.4A). 
To my knowledge, this is the first report of primarily neuron-specific TDP-43 (both mutant and 
WT) binding in the mammalian spinal cord. In this section, I will describe our findings and 
compare them with published datasets. 
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3.2 Results 
hTDP-43 RNA targets in the τON mouse spinal cord 
 To characterize hTDP-43-RNA interactions in the τON mouse spinal cord, and assess 
potential effects of the M337V mutation on binding of hTDP-43 to RNA, we 
immunoprecipitated myc-hTDP-43 cross-linked to radio-labeled RNA from three τONhTDP-43WT 
and three τONhTDP-43M337V mouse spinal cords, prepared stranded cDNA libraries from the 
bound RNA, and submitted these libraries for high-throughput sequencing (Figure 3.1A). The 
number of unique CLIP tags obtained ranged from 80,000 to over 1 million (Supplementary 
Figure S3.1A).  Overall, we obtained more unique tags from hTDP-43WT than from hTDP-
43M337V spinal cords, necessitating normalization of cluster counts to the total number of tags in 
each experiment for genotype-specific comparative analyses.*  By pooling tags from all 
experiments and using stringent filtering, we identified 30,406 significant binding sites, or CLIP 
tag clusters, in 5,387 genes, indicating that myc-hTDP-43 binds to approximately 25% of the 
murine transcriptome. Bound genes were enriched for neuronal cell and synaptic transmission 
pathway components, as well as for genes involved in cytoskeletal protein binding. Enriched 
pathways by KEGG pathway analysis include long term potentiation, ErbB signaling, and 
ubiquitin-mediated proteolysis (Figure 3.2B).  
  
TDP-43 binding is detected primarily in introns, although tag density is equally high in 3’UTRs 
We were interested in the region of mRNA to which hTDP-43WT and M337V bind in the 
τON spinal cord.  We addressed this question in two different ways.  In the first case, we 
considered each binding site as a binary entity (present=1, not present=0) and summed the 
number of sites found in each gene region.  In this case, we see almost 2-fold greater binding to 
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introns than to the next most highly bound region, 3’UTRs (Figure 3.1B). In the second case, we 
summed the number of tags found in binding sites for each genic region, and found almost equal 
binding to 3’UTRs and introns when considering the number of tags per cluster (Figure 3.1C). 
Therefore, while the greatest percentage of hTDP-43 binding sites occur within introns, CLIP 
tags distribute evenly between 3’UTR and intronic binding sites. TDP-43WT and M337V did not 
exhibit significant differences in binding to each genic region in either analysis.   
 
TDP-43 binds primarily to mRNAs, lncRNAs and mitochondrial RNA  
Similarly, we determined whether the M337V mutation altered the type of RNA to which 
hTDP-43 binds. We found that protein-coding mRNA accounted for 75% of the total RNA 
bound by both the WT and mutant proteins. The next most bound type of RNA was long non-
coding RNA (lncRNA), and mitochondrial RNA, representing about 4% of binding for both 
genotypes. We did not probe deeply into the binding of TDP-43 to mitochondrial RNA, first 
because the binding in certain regions was so ubiquitous that it would be difficult to comment on 
binding at specific sites, and second because expression of mitochondrial RNA as detected by 
RNA-Seq (see Section 3.3). All other types of RNA represented 2% of binding or less, 
supporting a major role for TDP-43 in mRNA processing (Figure 3.1D). 
 
The Effect of TDP-43M337V on RNA binding  
In comparing binding of hTDP-43WT to that of M337V, we investigated the overlap in 
binding between the two samples. Both WT and mutant hTDP-43 bound to 98.7% of the 
identified binding sites (Figure 3.2A, upper panel). In agreement with this result, both hTDP-
43WT and M337V bound to 99.6% of transcripts containing the binding sites (Figure 3.2A, lower 
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panel). We identified 399 sites bound exclusively by hTDP-43WT, the highest ranking of which 
was found in the first intron of the sarcoglycan zeta (Sgcz) gene (Supplementary Figure S3.1B). 
The 318 genes containing hTDP-43WT exclusive binding sites showed enrichment for neuronal 
development and function, as well as ubiquitin proteasome and cell adhesion pathways. Almost 
all of these genes, however, contained hTDP-43M337V tags mapping to points within their 
transcripts. We did not identify any sites bound exclusively by hTDP-43M337V.*  
We next assessed the quantitative differences in binding of mutant and wild type TDP43 
to identify differential binding sites (DBSs). When we consider each site independently, we 
detect differential binding at 1511 sites in almost 1000 genes. However, upon p-value correction 
for multiple comparisons, even with a relaxed significance cut-off of adjusted p-value<0.10, we 
find only a single site in the first intron of the Lsamp gene with significantly greater tags in 
hTDP-43WT compared hTDP-43M337V samples (Supplementary Figure S3.1C). Thus, the 
differential binding sites, identified by independent testing, likely represent false positives. We 
find that mutation in hTDP-43 does not quantitatively affect binding to RNA compared to WT 
hTDP-43 within the detection limits of our experiment. 
 
TDP-43 Binding Motif Analysis 
In addition to assessing patterns in the functional classification of all genes bound by 
TDP-43, as well as genes containing DBSs, we were also interested in whether hTDP-43 in the 
τON mouse spinal cord binds to canonical UG-rich binding sites, and what effect the mutation has 
on this sequence specificity. We found enrichment of UG-rich sequences ranging in length from 
4-12 nucleotides (Figure 3.2C). With increasing motif base pair length, the percentage of 
sequences that contain the motif initially decreased and then reached a plateau, with a correlated 
	  
	   77	  
decrease in the percentage of scrambled background sequences containing the motif. Because we 
took an unbiased approach to this analysis, the motifs identified differ in more than just 
nucleotide length. Up to six nucleotides, each base has roughly equal likelihood of replacement 
with either one of the three other nucleotides, indicating the rather common occurrence of motif 
interruption by a non-UG nucleotide at a given position. With the longer decamer and dodecamer 
motifs, random sequence interruptions decrease while the likelihood of solely an A at the final 
nucleotide position increases. We do identify other significantly enriched motifs, most notably 
A-rich tracts, although these are present in a greater number of background sequences than UG 
tracts. Thus, while we certainly identify smaller UG-rich motifs in a majority of our binding 
sites, roughly 30% of identified sites contain longer, definitive, UG motifs, and our data do not 
reveal as strong a preference of TDP-43 for any other sequences. 
The above analysis assesses the prevalence of UG-motifs of varying lengths at hTDP-43 
binding sites, while obscuring situations in which a single sequence contains multiple, non-
contiguous motifs. We analyzed the distribution of UG hexamers within 210 nucleotides 
upstream and downstream of the top 1000 binding peaks containing UG-rich sites (Figure 3.2D). 
We considered only non-overlapping hexamers and plotted their frequency starting within the 
previous ten base pairs of each sequence. Interestingly, at the binding peak in our data, we 
observe a relative decrease in the hexamer frequency, with the hexamer peak approximately 50 
base pairs upstream of the binding site, a pattern that persists in the top 5000 binding sites, as 
well. This offset of hTDP-43 binding may represent lower affinity sites not occupied by 
endogenous mouse TDP-43. Despite the dip in hexamer frequency at the specific binding site, 
UG-rich sequences persist even within 200 base pairs from the binding site, potentially 
indicating cooperative TDP-43 binding across a broad region of RNA. 
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*Note: In multiple analyses described in this section, apparent genotype-specific differences, 
specifically those in which a greater number of binding sites are identified in hTDP-43WT 
samples compared to M337V, are likely a result of technical variability within the HiTS-CLIP 
protocol rather than a true biological difference between the two genotypes.  
 
Effect of hTDP-43M337V on gene expression and splicing in the τON mouse spinal cord 
To investigate the effects of hTDP-43M337V expression on the mouse nervous system 
transcriptome, and whether any site specific binding changes led to expression changes, we 
collected the whole brain (WB) and whole spinal cord (SC) from two τONhTDP-43WT, and two 
τONhTDP-43M337V mice. We lysed whole brain and spinal cord samples for RNA isolation, 
library preparation and subsequent high-throughput sequencing (RNA-Seq). Samples contained a 
minimum of 80 million reads mapping to the mouse genome (Figure 3.3A). Through the 
Expression Plot Webserver, we calculated the number of reads per kilobase of exon per million 
reads mapped (RPKM) as a representation of the expression level of each gene (Friedman et al. 
2011). Samples strongly correlate by tissue-type, although the differences between samples are 
quite small, as indicated by the range of correlation coefficient from 0.9 – 1.0 (Figure 3.3B).  
 In order to determine the transcriptional effects of hTDP-43M337V expression, we used the 
DESeq algorithm contained within the Expression Plot Webserver, and identified 32 and 104 
differentially expressed genes in whole brain and spinal cords, respectively (fold change>2, p-
value<1.0x10-4) (Figure 3.3C-D). Six genes were significantly upregulated in both the hTDP-
43M337V brain and spinal cord samples (Table 3.1). Gene ontology (GO) analysis revealed an 
inflammatory signature among genes upregulated in the hTDP-43M337V spinal cord compared to 
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hTDP-43WT, particularly composed of neutrophil-specific genes. This may indicate an early 
response to an insult within the spinal cord. These findings are consistent with identified roles of 
inflammatory pathways in ALS, and particularly the recently discovered ALS-causing mutations 
in the inflammatory protein TBK-1 (Phillips&Rothstein 2014, Cirulli et al. 2015). We sought to 
validate the RNA-Seq results by quantitative RT-PCR for 14 transcripts tested in biological 
triplicate, and found that 86% showed the same direction of expression level change in hTDP-
43M337V spinal cord compared to hTDP-43WT, although only 36% of these validated changes 
were significant (Supplementary Figure S3.2).   
 In addition to information about gene expression, RNA-Seq data can also provide 
information about the splice variants of each transcript expressed in the sequenced sample. We 
originally hypothesized that mutant hTDP-43 would affect splicing, either of transcripts 
previously identified as TDP-43 splicing targets in knockdown or disease systems, or of novel 
transcripts. Consistent with the lack of differential binding, however, we identified only a single 
altered splicing event in Exon 30 of the FlnB gene. We were unable to validate this splicing 
change in independently isolated spinal cord RNA (Supplementary Figure S3.2).   
 
Effect of hTDP-43 Binding on Gene Expression and Splicing 
To determine whether gene expression changes detected by RNA-Seq might relate to 
hTDP-43 binding, we compared binding to differential expression in the τON spinal cord. We 
first compared differentially expressed genes with the 318 genes containing hTDP-43WT specific 
binding sites, and found no overlap. This indicates that lack of TDP-43M337V binding at the 
identified sites does not alter expression of the transcript, at least within the detection limits of 
our experiment. We then compared the differentially expressed genes to the 5,387 genes 
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containing TDP-43 binding sites, and found that transcripts encoding nine of these genes are 
bound by both WT and mutant hTDP-43 (Table 3.1). Although not significant, we detect slight 
changes in binding within the differentially expressed Zbtb16 and Luzp2 transcripts. Our data 
does not provide enough examples of altered binding and altered expression within the same 
transcript to draw conclusions about the effect of binding on transcript levels. 
 
Comparative Analysis with published TDP-43 RNA Targets and Transcriptional Profiles 
In order to evaluate the degree of overlap between TDP-43 RNA targets in various 
systems, both directly bound, and altered by TDP-43 modification, we compared our findings in 
the τON mouse spinal cord to published TDP-43 binding and expression data. 
 
Pathways Represented Among TDP-43 RNA Targets 
We compared the genes encoded by TDP-43-bound RNAs in the τON mouse spinal cord 
to those identified by CLIP experiments in the mouse brain, human brain, and by RIP 
experiments in the rat brain. When we search for enriched pathways in each individual dataset, 
we find that of the top 90 enriched pathways (Table 3.3), 90% show enrichment in all four 
datasets, indicating a high degree of overlap in TDP-43 binding to the mRNAs contained within 
these pathways. Unsurprisingly, TDP-43 targets, all derived from neuronal tissue, show 
enrichment of multiple pathways involved in neuronal processes such as axon guidance, 
glutamate receptor signaling (a process perturbed in ALS patients and model systems), long-term 
potentiation, and neuropathic pain. TDP-43 targets are also enriched for neurodegeneration 
related pathways such as ALS signaling, Huntington’s disease signaling, and protein 
ubiquitination pathway components. Enrichment in inflammatory and immune pathways may 
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explain why hTDP-43 activates these pathways in multiple systems by expression analysis. 
Some enriched pathways seem out of place in an analysis of nervous system tissue, such as 
cardiac, renal cell carcinoma, or gonadotrophin-releasing hormone signaling. The factors that 
represent enrichment of these pathways, however, can also be found in other categories, 
particularly broad signaling pathways upon which many other pathways converge, such as 
protein kinase A and ERK/MAPK signaling. Thus, the enrichment of these pathways indicates 
only the unbiased nature of the analytical method used.  
Moving from pathway analysis to overlapping the genes encoded by TDP-43 RNA 
targets, we found 504 genes overlapping between the four datasets (Table 3.3). Strikingly, 81% 
of the top ninety pathways enriched in individual datasets also showed enrichment among the 
504 genes shared between all datasets, and not within the genes specific to each dataset. This 
pattern of enrichment among shared but not individual targets persisted in master regulator and 
functional enrichment analyses. Thus the shared genes accurately represent the pathways whose 
mRNAs bind to TDP-43, and may constitute a robust TDP-43 RNA targetome in the nervous 
system, regardless of the immunoprecipitation technique or mammalian species studied.  
Two additional TDP-43 binding experiments overlap with previously identified targets, 
and discover novel targets. TDP-43 binding in the human neuroblastoma SHSY5Y cell line, as 
detected by low throughput sequencing methods, identifies 127 genes bound by TDP-43, 78% of 
which also bind to TDP-43 in at least one additional dataset, and 19% of which overlap with the 
504 shared TDP-43 targets. As in the shared targets, TDP-43 targets in SHSY5Y cells were 
enriched for genes involved in cytoskeletal organization and cell adhesion, as well as in the 
neurodegenerative pathways of ALS, Alzheimer’s Disease, and Progressive Motor Neuropathy 
(Xiao et al. 2011). RIP-chip experiments in the cytoplasmic fraction of mouse motor-neuronal 
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cell line NSC-34 identified 168 transcripts bound by TDP-43, 83% of which also bind to TDP-43 
in at least one additional dataset, and 9% of which overlap with the 504 shared TDP-43 targets. 
The relatively low overlap with shared targets likely results from the cytoplasmic specificity of 
this experiment. Enriched processes in NSC-34 cells, however, are also enriched among shared 
TDP-43 targets including Wnt signaling, transcription regulation, and neuritogenesis 
(Colombrita et al. 2012). Low throughput approaches, then, also identify a subset of the 504 
common TDP-43 targets. 
We were additionally interested in whether TDP-43 mRNA targets are enriched for genes 
regulated by specific transcription factors. Transcriptional targets of HDAC4 are enriched in the 
504 overlapping genes and not in the genes unique to each dataset. A recent study found that 
TDP-43 suppression of the miRNA mir-1 leads to increased HDAC4 protein levels (King et al. 
2014). This may indicate cooperation between these two proteins, potentially through a set of 
genes and mRNAs that they coordinately regulate. In addition, HDAC4 plays a role in neuronal 
death, and HDAC4 upregulation in muscles correlates with worse outcomes for ALS patients 
(Simoes-Pires et al. 2013, Bruneteau et al. 2013). Thus, the interaction between HDAC4 and 
TDP-43, both in physiological and pathological conditions, warrants further study.  
Previous studies have noted interactions of TDP-43 with mRNAs that code for 
neurodegenerative disease-related proteins (Figure 3.4A). Through our upstream regulator 
analysis, we find that the targets of five neurodegeneration related regulators are enriched among 
shared TDP-43 targets and not experiment-specific targets. The enrichment of each regulator is 
not accounted for by target overlap between the regulators. These regulators include the 
Huntington’s disease gene huntingtin (HTT), the Alzheimer’s disease genes presenilin-1 
(PSEN1) and amyloid precursor protein (APP), the neurodegenerative disease gene microtubule-
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associated protein tau (MAPT), and ALS-associated hnRNPA2B1. We also see enrichment of 
the muscular dystrophy gene dystrophin (DMD) targets. TDP-43 inclusions have been identified 
in almost all of these disorders, supplemented by reports of pathological and functional overlap 
between neurodegenerative diseases (Colombrita et al. 2009, Rahimi et al. 2014, Clippinger et al. 
2013, Tada et al. 2012). While specific downstream targets of these disease genes may differ, 
their similarities detected here supports hypotheses of overlapping disease mechanisms. 
 
TDP-43 Binds to Subsets of non-coding RNAs 
 Overall, the vast majority of TDP-43 maps to mRNAs. In all datasets that report it, 
including ours, the next most common type of RNA bound, representing ~5% of binding sites, 
are non-coding RNAs (ncRNAs). TDP-43 in FTLD-TDP human brain shows increased binding 
to four subsets of RNAs (small nucleolar (sno)RNAs, small nuclear (sn)RNAs, ribosomal 
(r)RNAs and telomeric ncRNAs), however our dataset did not contain enough CLIP tags binding 
to these subsets to assess differential binding.  
FTLD-TDP human brains also contain a greater proportion of TDP-43-bound cDNAs 
mapping to Malat1 and Neat1 long non-coding RNAs (lncRNAs) compared to controls 
(Tollervey et al. 2011). In the mouse spinal cord, hTDP-43 binds to both of these lncRNAs, and 
quite extensively to Malat1, but we do not detect a genotype-specific difference in binding. We 
do, however, find non-significant DBSs in 26 other lncRNAs, 20 of which show a trend toward 
greater binding, and four of which contain exclusive binding, by hTDP-43WT. In the human brain 
samples, increased expression of both Malat1 and Neat1 may explain the apparent increase in 
binding by TDP-43. Expression levels of these transcripts and other lncRNAs are not altered in 
τON mouse spinal cords. The list of functions of lncRNAs continues to expand, but established 
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functions in transcriptional regulation and nuclear organization make these RNAs unsurprising 
partners for a multifunctional RNA binding protein such as TDP-43 (Geisler & Coller 2013). 
 
TDP-43 Binding Sites Fall Primarily in Introns and 3’UTRs of mRNA 
Within mRNA precursors, TDP-43 binds primarily to intronic regions, although myc-
hTDP43 binds to the lowest percentage of introns compared to TDP-43 binding in published 
datasets (Figure 3.4C). Differences in intronic compared to 3’UTR binding between datasets may 
reflect differential stability of mRNA precursors compared to mature RNA, or differences in the 
subcellular localization of hTDP-43. The former possibility may explain why the next lowest 
percentage of intronic binding is found in post-mortem human brain tissue (Tollervey et al. 
2011). Similarly, in non-crosslinked TDP-43-RNA complexes from rat brain nuclear extracts, 
however, while a majority of raw reads mapped to intronic regions, the highest read density lay 
within 3’UTRs, mirroring our finding in the mouse spinal cord (Sephton et al. 2011). We can 
account for inconsistencies between our spinal cord data and other TDP-43 CLIP datasets with 
three hypotheses. The preference of human TDP-43 for introns may differ from mouse TDP-43, 
however, this is unlikely based on the high intronic binding of hTDP-43 in cell lines (Tollervey 
et al. 2011). Spinal cord TDP-43 binding may differ from TDP-43 binding in brain samples, as 
ours is the only dataset to look specifically at TDP-43 binding in the spinal cord. The affinity of 
endogenous mouse TDP-43 for its target RNAs may differ from exogenous human TDP-43. 
Thus, TDP-43 clearly prefers intronic and 3’UTR binding sites, however the tissue-specific and 
organism-specific extent of this preference is not yet clear. 
We can further assess binding within introns by considering whether binding sites fall 
within 2kb of an exon junction (proximal binding) or further than 2kb from an exon junction 
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(distal binding). In the mouse brain, the percentage of distal intronic binding was double that of 
proximal binding (Polymenidou et al. 2011). In the spinal cord, we found an almost 3-fold 
increase in distal binding compared to proximal. While this may represent a unique feature of 
TDP-43 binding to RNA, it might simple reflect the comparative length of proximal and distal 
intronic sites, particularly in neurons, which express genes containing significantly longer introns 
compared to other tissues (Polymenidou et al. 2011). 
In the rat brain, genes containing predominantly intronic, exonic, or both intronic and 
exonic TDP-43 binding are involved in different cellular processes. For example, genes with 
predominantly intronic reads play a role in synaptic formation and function, as well as in 
neurotransmission. Predominantly exonic binding was identified in genes involved in more 
generic, non-neuronal processes such as mRNA processing. Finally, genes with binding in both 
regions were involved in developmental processes (Sephton et al. 2011). We also found 
developmental, particularly neurodevelopmental, genes enriched among shared intronic and 
exonic hTDP-43 targets in τON spinal cords. In contrast to findings in the rat brain, however, we 
found hTDP-43 intronic, and not exonic, binding partners enriched for RNA metabolic factors, 
although exonic targets are enriched for RNA binding factors. We corroborate, then, that TDP-43 
binding in both exonic and intronic regions may indicate a developmental role for the target 
gene, however roles for predominantly intronic and exonic targets did not correlate between the 
rat brain and mouse spinal cord.  
 
The Effect of Disease State or Mutation on TDP-43 Binding 
None of the available datasets compare TDP-43 WT and mutant binding to RNAs, 
however one dataset does compare TDP-43 binding in control brains to binding in FTLD-TDP 
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brains (Tollervey et al. 2011).  While the disease state in this experiment also examines binding 
of WT TDP-43, it is most comparable to our dataset, as both FTLD-TDP and an ALS-causing 
mutation can lead to TDP-43 aggregation and neuronal pathology. Although not significant in 
our spinal cord data, both datasets contain a greater number of sites that are more highly bound 
in the control samples than the disease-related samples. In both cases, genes more highly bound 
in control samples are enriched for neuronal cell components and nervous system developmental 
factors. Thus, TDP-43 alteration, either by disease state or mutation, may decrease global 
binding to RNA, however a definitive conclusion requires further experiments. 
 
TDP-43 Alteration Causes Gene Expression Changes 
Surprisingly, few robust datasets assess differential gene expression, either through 
microarray or RNA-Seq approaches, in a TDP-43 disease relevant context, and either mutation 
or disease state. Among the datasets within our comparative analysis, only one described the 
results of their differential expression analysis in the TDP-43 knockdown mouse brain compared 
to control brains (Polymenidou et al. 2011). Interestingly, TDP-43 knockdown induced an 
upregulation of genes involved in inflammatory and defense pathways, similar to the profile of 
upregulated genes we identified in the τONhTDP-43M337V spinal cords. In addition, of the twelve 
differentially expressed genes that overlap between the two datasets, ten change in the same 
direction, i.e. upregulated in either the TDP-43 knockdown brain or TDP-43 mutant spinal cord, 
and five of these compose part of the inflammatory profile (Table 3.2). This implies at least a 
partial loss of function induced by TDP-43 mutation at the level of gene expression.  
Downregulated genes in the TDP-43 knockdown dataset contained very long introns 
(Polymenidou et al. 2011). These genes also showed an increase in TDP-43 binding, although 
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this may have resulted simply from the increased likelihood of a longer intron containing a TDP-
43 binding site. In the τON spinal cord, however, differentially expressed genes that contain TDP-
43 binding sites consist of five up- and four down-regulated genes, and range in longest intron 
length from 0 – 217 kilobases, with no correlation between intron length and expression change. 
Therefore, although difficult to ascertain because of the small sample size, the pattern found in 
the mouse brain seems not to be consistent with our dataset. 
We additionally compared these two datasets to genes in the mouse spinal cord 
misregulated by WT TDP-43 overexpression (Shan et al. 2010). Interestingly, 18 genes 
upregulated by TDP-43 knockdown are also upregulated by overexpression of WT TDP-43. In 
addition, defense and immune pathways are activated by both perturbations in TDP-43 
expression, indicating that upregulation of these pathways and genes represents a general feature 
of TDP-43 misregulation rather than a feature specific to loss or gain of function of the protein. 
A comparison of differential gene expression in a drosophila model of TDP-43 toxicity, 
however, found mostly inverse regulation of TDP-43 target genes with overexpression compared 
to knockdown, and little overlap overall between differentially expressed genes in the two 
conditions (Hazelett et al. 2012). Thus, available gene expression datasets do not yet reveal 
whether TDP-43 mutation correlates with a loss of gain of function mechanism of toxicity. 
 
TDP-43 Alteration Indirectly Leads to Altered Splicing 
 Although TDP-43 mutation in our τON system did not alter splicing, both knockdown of 
TDP-43 and FTLD-TDP resulted in splicing changes in mouse and human brain samples 
(Polymenidou et al. 2011, Tollervey et al. 2011). We sought to confirm these splicing changes. A 
re-analysis of deep sequencing data from mouse brain samples, kindly provided by Chaolin 
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Zhang, revealed significantly altered splicing in only 46 cassette exons, as opposed to the 
reported 203 cassette exons (Polymenidou et al. 2011). For comparison, we chose only the set of 
36 cassette exons with validated splicing changes in human brain tissue (Tollervey et al. 2011). 
We found no overlap between these two sets of altered splicing events, nor was the single 
cassette exon identified in our data contained within either dataset. Although the specific TDP-43 
regulated exons do not overlap from mouse and human brain samples, genes containing these 
exons did share enrichment for neuronal projection factors. Mouse alternatively spliced 
transcripts, however, are enriched for translation factors, while human alternatively spliced 
transcripts are enriched for cell surface receptor signaling pathways (Polymenidou et al. 2011, 
Tollervey et al. 2011).  
In seeking to define the disease relevance of altered splicing events, Xiao and colleagues 
found that five cassette exons with adjacent TDP-43 binding sites in the human neuroblastoma 
SHSY5Y cell line show altered splicing in ALS patient spinal cords compared to controls (Xiao 
et al. 2011). These cassette exons also contain adjacent TDP-43 binding sites in the mouse spinal 
cord, however they do not exhibit genotype or phenotype-specific altered splicing in ours or 
other available datasets. This lack of overlap among the available data may reflect differences in 
mouse compared to human samples, the different brain regions probed, or technical variations in 
these experiments. In addition, it may indicate an indirect role for TDP-43 in splicing, through 
regulation of the transcription and processing of RNAs encoding splicing factors, but not directly 
regulating splicing of specific transcripts. 
Consistent with the hypothesis of an indirect role for TDP-43 in splicing, most of the 
TDP-43 knockdown-mediated alternatively spliced exons do not contain TDP-43 binding sites 
with 2kb of their splice sites. Furthermore, mRNAs coding for RNA binding proteins contain 
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TDP-43 binding sites and become dysregulated with TDP-43 knockdown (Polymenidou et al. 
2011). In the τON mouse spinal cord, we find that the mRNA coding for 34% of mouse RNABPs 
contain TDP-43 binding sites. RNABPs are also bound by TDP-43 in rat and human brain 
samples (Figure 3.4D, Cook et al. 2011). Because TDP-43 binds to 25% of mouse transcripts, 
however, we must interpret this data cautiously as the high percentage of binding to RNABPs 
might just result from the high number of all transcripts bound by TDP-43. Thus, our findings 
support, but do not confirm, the hypothesis that TDP-43 binds to transcripts coding for RNABPs 
as a potential indirect mechanism of altered splicing.  
Our data also indicates that, contrary to the generally accepted view that TDP43 functions 
primarily as a splicing factor, there is little evidence that this is actually the case. In vitro and 
overexpression experiments have certainly revealed a role for TDP-43 in splicing ((Lagier-
Tourenne et al. 2010, Buratti & Baralle 2010, Dreumont et al. 2009) but this role is likely heavily 
influenced by interactions with other proteins, and regulation by TDP-43 of transcripts encoding 
RNA processing proteins. In addition, it may depend on the presence of highly UG-rich sequence 
in order for TPD-43 to bind directly to an RNA target and influence its splicing. Binding of 
TDP-43 to lower affinity sites, of which CLIP experiments identify a myriad that possess few 
extended UG tracts, may exert another function, such as regulating RNA stability, rather than a 
direct splicing function. 
 
TDP-43 Binds to UG-rich motifs 
 Different studies use different methods to identify the preferred binding motif of TDP-43. 
Consistent with in vitro results, all reports identify UG-rich tracts within TDP-43 binding sites. 
In the mouse brain, UG hexamers, followed by A-interrupted UG hexamers, are most enriched, 
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and 93% of binding sites contain at least one UG tetramer compared to only 54% in randomized 
sites (Polymenidou et al. 2011). In human brain samples, UG pentamers show the greatest 
enrichment at cross-link sites, with persistence of UG-enrichment even 100 nucleotides upstream 
and downstream of the site (Tollervey et al. 2011), a pattern also identified in the tON spinal cord. 
In the rat brain, only 16% of sequences contained UG-rich dodecamers, with frequent UA 
interruptions of the form (UG)nUA(UG)m, consistent with A-interrupted hexamers in the mouse 
brain and tON spinal cord. Cytoplasmic TDP-43 targets in NSC-34 cells contain UG-rich 
sequences (80%), and well as A-rich and T-rich elements, 35.7 and 26.7%, respectively 
(Colombrita et al. 2012). In SHSY5Y cells, however, TDP-43 binds to an UG-rich decamer in 
49% of sequences, with a pyrimidine rich tract present in 18% of targets (Xiao et al. 2011). 
Differing percentages of UG-rich binding likely results from the following: technical differences 
among the experiments, and differences in the bioinformatic approach to motif discovery. 
Combined the data indicate a definite preference of TDP-43 for UG-rich binding sites, however, 
these sites are often interrupted by other nucleotides, particularly adenine, and they are not 
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3.3 Discussion 
In this chapter, we identified over 30,000 hTDP-43 binding sites in over 5,000 genes in 
the τON mouse spinal cord. Although intronic binding predominates in our data, tag density 
analysis reveals almost equal distribution of binding sites between intronic and 3’UTR regions. 
Compared to other data sets, we detected the lowest percentage of intronic binding, potentially 
resulting from greater presence of hTDP-43 in the cytoplasm compared to endogenous mouse 
TDP-43, or higher occupancy of endogenous TDP-43 at intronic binding sites. Alternatively, and 
consistent with human brain data, this may reflect a preference of human TDP-43 for 3’UTR 
over intronic regions compared to mouse TDP-43 (Tollervey et al. 2011). A final explanation for 
differences in binding to intronic and 3’UTR regions lies in the differential stability of mature 
mRNAs compared to pre-mRNAs, and differential degradation during experimental processing.  
 Contrary to our original hypothesis, but consistent with lack of alteration in hTDP-43 
distribution and protein-protein interactions, hTDP-43M337V shows no significant differences in 
binding to RNA compared to hTDP-43WT in the τON mouse spinal cord at P90. While we do 
detect almost 400 sites bound exclusively by hTDP-43WT, these sites likely reflect a greater 
number of WT tags overall rather than altered binding resulting from mutation. Although few 
published data have investigated mutation-dependent differences in TDP-43 binding to RNA, 
one group found that mutations in TDP-43 did not alter binding to particular mRNAs in cell 
culture experiments (Colombrita et al. 2012). We do, however, detect changes in gene expression 
by RNA-Seq, consistent with a neutrophil-specific inflammatory response. This result fits a 
partial loss of function mechanism because of similarities with RNA-Seq results from TDP-43 
knockdown. We did not detect robust splicing alterations, which fits with a lack of altered 
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binding, particularly to RNA binding proteins through which TDP-43 likely exerts indirect 
effects on splicing. 
Our comparative analysis of TDP-43 binding reveals a core set of 504 mRNA targets. We 
identified the same enriched pathways both among individual datasets, as well as among these 
504 core targets. Additionally, these pathways were not enriched among targets specific to each 
dataset. Therefore, the shared targets represent a consensus set of pathways regulated by, or at 
least containing, TDP-43 binding, irrespective of the species or technique used for data 
collection.  These pathways include basic neuronal functions as well as neuropathological 
pathways, non-neuron specific ALS-associated pathways, and common downstream signaling 
pathways. Upstream regulators whose targets are enriched among TDP-43 targets include 
HDAC4, whose relation to ALS and neurodegeneration remains relatively unexplored, and 
multiple neurodegenerative (and muscle degenerative) genes. To our knowledge, this analysis 
represents the most comprehensive approach yet attempted to identify a core set of TDP-43 
interacting RNAs that spans multiple detection methods, tissues, and species, which should 
prove useful in subsequent studies of abnormal TDP-43-RNA interactions. 
 Our comparative motif analysis reveals a potential secondary preference of TDP-43 for 
A-interrupted UG-rich sequences as well as A-rich tracts. It is possible that UG preference 
accounts for the entirety of TDP-43 binding specificity, however basing this conclusion on the 
presence of UG tetramers is statistically unsound because these tetramers occur at relatively high 
frequency in background sequences. As we show in our τON data, with increasing size of the UG 
motif, we increase its statistical significance, but also decrease the number of sequences in which 
it is found. As multiple publications suggest, the distribution of UG-tracts may play a greater role 
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in determining TDP-43 binding rather than uninterrupted UG motifs. This renders difficult 
bioinformatic prediction of TDP-43 binding sites. 
 Thus, hTDP-43 binding and expression data from the τON mouse spinal cord shares both 
targets, target pathways and the UG-rich motif with published datasets. At the level of detection 
achieved by our HiTS-CLIP experiment, and consistent with in vitro experiments, we did not 
detect significant binding changes of mutant TDP-43 compared to WT. We did, however, detect 
upregulation of inflammatory genes by transcriptional profiling, potentially due to binding 
changes below our detection limit. Although consistent with the lack of an ALS-like phenotype 
resulting from τONhTDP-43M337V expression on a pure Bl6 genetic background, the lack of 
differences in RNA binding between the mutant and WT proteins argues against the hypothesis 
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Figure 3.1 HiTS-CLIP Identifies Type and Region of RNA bound by hTDP-43 
(A) Schematic of HiTS-CLIP experiment: Spinal cord cells were subjected to UV-crosslinking 
followed by (a) lysis, immunoprecipitation, 3’ linker ligation, and radiolabeling. Subsequent (b) 
SDS-PAGE reveals TDP-43-RNA complexes of varying molecular weight under low-RNAse 
conditions in (1) hTDP-43WT and (2) hTDP-43M337V samples. (c) Library preparation by RT-PCR 
reveals amplification of both samples and control –RT sample in gray. (B-C) Percentage of CLIP 










































































































Figure 3.2: Genotype, Enrichment and Motif Analysis of hTDP-43 RNA targets 
(A) High degree of overlap between sites and genes bound in each genotype. (B) Enriched gene 
ontology terms and pathways among the 5387 genes bound by TDP-43. (C-D) UG-rich motifs 
identified by increasing length and distribution of hexamers upstream and downstream of 
binding sites.  








































Term Identifier Genes* P-value
Neuron projection GO:0043005 390 4.21E-25
Synapse part GO:0044456 220 2.53E-22
Nerve impulse transmission GO:0019226 267 2.78E-17
Synaptic transmission GO:0007268 224 9.79E-17
Cytoskeletal protein binding GO:0008092 237 1.86E-08
Protein kinase binding GO:0019901 182 2.36E-09
Ion transporter activity GO:0015075 235 5.88E-06
Long-term potentiation KEGG4720 43 4.00E-04
ErbB signaling pathway KEGG4012 51 4.00E-04
Gap junction KEGG4540 46 6.50E-03
Glioma KEGG5214 35 8.90E-03
Ubiquitin mediated proteolysis KEGG4120 67 8.90E-03
Enrichment Analysis
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Figure 3.3: Differential gene expression in the τON mouse brain and spinal cord. 
(A) Type of mapped reads by sample from RNA-Seq experiment. (B) RNA-Seq samples are 
highly similar and correlate most by tissue type. (C-D) Genes upregulated (red circles) and 
downregulated (blue circles) in hTDP-43M337V compared to hTDP-43WT mouse spinal cord (C) 
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Figure 3.4: Comparison of TDP-43 RNA Targets. 
(A) List of experiments that identify TDP-43 RNA targets in neuronal samples. See Appendix 
for discussion of dataset 4. (B) 504 bound genes overlap from the 5 high-throughput sequencing 
experiments. (C-D) Comparison of intronic binding (C) and binding to transcripts that code for 











Code Sample TDP-43	Species Genotype Technique Binding	Sites Bound	Genes
Lehrer	-	τ	SC τ mouse	SC human WT,	M337V HiTS-CLIP 30,406 5,387
Polymenidou	et	al.	2011 1 mouse	brain mouse WT CLIP-Seq 39961 6304
Sephton	et	al.	2011 2 cultured	neurons rat WT RIP-Seq not	reported 4352
Tollervey	et	al.	2011 3 human	brain human WT iCLIP 111691 13647
Lehrer	-	iMN 4 iPS-MNs human WT,	M337V HiTS-CLIP 27874 6391
Xiao	et	al.	2011 5 SH-SY5Y	cells human WT UV-CLIP 102 127
Colombrita	et	al.	2012 6 NSC-34	cells,	cyto mouse WT RIP-chip not	reported 168
Ta
uO
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Supplementary Figure S3.1: HiTS-CLIP Sequencing Statistics and Binding Examples. 
(A) Bioinformatic processing of HiTS-CLIP results yielded 0.08 – 1.1 million unique tags per 
experiment. (B) Example of a WT exclusive peak in intron 1 of the sarcoglycan zeta gene. (C) 




Sample Separated Tags Mapped Tags Unique Tags Clusters
hTDP-43_M337V_1 10847164 3295114 148974 103107
hTDP-43_M337V_2 3680760 2160937 464419 295569
hTDP-43_M337V_3 10396054 2690673 81589 46694
hTDP-43_WT_1 7031946 2450344 641390 396935
hTDP-43_WT_2 7976511 4158711 374147 235609
hTDP-43_WT_3 14287622 6693370 1164905 653681
Total 54220057 21449149 2875424 1731595
200 bases mm10
38,391,700 38,391,800 38,391,900 38,392,000 38,392,100 38,392,200 38,392,300
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Supplementary Figure S3.2: RNASeq Validation Experiments 
(A) Reads from RNASeq experiments mapping to the FilaminB (FlnB) gene revealed greater 
inclusion of exon 30 (box) in τONhTDP-43M337V samples compared to τONhTDP-43WT. The upper 
schematic of exons 29-31 shows the different splicing patterns. Orange arrows represent primers. 
(B) Amplification of FlnB with primers against exons 29 and 31 reveal an upper band 
corresponding to exon 30 inclusion, and a lower band corresponding to exclusion of exon 30 
exclusion (size difference = 74 bp). Percentage inclusion is quantified in (C). (D) The fold 
change in gene expression, and associated p-value determined by RNASeq and RT-qPCR 
experiments. With a relaxed p-value cutoff of p<0.1, 36% of gene expression changes were 

























































Gene Fold Change p-value Fold Change p-value
Pglyrp1 2.24 3.24E-04 1.34 0.04
Ngp 2.81 1.04E-21 2.43 0.04
Cybb 2.57 2.27E-07 1.57 0.06
Rac2 2.06 8.83E-05 1.31 0.06
Rin3 2.06 1.52E-06 1.45 0.06
S100a9 3.17 5.57E-12 1.54 0.16
Lcn2 3.28 3.54E-13 1.71 0.16
Ltf 2.6 4.61E-15 1.98 0.20
Nrros 2.15 2.72E-08 1.4 0.23
S100a8 3.14 7.15E-09 1.34 0.28
Lyz2 2.3 7.40E-16 1.15 0.29
Luzp2 0.69 5.27E-02 1.09 0.30
Plin4 4.64 2.60E-53 1.12 0.40
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Gene	   Description	   Process	   SC	   Brain	   Binding	  
Plin4	   Perilipin	  4	   Lipid	  storage	   2.26	   2.08	   N	  
Lcn2	   Lipocalin	  2	   Defense/Immunity	   1.75	   2.04	   N	  
S100a9	   S100	  calcium	  binding	  protein	  A9	   Defense/Immunity	   1.70	   NS	   N	  
S100a8	   S100	  calcium	  binding	  protein	  A8	   Defense/Immunity	   1.69	   NS	   N	  
Ngp	   Neutrophilic	  granule	  protein	   Defense/Immunity	   1.53	   NS	   N	  
Ltf	   Lactotransferrin	   Defense/Immunity	   1.41	   NS	   N	  
Cybb	   Cytochrome	  b-­‐245,	  β	  polypeptide	   Defense/Immunity	   1.40	   NS	   N	  
Zbtb16	   Zinc	  finger	  and	  BTB	  domain	  containing	  16	   Immunity	   1.39	   1.05	   Y	  
Alas2	   Aminolevulinic	  acid	  synthase	  2,	  erythroid	   Stress	  Response	   1.33	   NS	   Y	  
Lyz2	   Lysozyme	   Defense	   1.24	   NS	   N	  
Pglyrp1	   Peptidoglycan	  recognition	  protein	  1	   Defense/Immunity	   1.20	   1.23	   Y	  
Nrros	   Negative	  regulator	  reactive	  oxygen	  species	   Defense/Immunity	   1.14	   0.97	   N	  
Hif3a	   Hypoxia	  inducible	  factor	  3,	  α	  subunit	   Stress	  Response	   1.12	   0.93	   Y	  
Rin3	   Ras	  and	  Rab	  interactor	  3	   Defense/Immunity	   1.09	   1.18	   Y	  
Rac2	   RAS-­‐related	  C3	  botulinum	  substrate	  2	   Defense/Immunity	   1.08	   NS	   N	  
Luzp2	   Leucine	  zipper	  protein	  2	   	  	   -­‐0.50	   NS	   Y	  
Lap3	   Leucine	  aminopeptidase	  3	   Ion	  binding	   -­‐0.60	   NS	   Y	  
Ptar1	   Protein	  prenyltransferase	  α	  repeat	  1	   	  	   -­‐0.83	   NS	   Y	  
Cdr1	   Cerebellar	  degeneration	  related	  antigen	  1	   	  	   -­‐1.33	   -­‐1.00	   Y	  
Table 3.1 Bound and differentially expressed genes in τON spinal cord (SC) and Brain. 
Values in SC and Brain columns represent the log2 of the fold change of hTDP-43M337V 
compared to WT samples, p<0.05. NS=not signficiant. Blue highlighting indicates validation of 
differential expression by qPCR. 
	  
Overlap	  with	  Cleveland	   τON	   Polymenidou,	  2011	  
Gene	   Description	   logFC	  	   Binding	   logFC	   Binding	  
Lcn2*	   Lipocalin	  2	   1.69	   N	   2.00	   N	  
Cybb*	   Cytochrome	  b-­‐245,	  β	  polypeptide	   1.43	   N	   2.67	   N	  
Cd300lf*	   CD300	  antigen	  like	  family	  member	  F	   1.37	   N	   2.28	   N	  
Alas2	   Aminolevulinic	  acid	  synthase	  2,	  erythroid	   1.15	   Y	   -­‐0.92	   N	  
Cdkn1a	   Cyclin-­‐dependent	  kinase	  inhibitor	  1A	   1.13	   N	   1.51	   N	  
Rac2*	   RAS-­‐related	  C3	  botulinum	  substrate	  2	   1.03	   N	   1.50	   N	  
Arhgdib	   Rho,	  GDP	  dissociation	  inhibitor	  (GDI)	  beta	   0.83	   N	   1.01	   N	  
Ptprc	   Protein	  tyrosine	  phosphatase,	  receptor	  type,	  C	   0.8	   N	   1.24	   Y	  
Cd74*	   Invariant	  MHC,	  class	  II-­‐associated	   0.72	   N	   1.20	   Y	  
Igfbp5	   Insulin-­‐like	  growth	  factor	  binding	  protein	  5	   0.71	   N	   1.01	   N	  
Hmgcr	   3-­‐hydroxy-­‐3-­‐methylglutaryl-­‐CoA	  reductase	   -­‐0.55	   N	   -­‐0.51	   N	  
Fabp7	   Fatty	  acid	  binding	  protein	  7,	  brain	   -­‐0.98	   N	   1.18	   N	  
Table 3.2: Genes differentially expressed in τON spinal cord and TDP-43 brain KD. 
LogFC represent log2 of the fold change of mutant (M337V) or KD compared to WT or control 
(p<0.05). *Part of inflammatory pathway. 
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Note: Tables 3.3-5 show output from the Ingenuity Pathway Analysis software. Full dataset 
columns include all genes in each dataset. The “All” represents the 504 genes shared in all 
datasets and “Exclusive Genes” and genes specific to each dataset. 
	  
Table 3.3 Ingenuity Pathways Among TDP-43 RNA Targets 
  Full Dataset     Exclusive Genes 










1 Axonal Guidance Signaling                         
4 Ephrin Receptor Signaling                 
9 Dopamine-DARPP32 Signaling                 
10 Synaptic Long Term Potentiation                 
11 Neuropathic Pain Signaling                 
3 CREB Signaling in Neurons                 
16 Glutamate Receptor Signaling                 
35 Netrin Signaling                 
38 CDK5 Signaling                 
41 ErbB Signaling                 
49 Neuregulin Signaling                 
54 Reelin Signaling in Neurons                 
62 GABA Receptor Signaling                 
63 Calcium Signaling                 
65 NGF Signaling                 
67 Synaptic Long Term Depression                 
72 Semaphorin Signaling in Neurons                 
80 Neurotrophin/TRK Signaling                 















e 21 Integrin Signaling                 
23 Gap Junction Signaling                 
42 Rac Signaling                 
48 Epithelial Adherens Junction Signaling                 
47 Actin Cytoskeleton Signaling                 
46 FAK Signaling                 
50 14-3-3-mediated Signaling                 
75 Paxillin Signaling                 
83 ILK Signaling                 








n 28 CXCR4 Signaling                 
29 PPARα/RXRα Activation                 
















6 Protein Kinase A Signaling                 
8 Signaling by Rho Family GTPases                 
17 ERK/MAPK Signaling                 
18 RhoGDI Signaling                 
22 PI3K/AKT Signaling                 
31 GPCR Signaling                 
36 p70S6K Signaling                 
44 G Beta Gamma Signaling                 
45 AMPK Signaling                 
53 P2Y Purigenic Receptor Signaling                 
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59 cAMP-mediated signaling                 
68 RhoA Signaling                 
69 Wnt/β-catenin Signaling                 
70 PAK Signaling                 
71 α-Adrenergic Signaling                 
81 SAPK/JNK Signaling                 
82 mTOR Signaling                 

























5 GNRH Signaling                 
20 Insulin Receptor Signaling                 
24 Renin-Angiotensin Signaling                 
25 HIPPO signaling                 
26 B Cell Receptor Signaling                 
27 Thrombin Signaling                 
30 HGF Signaling                 
32 PTEN Signaling                 
33 Germ Cell-Sertoli Cell Signaling                 
34 IGF-1 Signaling                 
37 Melatonin Signaling                 
40 Cellular Effects of Sildenafil (Viagra)                 
43 Aldosterone Signaling in Epithelium                  
51 Sertoli Cell-Sertoli Cell Signaling                 
52 Leptin Signaling in Obesity                 
56 Relaxin Signaling                 
58 Melanocyte Signaling                 
66 CRH Signaling                 
73 VEGF Signaling                 
76 GM-CSF Signaling                 
78 NRF2 Oxidative Stress Response                 
79 EGF Signaling                 
84 PDGF Signaling                 
85 FGF Signaling                 
87 PI3K Signaling in B Lymphocytes                 





 7 Role of NFAT in Cardiac Hypertrophy                 
14 Cardiac β-adrenergic Signaling                 
19 Cardiac Hypertrophy Signaling                 





2 Molecular Mechanisms of Cancer                 
12 Stathmin1 Breast Cancer Regulation                 
55 Renal Cell Carcinoma Signaling                 
60 Glioma Signaling                 
61 Telomerase Signaling                 
77 Prostate Cancer Signaling                 








 15 Protein Ubiquitination Pathway                 
13 Huntington's Disease Signaling                 
57 ALS Signaling                         
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Table 3.4 Master Regulators among TDP-43 RNA Targets 
  Full Dataset     Exclusive Genes 
Regulators τ   1 2 3 4   All τ   1 2 3 4 
HDAC4                         
Sos   
    
  
     
  
CREBBP   
    
  
     
  
MAPT*   
    
  
     
  
Mir-451   
    
  
     
  
Mir-144   
    
  
     
  
PSEN1*   
    
  
     
  
EP300   
    
  
     
  
FOS   
    
  
     
  
HNRNPA2B1*   
    
  
     
  
IGFBP2   
    
  
     
  
CTNNB1   
    
  
     
  
Calmodulin   
    
  
     
  
VAX2   
    
  
     
  
NR3C1   
    
  
     
  
SLC30A3   
    
  
     
  
SHANK3   
    
  
     
  
ZNF217   
    
  
     
  
CDKN1B   
    
  
     
  
RELN   
    
  
     
  
REST   
    
  
     
  
APP*   
    
  
     
  
SIRT6   
    
  
     
  
HMG20B   
    
  
     
  
CACNA1D   
    
  
     
  
DMD*   
    
  
     
  
TSPYL5   
    
  
     
  
HTT*   
    
  
     
  
Pln   
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Table 3.5 Ingenuity Functions enriched among TDP-43 Targets 
  Full Dataset     Exclusive Genes 
Diseases and Bio Functions τ  1 2 3 4   All τ  1 2 3 4 
Cancer                         
formation of plasma membrane projections   
   
      
    
  
development of neurons   
   
      
    
  
neuritogenesis   
   
      
    
  
organization of cytoskeleton   
   
      
    
  
organization of cytoplasm   
   
      
    
  
microtubule dynamics   
   
      
    
  
formation of cellular protrusions   
   
      
    
  
morphogenesis of neurites   
   
      
    
  
neurotransmission   
   
      
    
  
behavior   
   
      
    
  
organismal death   
   
      
    
  
locomotion   
   
      
    
  
axonogenesis   
   
      
    
  
shape change of neurons   
   
      
    
  
branching of neurons   
   
      
    
  
Movement Disorders   
   
      
    
  
morphology of nervous system   
   
      
    
  
morphology of central nervous system   
   
      
    
  
shape change of neurites   
   
      
    
  
synaptic transmission   
   
      
    
  
morphology of brain   
   
      
    
  
branching of cells   
   
      
    
  
branching of neurites   
   
      
    
  
sprouting   
   
      
    
  
abnormal morphology of nervous system   
   
      
    
  
Schizophrenia   
   
      
    
  
long-term potentiation   
   
      
    
  
abnormal morphology of brain   
   
      
    
  
morphology of head   
   
      
    
  
quantity of neurons   
   
      
    
  
seizure disorder   
   
      
    
  
development of body axis   
   
      
    
  
abnormal morphology of head   
   
      
    
  
development of central nervous system   
   
      
    
  
abnormal morphology of CNS   
   
      
    
  
neuronal cell death   
   
      
    
  
formation of brain   
   
      
    
  
transcription   
   
      
    
  
Mood Disorders   
   
      
    
  
long-term potentiation of synapse   
   
      
    
  
proliferation of cells   
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Chapter 4 
Characterization of hTDP-43-containing Ribonucleoprotein Complexes 
4.1 Introduction 
According to the altered “ribostasis” model of ALS, TDP-43 and other ALS-associated 
proteins normally reversibly assemble into higher order RNP granules in response to cellular 
stress. In ALS, increased formation and decreased clearance of RNP granules can lead to their 
transformation into pathogenic inclusions. These inclusions sequester RNA binding proteins and 
their RNA targets, and can activate signaling pathways, such as those involved in 
neuroinflammation (Ramaswami et al. 2013).  
Strong evidence exists for the normal cellular formation and function of RNP granules. 
Stress granules and P-bodies, for instance, interact to regulate translation in response to cellular 
and extracellular conditions (Buchan&Parker 2009). TDP-43-containing RNPs transport mRNAs 
within neuronal processes (Alami et al. 2014). Immunoprecipitation experiments have outlined 
many of the components of these RNPs (Kato et al. 2012), however, a recently developed cell 
free system has revealed key aspects of RNP biology. The small molecule biotinylated isoxazole 
(b-isox) forms a precipitate within cell lysates that contains many of the components previously 
identified in cellular RNP granules. Precipitates contain RNAs previously identified within 
neuronal transport granules (Han et al. 2012). Precipitate formation depends upon the low 
complexity (LC) C-terminal domain of RNABPs. Hydrogels formed from concentrated LC 
domains of two RNABPs, FUS and hnRNPA2, can “trap” LC domains of other RNABPs and 
RNAs precipitated by b-isox. Ultrastructurally, LC domain-containing hydrogels reveal dynamic, 
amyloid-like fibrils (Kato et al. 2012). The LC domain, then, represents a very important feature 
in modulating the assembly and disassembly of RNABPs in RNP granules. 
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Of the 49 RNA binding proteins containing low complexity, or prion-like, domains, 
twelve have already been linked to neurodegenerative diseases, with likely more awaiting 
discovery. Disease-causing mutations in many of these proteins have been shown to promote 
misfolding and pathological amyloid formation (Li et al. 2013). The M337V and Q331K 
mutations in TDP-43, for example, increase stability, accelerate protein misfolding in in vitro, 
and increase aggregation in yeast (Ling et al. 2010, Johnson et al. 2009). In addition, mutations 
in FUS increase its recruitment into stress granules (Bosco, Lemay et al. 2010). This suggests 
that, although the prion-like domains of RNABPs allow these proteins to form RNP granules for 
normal cellular functions, mutation and other factors can transform functional RNP granules into 
pathogenic inclusions. It is important to note that inclusion formation may initiate toxicity, but it 
may also represent a downstream, and potentially protective response to an alternative primary 
insult. 
If RNP aggregates cause toxicity, then their clearance should ameliorate this toxicity. 
Support for this hypothesis comes from the observation that depletion of, and pathogenic 
mutations in VCP, an ALS-associated gene involved in autophagy, reduce stress granule 
clearance and can lead to the accumulation of TDP-43-containing granules (Buchan et al. 2013). 
In Drosophila, mutant VCP-mediated neurodegeneration is rescued by knockdown of the fly 
homologue of TDP-43 (Ritson et al. 2010). While these examples focus on VCP and TDP-43, 
they are likely representative of the importance of protein degradation pathways in clearing 
accumulated RNP aggregates, and defects in both RNP function and degradation pathways may 
together lead to neurodegeneration.  
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In summary, prion-like domains of RNABPs facilitate their assembly into RNP granules. 
ALS-causing mutations, defects in degradation pathways, and other factors can lead to the 
accumulation of pathogenically transformed RNP granules. A better understanding of the 
composition of these RNP granules, even in the absence of detectable aggregation, can shed light 
on pathways and molecules that may play a role in ALS disease mechanisms. In the previous 
chapter, we characterized the RNA components of TDP-43 RNP complexes. Here, we 
characterize interactions between TDP-43 and its protein-binding partners in cultured motor 
neurons in order to define the protein components of TDP-43 RNP complexes. We additionally 
investigated whether the ALS-causing M337V mutation might alter these interactions. We 
identify almost exclusively RNA-dependent interactions between TDP-43 and many proteins 
involved in RNA metabolism. Although we do not detect mutation-dependent alterations in 
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4.2 Results 
hTDP-43 Protein Binding Partners identified by mass spectrometry 
To establish a motor neuronal signature of hTDP-43 binding, and address the hypothesis 
that the M337V mutation alters interactions between TDP-43 and its protein binding partners, we 
immunoprecipitated myc-hTDP43WT and M337V with an anti-myc antibody from lysates of un-
purifed MN-differentiated ESCs (uES-MNs) collected at five days after MN induction.   In order 
to control for non-specific interactions between the lysate and the antibody or bead matrix, we 
additionally performed all experiments in an ESC line that contained only the Hb9::GFP 
transgene and not the τON allele. We submitted myc-peptide eluted protein samples, both RNAse-
treated and without RNAse treatment, for mass spectrometry, or MS (Figure 4.1A). We verified 
the presence of interacting proteins in the myc-tagged samples by silver staining (Figure 4.1B) 
and colloidal blue staining (Figure 4.1A schematic). The pattern of bands appears similar 
between the WT and M337V samples without (Figure 4.1B, lanes 2 and 4) or with (Figure 4.1B, 
lanes 3 and 5) RNAse treatment. We hypothesized that genotype-specific qualitative or 
quantitative differences in proteins with lower affinity for hTDP-43, might only be detectable 
with the sensitivity of an MS experiment.  
Although previous publications have identified TDP-43 interacting proteins in cell lines 
and the mouse brain, we sought to identify hTDP-43 protein-protein interactions within ES cell-
derived motor neurons (uES-MNs). MS revealed that myc-hTDP-43 interacts with 83 proteins, 
almost exclusively in an RNA-dependent manner (Table 4.1). To stratify interacting proteins by 
the strength of their interaction with myc-hTDP-43, we ranked the protein list by the sum of 
spectral counts in the non-RNAse treated samples. The MS data contained the greatest number of 
spectral counts for TDP-43, with peptide fragments mapping to both the endogenous and 
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exogenous proteins, to which we assigned a ranking of 0. The top ten interactors are listed in 
Figure 4.1G. 
Enrichment analysis of TDP-43 interacting proteins revealed enriched GO terms and 
KEGG pathways related to RNA processing, and enrichment of proteins involved in motor 
neuron disease (Figure 4.1H). Proteins involved in mRNA splicing compose 42% of hTDP-43 
interactors, while proteins involved in non-splicing RNA processing events compose 16% of 
interactors. Interestingly, 50% of interacting proteins associate with the nucleolus, and KEGG 
pathway analysis revealed an enrichment of proteins involved in ribosome biogenesis (p-value = 
5x10-4). These data corroborate previous reports of TDP-43 sub-nuclear localization to the 
nucleolus (Sasaki et al. 2010) and interaction with nuclear GEMs (Shan et al. 2010). Interacting 
proteins involved in motor neuron disease pathways predominantly linked to ALS (TDP-43, 
SNRPB2, EWSR1, and MATR3), although COIL interacts with SMN and therefore links to 
SMA (Herbert et al. 2001), while mutations in NOP56 cause a form of spinocerebellar ataxia, 
SCA36 (Kobayashi et al. 2011). Thus, TDP-43 interacting proteins predominantly mirror the 
roles of TDP-43 in RNA metabolism with particular enrichment of proteins that associate with 
the nucleolus and a subset of proteins involved in motor neuron diseases. 
In comparing hTDP-43WT protein interactors to those identified for hTDP-43M337V, we 
found that very few interactions showed any genotype-specific differences. The greatest 
genotype-specific difference occurred in interactions with γ-actin, which binds to hTDP-43WT 
and not to hTDP-43M337V in the non-RNAse treated samples. However, we were unable to 
validate this result by Western Blotting, as we could not detect γ-actin in our 
immunoprecipitates. Although published immunoprecipitation datasets did not identify an 
interaction between TDP-43 and γ-Actin, γ-Actin does decrease in the detergent insoluble 
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fraction of TDP-43 transfected HEK cells, supporting our MS data. Increasing evidence indicates 
a role for TDP-43 in cytoskeletal regulation and interactions (Wang et al. 2008, Godena et al. 
2011, Strong et al. 2007), however we do not yet understand the details of these interactions. 
Likewise, the role of γ-actin in neuronal cells, aside from hair cells in the ear that are 
compromised by mutations in γ-actin (Morin et al. 2009), requires further study to determine 
how disruption of the γ-actin cytoskeleton may cause neuronal dysfunction. 
 
Validation of hTDP-43 Protein Binding Partners in τON model systems 
Although MS data is highly sensitive, we sought to validate highly ranked interactions by 
Western blot, both in uES-MNs, as well as to test whether similar interactions could be detected 
in the mouse spinal cord. By Western blotting of immunoprecipitates, we were able to validate 
interactions in uES-MNs between hTDP-43 and Dhx9, Matrin3, IGF2BP3, and hnRNPU (Figure 
4.1F, and data not shown). In whole spinal cord τON immunoprecipitates, we also validated the 
interaction with Dhx9, as well as with ElavL proteins, of which Elavl2 was identified as an 
interacting partner (Figure 4.1E). Our validation experiments provide confidence in the 
biological relevance of the MS data.  
We were additionally interested in whether hTDP43 interacts with endogenous mouse 
TDP43.  We found that both hTDP43WT and M337V interact with endogenous mouse TDP43 in 
uES-MNs as well as in τON mouse spinal cords. This interaction is partially RNA-dependent in 
the ES-MNs and completely RNA-dependent in the spinal cord. The levels of interaction did not 
differ between the two genotypes in either system (Figure 4.1C-D). Because TDP-43 
homodimerizes (Kuo et al. 2009), we recognize that some, or all, of these interactions may result 
from dimerization of myc-hTDP-43 with endogenous mouse TDP-43.  In any case, these data 
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clearly indicate that the endogenous and exogenous proteins interact through oligomerization, 
dimer-dimer interactions, or indirectly in higher order protein complexes. 
 
Comparative Analysis with published TDP-43 Protein Binding Partners 
 Having validated specific interactions by Western Blotting, we were interested in the 
extent to which our uES-MN hTDP-43 interactors overlap with published TDP-43 interactomes. 
We found that covereage of our interactors ranges from 53% in the most extensive interactome 
from HEK293 cells (Freibaum et al. 2010), to 12 and 13% coverage of our targets in a TDP-43 
aggresome (Dammer et al. 2012), and in a mouse brain interactome (Sephton et al. 2012) 
respectively (Table 4.2). Aside from the extensive interactome (261 targets) that Freibaum and 
colleagues obtained from Flag-tagged TDP-43 transfected HEK cells, the three other published 
sets of TDP-43-associated proteins consist of only 46 targets of tagged TDP-43 transfected into 
HeLa cells (Ling et al. 2010), 41 co-aggregating proteins with transfected TDP-43 in HEK cells 
(Dammer et al. 2012), and 25 TDP-43 protein targets in the mouse brain (Sephton et al. 2012). 
As in all overexpression experiments involving TDP-43, results must be interpreted carefully as 
they may represent abberant, aggregation-induced interactions rather than physiological 
interactions with TDP-43 expressed at endogenous levels. 
To our knowledge, our uES-MN hTDP-43 interactors contain the second greatest number 
of TDP-43 interacting proteins identified in a single study, and the greatest number identified 
from a neuronal or motor neuronal cell population. In addition, uES-MNs most closely mimics 
the cell population of interest in ALS, namely in vivo MNs, and we are detecting interactions 
with the human proteins expressed at only a fraction of physiological levels, albeit in a mouse 
cells. The only other study approaching this disease-relevant context identified TDP-43 protein 
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binding partners in the mouse brain (Sephton et al. 2012), however brain tissue contains a wide 
variety of different cell types, including many non-neuronal cells, that might dilute relevant 
interactions. 
 As in our hTDP-43 targets, enrichment analyses reveal proteins involved in RNA 
processing, particularly mRNA splicing, in all TDP-43 interactomes. Identification of proteins 
involved in non-splicing aspects of RNA processing, however, differs among the datasets. One 
inconsistency among TDP-43 interacting proteins is whether TDP-43 interacts with components 
of the translational machinery, most commonly ribosomal proteins and translation initiation 
factors. The extent of interaction with components of the translational machinery ranges from 
almost half of the identified targets (Friebaum et al. 2010) to none of the identified targets (Ling 
et al. 2010). The TDP-43 aggresome is enriched for translation factors, however these 
interactions may be indirect because their identification did not involve an immunoprecipitation 
step (Dammer et al. 2012). Not surprisingly, TDP-43 interacting proteins were not significantly 
enriched for translational machinery in mouse brain nuclear extracts, however 2 of the 25 
interactors do play a role in translation (Sephton et al. 2012). Our analysis of uES-MN hTDP-43 
targets, as well as targets identified by stringent immunoprecipitation techniques in HEK cells 
(Ling et al. 2010), did not reveal enrichment for proteins involved in translation. Previous studies 
of TDP-43 in neuronal processes and stress granules indicate that its role in translation may be 
primarily inhibitory (Dewey et al. 2012, Wang et al. 2008).  Thus, TDP43 may not directly 
associate with the translational machinery, but rather sequester mRNA away from ribosomes in 
response to cellular signals. Additional studies of the cytoplasmic TDP-43 interactome will 
likely reveal the extent to which TDP-43 interacts with the translational machinery, and therefore 
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whether components of translation may aberrantly aggregate with TDP-43 in the context of 
TDP-43 proteinopathies. 
 In addition to its participation in translation, TDP-43 has been proposed to regulate 
microRNA processing through interactions with the microprocessor proteins Drosha and Dicer 
(Kawahara et al. 2012). However, co-IP/MS experiments have failed to confirm these 
interactions. In all immunoprecipitates studied (Table 2.2), including those from uES-MNs, 
TDP-43 interacts with ILF2, a negative regulator of microRNA processing.  In addition, TDP-43 
immunoprecipitates (Ling et al. 2010, Freibaum et al. 2010) and aggresomes (Dammer et al. 
2012) from HEK cells, as well as immunoprecipitates from uES-MNs, reveal an interaction with 
DDX5, a component of the microprocessor (Gregory et al. 2004).  Finally, TDP-43 interacts with 
microRNA processing proteins ILF3 and DDX17 in both HEK and uES-MN immunoprecipitates 
(Ling et al. 2010, Freibaum et al. 2010). While these interactions, in conjunction with 
identification of TDP-43 binding to miRNAs, suggest a possible role for TDP-43 in miRNA 
processing, these proteins also all perform other roles within the cell (Fuller-Pace 2006), and 
association through aggregate formation, in the case of overexpression and aggresome data, does 
not provide a strong argument for functional relevance. Therefore, further studies are necessary 
to elucidate the nature of the interaction between TDP-43 and microRNA processing 
components, and possible functional significance. 
Both HEK cell interactomes, as well as our uES-MN interactors and western blotting of 
immunoprecipitates from mouse spinal cords show that hTDP-43 interacts with Dhx9 (Ling et al. 
2010, Friebaum et al. 2010).  Interestingly, TDP-43 was not found to interact with Dhx9 in the 
adult mouse brain (Sephton et al. 2012), making our report the first to show an interaction 
between these two proteins in the mammalian central nervous system. Dhx9, or RNA helicase A 
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(RHA), is a multi-functional RNA and DNA binding protein that participates in X-chromosome 
dosage compensation, transcriptional activation, splicing, and nuclear export (reviewed in Fuller-
Pace 2006). In addition, Dhx9 plays a role in innate immunity both through binding to pathogen 
nucleotides, and through triggering cellular responses to these pathogens, such as the interferon 
response (reviewed in Fullam et al. 2013). Because inflammatory pathways have been shown to 
play a role in ALS pathogenesis (Boillee et al. 2006), the interaction between TDP-43 and Dhx9 
might factor in to this response. 
In HEK cells, as well as in our uES-MN interactome, both from cells in early stages of 
development, TDP-43 interacts with the three components of the IGF2BP complex (Ling et al. 
2010, Friebaum et al. 2010). We validated the interaction with IGF2BP3 by Western Blot of 
uES-MN immunoprecipitates (Figure 4.1F). This interaction was not found in the adult mouse 
brain (Sephton et al. 2012), and western blotting for IGF2BP3 in the mouse spinal cord produced 
no signal for this protein, suggesting that an IGF2BP complex with TDP-43 may play a 
developmental role. Zhang and colleagues reported that transport of β-actin mRNA to the growth 
cone and subsequent neurite extension requires IGF2BP1 (ZBP1) binding to a “zipcode” 
sequence in the β-actin mRNA 3’UTR (Zhang et al. 2001). Wang et al. reported that TDP-43 
associates with β-actin mRNA in mature hippocampal neurons (Wang et al. 2008). Based on 
these reports and our interactome data, we hypothesize that developing neurons require a 
complex of IGF2BPs and TDP-43 for transport of mRNAs necessary for neurite outgrowth, 
while mature neuronal synapses are maintained by TDP-43-mRNA complexes alone. 
Compared to published datasets, we identified 22 novel hTDP-43 interactors in uES-MNs 
with a combined spectral count in non-RNAse treated samples of >5, corresponding to a ranking 
<72, and a spectral count of zero in the control sample. Of these novel interactors, 14 (58%) are 
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involved in RNA metabolism, and four of these, DHX15 and three components of the SF3B 
complex, associate with both the minor U12-type spliceosome as well as the major U2 
spliceosome (Will et al. 1999, Will et al. 2004). Interestingly, Ishihara and colleagues found that 
sALS patient spinal cords contain significantly lower levels of U12 snRNA by qRT-PCR, as well 
as a marked decrease in nuclear immunofluorescence signal for a U12 snRNP component 
(Ishihara et al. 2013). Our finding that both hTDP-43WT and M337V interact with U12 spliceosome 
components provides support for the hypothesis that TDP-43 aggregation in ALS might interfere 




	   116	  
4.3 Discussion 
In this chapter, we have identified proteins that co-immunoprecipiate with hTDP-43 in an 
ALS-relevant cell culture system. Almost all interactions showed complete RNA dependence, 
and are therefore likely indirect indirections resulting from RNA binding. Aside from 
interactions with γ-actin, our data provides little support for the hypothesis that hTDP-43M337V 
interacts with its protein-binding partners in qualitatively or quantitatively different ways 
compared to hTDP-43WT. We did identify 22 novel TDP-43 interacting proteins not present in 
published datasets, including proteins that associate with both the U12 and U2 spliceosomes. 
Further studies are necessary to understand the potential differential role of TDP-43 in splicing, 
if any, by the major and minor spliceosomes.  
Comparisons between uES-MN hTDP-43 interacting proteins and published datasets 
reveals agreement about the role of TDP-43 in many aspects of RNA processing including, most 
conclusively, mRNA splicing. These data also provide support for the role of TDP-43 in miRNA 
processing, or at least its interaction with proteins that have been identified in the microprocessor 
complex. TDP-43 interactions with translational machinery are identified in some datasets and 
not others, potentially resulting from cellular stress caused by TDP-43 overexpression and the 
resulting formation of stress granules or abberant RNP granules. Multiple experiments, including 
ours, reveal an interaction between TDP-43 and Dhx9, which may be important in cellular 
responses to stress or exogenous nucleotides. Interactions between TDP-43 and IGF2BPs appear 
limited to non-mature cells and may represent a method of translational regulation restricted to 
developmental timepoints. 
Interestingly, despite reported associations between FUS and TDP-43 (Ling et al. 2010, 
Yamazaki et al. 2012), we do not detect interactions between FUS and myc-hTDP-43 in τON 
	  
	   117	  
model systems. In fact, we see only one overlap, ElavL1, between a published FUS interactome 
from HeLa cells (Yamazaki et al. 2012) and uES-MN hTDP-43 interactors. In terms of 
categories of proteins, like TDP-43, FUS interacts with spliceosomal components (Yamazaki et 
al. 2012, Gerbino et al. 2013) and spliceosome integrity is compromised in ALS (Tsuiji et al. 
2013). The lack of interaction between these proteins in τON systems may result from the 
presence of endogenous mouse TDP-43 competing with hTDP-43 in binding to FUS. 
Alternatively, direct indirections between FUS and TDP-43 may be more common in non-
neuronal cell lines but less so in neurons. Despite a lack of interaction, these proteins may very 
well function in a common pathway (Wang et al. 2011), and their aggregation in ALS may result 
in common pathogenic mechanisms of altered ribostasis. 
Thus, our data strengthens some previous conclusions regarding the physiological 
functions of TDP-43, weakens others, and offers potential new roles for TDP-43 in RNA 
metabolism. In addition, we can conclude that, at the expression levels present in our TDP-43 
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Figure 4.1: TDP-43 interacts with its protein targets in an RNA-dependent manner 
(A) Schematic of mass spectrometry experiment. Orange triangle represents myc peptide. Gel 
image is Coomassie stain of samples used for MS. (B) Silver stain of samples submitted for MS, 
arrow indicates myc-hTDP-43, arrowhead indicates endogenous mTDP-43. (A and B) 1=control, 
2 and 4 = no RNAse treatment, 3 and 5 = RNAse-treated. Western blot of co-immunoprecipitates 
from mouse spinal cord (C and E), and uES-MNs (D and F). (C and D) Mouse TDP-43 
interaction with hTDP-43 is RNA-dependent, asterisk indicates band of unknown origin. (E and 
F) Probe for interaction with indicated proteins identified by MS. (C-F) 1,4,7 = Ctrl; 2,5,8= myc-
hTDP-43WT; 3,6,9 = myc-hTDP-43M337V. (G) Top 10 interacting proteins from MS experiment 
and summary of validation experiments in uES-MN and mouse spinal cord samples. (H) Selected 
gene ontology (GO) terms and pathways enriched among TDP-43 interacting proteins.
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Term Identifier % of Proteins P-value
RNA processing GO:0006396 59 1.9E-46
mRNA Splicing GO:0000398 42 6.8E-44
nucleolus GO:0005730 51 5.0E-23
Spliceosome KEGG3040 27 3.7E-30
Ribosome biogenesis KEGG3008 5 5.0E-04
Motor Neuron Disease DB_ID:PA446329 6 1.5E-03
Enrichment Analysis
Rank Gene Name uES-MN Spinal Cord
0 TARDBP Y Y
1 IGF2BP1 ND ND
2 YBOX1 ND ND
3 DHX9 Y Y
4 MATR3 Y N
5 ELAVL2 ND Y
6 IGF2BP3 Y N
7 HNRNPL ND ND
8 HNRNPU Y ND
9 PABPC1 ND ND
10 HNRNPH1 ND ND
Validation
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Table 4.1: Proteins that interact with myc-hTDP-43 in uES-MNs. 
  No RNAse RNAse-treated 
Rank Gene Name MW Ctrl WT M337V WT+ M337V+ 
0 TARDBP 45 kDa 0 143 136 135 125 
1 IGF2BP1 63 kDa 0 127 115 18 23 
2 YBOX1 36 kDa 0 81 99 5 0 
3 DHX9 150 kDa 0 88 90 0 0 
4 MATR3 95 kDa 0 84 83 0 0 
5 ELAVL2 43 kDa 0 76 76 0 0 
6 IGF2BP3 64 kDa 0 81 65 7 15 
7 HNRNPL 67 kDa 0 57 68 0 0 
8 HNRNPU 87 kDa 0 60 57 3 2 
9 PABPC1 71 kDa 0 55 61 0 0 
10 HNRNPH1 49 kDa 0 52 58 0 0 
11 HNRNPC1 33 kDa 0 50 43 0 0 
12 IGF2BP2 66 kDa 0 53 38 0 0 
13 ILF3 98 kDa 0 45 42 0 0 
14 HNRNPA3 34 kDa 0 39 46 0 0 
15 HNRNPA2B1 37 kDa 0 34 43 0 0 
16 RBMXL1 42 kDa 0 37 34 0 0 
17 HSPA8 71 kDa 2 33 38 68 49 
18 NOLC1 74 kDa 0 34 33 0 0 
19 DDX5 69 kDa 0 34 29 0 0 
20 HNRNPM 74 kDa 0 33 27 9 12 
21 DDX17 73 kDa 0 32 26 0 0 
22 HNRNPF 44 kDa 0 32 25 0 0 
23 NOP58 60 kDa 0 31 24 0 0 
24 ELAVL3 40 kDa 0 24 31 0 0 
25 GM7729 34 kDa 0 31 23 0 0 
26 ACTG1 42 kDa 0 49 0 13 6 
27 COIL 62 kDa 0 25 24 0 0 
28 NOP56 64 kDa 0 21 17 0 0 
29 SNRNP200 245 kDa 0 19 19 0 0 
30 RALY 32 kDa 0 15 23 0 0 
31 DKC1 57 kDa 0 21 16 0 0 
32 CHTOP 22 kDa 0 19 18 0 0 
33 HNRNPR 60 kDa 0 17 19 0 0 
34 SF3B1 146 kDa 0 15 21 0 0 
35 ILF2 43 kDa 0 16 19 0 0 
36 HNRNPAB 36 kDa 0 17 17 0 0 
37 EFTUD2 109 kDa 0 19 14 0 0 
38 HNRNPK 49 kDa 0 17 16 0 0 
39 SF3A1 89 kDa 0 16 17 0 0 
40 GM10110 68 kDa 0 16 14 0 0 
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41 FBL 34 kDa 0 15 15 0 0 
42 EIF4A2 41 kDa 0 11 18 0 0 
43 PCBP2 35 kDa 0 17 10 0 0 
44 HNRNPD 33 kDa 0 12 14 0 0 
45 ZNF326 65 kDa 0 13 11 0 0 
46 DDX3Y 73 kDa 0 13 11 0 0 
47 UPF1 123 kDa 0 14 9 0 0 
48 SF3B3 125 kDa 0 12 11 0 0 
49 DHX15 91 kDa 0 11 10 0 0 
50 ELAVL1 36 kDa 0 11 10 0 0 
51 SFPQ 75 kDa 0 10 6 0 0 
52 RBM14 69 kDa 0 6 10 0 0 
53 PRPF8 274 kDa 0 8 7 0 0 
54 SSB 48 kDa 0 9 5 0 0 
55 SYNCRIP 52 kDa 0 8 6 0 0 
56 GM5449 14 kDa 0 8 5 0 0 
57 SNW1 61 kDa 0 7 6 0 0 
58 PABPN1 34 kDa 0 8 4 0 0 
59 SNRPA1 28 kDa 0 5 6 0 0 
60 PTBP1 57 kDa 0 3 8 0 0 
61 THRAP3 108 kDa 0 3 7 0 0 
62 SF3B2 98 kDa 0 4 5 0 0 
63 RBM39 59 kDa 0 4 5 0 0 
64 DSG1B 114 kDa 0 0 9 9 7 
65 TRY10 26 kDa 0 8 0 0 0 
66 NEFM 96 kDa 0 4 4 41 60 
67 EWS 68 kDa 0 0 7 0 0 
68 PININ 82 kDa 0 6 0 0 0 
69 PRPF19 57 kDa 0 3 3 0 0 
70 ERH 12 kDa 0 3 3 0 0 
71 RPL13 24 kDa 0 5 0 0 0 
72 ZC3H14 65 kDa 0 3 2 0 0 
73 SNRPB2 25 kDa 0 0 5 0 0 
74 FAM120A 122 kDa 0 0 5 0 0 
75 SF3A3 59 kDa 0 4 0 0 0 
76 HIST1H2AL 14 kDa 0 4 0 0 0 
77 AINX 55 kDa 0 2 2 65 89 
78 NCOA5 65 kDa 0 3 0 0 0 
79 BCLAF1 100 kDa 0 0 3 0 0 
80 ANXA2 39 kDa 0 2 0 0 0 
81 LRP1 505 kDa 0 0 2 2 0 
82 LRP2 519 kDa 0 0 2 0 0 
83 RBM25 100 kDa 0 0 2 0 0 
*Ctrl represents uES-MNs from a pure Bl6 background with no τ allele. 
Green highlighting indicates the only genotype-specific differential interactor. 
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Table 4.2: Overlap between uES-MN hTDP-43 Interactions and published TDP-43 
Interactomes/Aggregesome. 
Rank Gene Name Freibaum et al. 2010 
Ling et al. 
2010 
Dammer 
et al. 2012 
Sephton 
et al. 2012 Sum 
1 TARDBP 1 0 1 1 3 
4 DHX9 1 1 1 0 3 
8 HNRNPL 1 1 0 1 3 
10 PABPC1 1 1 1 0 3 
12 HNRNPC 1 1 0 1 3 
16 HNRNPA2B1 1 1 0 1 3 
17 RBMX 1 1 0 1 3 
20 DDX5 1 1 1 0 3 
36 ILF2 1 1 0 1 3 
37 HNRNPAB 1 1 0 1 3 
39 HNRNPK 1 1 0 1 3 
52 SFPQ 1 0 1 1 3 
2 IGF2BP1 1 1 0 0 2 
3 YBX1 1 1 0 0 2 
5 MATR3 1 1 0 0 2 
7 IGF2BP3 1 1 0 0 2 
9 HNRNPU 1 1 0 0 2 
11 HNRNPH1 1 1 0 0 2 
13 IGF2BP2 1 1 0 0 2 
14 ILF3 1 1 0 0 2 
15 HNRNPA3 1 1 0 0 2 
21 HNRNPM 1 1 0 0 2 
22 DDX17 1 1 0 0 2 
24 NOP58 1 0 1 0 2 
31 RALY 1 1 0 0 2 
34 HNRNPR 1 0 0 1 2 
45 HNRNPD 1 1 0 0 2 
51 ELAVL1 1 1 0 0 2 
53 RBM14 0 1 1 0 2 
56 SYNCRIP 1 1 0 0 2 
61 PTBP1 1 1 0 0 2 
6 ELAVL2 1 0 0 0 1 
18 HSPA8 1 0 0 0 1 
23 HNRNPF 0 1 0 0 1 
27 ACTG1 0 0 1 0 1 
29 NOP56 1 0 0 0 1 
30 SNRNP200 1 0 0 0 1 
32 DKC1 0 0 1 0 1 
38 EFTUD2 1 0 0 0 1 
40 SF3A1 0 0 0 1 1 
42 FBL 1 0 0 0 1 
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44 PCBP2 1 0 0 0 1 
46 ZNF326 0 1 0 0 1 
48 UPF1 1 0 0 0 1 
55 SSB 1 0 0 0 1 
60 SNRPA1 1 0 0 0 1 
64 RBM39 1 0 0 0 1 
68 EWSR1 0 0 1 0 1 
70 PRPF19 1 0 0 0 1 
72 RPL13 1 0 0 0 1 
19 NOLC1 0 0 0 0 0 
25 ELAVL3 0 0 0 0 0 
26 GM7729 0 0 0 0 0 
28 COIL 0 0 0 0 0 
33 CHTOP 0 0 0 0 0 
35 SF3B1 0 0 0 0 0 
41 GM10110 0 0 0 0 0 
43 EIF4A2 0 0 0 0 0 
47 DDX3Y 0 0 0 0 0 
49 SF3B3 0 0 0 0 0 
50 DHX15 0 0 0 0 0 
54 PRPF8 0 0 0 0 0 
57 GM5449 0 0 0 0 0 
58 SNW1 0 0 0 0 0 
59 PABPN1 0 0 0 0 0 
62 THRAP3 0 0 0 0 0 
63 SF3B2 0 0 0 0 0 
65 DSG1B 0 0 0 0 0 
66 TRY10 0 0 0 0 0 
67 NEFM 0 0 0 0 0 
69 PNN 0 0 0 0 0 
71 ERH 0 0 0 0 0 
  Sum 43 29 10 11   
  uES-MN (%) 51.8% 34.9% 12.0% 13.3%   
  Dataset (%) 16.5% 63.0% 24.4% 44.0%   
Note: 1 indicates the presence of the interactor in a given dataset while 0 indicates its absence.  Percentages indicate 













 TDP-43 and ALS research converged with the two seminal discoveries of TDP-43 as the 
major protein component of aggregates in the post-mortem ALS nervous system in both sporadic 
and familial cases, and mutations in TDP-43 accounting for a small percentage of familial ALS 
cases. As a ubiquitous RNA binding protein, TDP-43 is thought to play a role in various aspects 
of RNA metabolism from transcription to translation and sequestration of RNA in stress 
granules. However, a clear understanding of the function of TDP43 in any of these cases has not 
yet emerged.  For example, in spite of much effort, the direct role of TDP43 in splicing remains 
uncertain.  Efforts to determine how mutation affects these proposed functions, and which 
functions might be perturbed in ALS, have met with great difficulty, primarily because mouse 
models have shown that conditional knockdown, WT overexpression, and mutant overexpression 
can all yield motor phenotypes. It is difficult to ascertain the relationships of these phenotypes to 
ALS disease. Therefore, my dissertation research has focused on a novel mouse and cell culture 
model of TDP-43. By controlling and equalizing the expression levels of mutant and WT TDP-
43, we hoped to create a system that would more accurately reveal mutation-dependent, ALS-
related changes while also providing information about the physiological role of TDP-43 in 
MNs. 
 We found that expression of both WT and mutant human TDP-43 at 30% of endogenous 
levels, from the mouse τ locus, did not downregulate endogenous TDP-43. Although present in 
the cytoplasm to a greater extent than mTDP-43, subcellular localization of hTDP-43WT did not 
differ from that of hTDP-43M337V.  Protein-protein interaction assays revealed that hTDP-43 
interacts with other hnRNPs, splicing factors, and RNA processing proteins, twenty-two of 
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which have not been identified previously.  Importantly, we found that this association was  
highly RNA-dependent.  We identified over 5000 RNAs to which hTDP-43 binds in the τON 
mouse spinal cord, a proportion of which is shared with published datasets of TDP-43 RNA 
targets, and that reveal consensus pathways whose RNAs are bound by TDP-43. In terms of 
RNA targets, we did not detect significant genotype-specific differences. Through transcriptional 
profiling, we did identify an inflammatory phenotype among genes upregulated in the τONhTDP-
43M337V spinal cord, however, it is difficult to ascertain the relevance of this profile in the context 
of phenotypic analyses. Despite the detection of an ALS-like phenotype from mice on a mixed 
genetic background, hTDP-43M337V mice and ES-MNs from a pure genetic background did not 
exhibit any signs of decreased MN viability or molecular hallmarks of motor neuron disease 
compared to hTDP-43WT. 
 Our studies have gathered some important novel information about normal functions of 
TDP-43, such as confirming its interactions with Dhx9 in nervous system tissue and revealing 
potential interactions with the U12 spliceosome. In addition, we have clarified the size and 
distribution of UG-rich motifs at TDP-43 RNA binding sites, and have developed a broadly 
relevant set of pathways regulated by TDP-43-RNA interactions. Interestingly, in the assays 
described in this thesis, cells and mice expressing hTDP-43M337V differ very little from those 
expressing hTDP-43WT, despite indications of phenotypic differences on a mixed genetic 
background. 
  The results of studies of the majority of mice analyzed in this thesis indicate that hTDP-
43M337V expression does not result in differences in autoregulation, subcellular localization, 
protein-protein interactions, protein-RNA interactions, or MN viability.  However, it is important 
to note that these results do not represent a strong deviation from published studies.. A primary 
	  
	   125	  
obstacle in TDP-43 research lies within the tight regulation of homeostatic protein levels. 
Because both overexpression and lack of expression of the WT protein can result in motor 
deficits, perturbation of this tight regulation by a variety of factors, including mutation, stressors, 
diet, genetic modifiers, etc., might itself lead to the motor neuron dysfunction characteristic of 
ALS (Figure 5.1). In ALS, then, a trigger likely initiates loss of TDP-43 autoregulation leading 
to mislocalization and potentially a gain of toxic properties in the cytoplasm. In the pure 
background τON system, then, hTDP-43M337V and WT expression occurred at levels too low to tip 
the balance of total TDP-43 in the pathogenic direction.  However TDP43 levels too high might 
have yielded a phenotype in both the mutant and WT cases. In a way, then, we may have created 
a titrateable system, potentially susceptible to stressors that might trigger disease.  
The genetic modifier that is likely present in mice of mixed genetic background may 
represent a second “hit” that can, together with TDP-43 mutation, lead to motor neuron disease.  
This second “hit” could occur in a variety forms. It might affect cellular transport leading to local 
accumulations of RNA granules that could disrupt TDP-43 proteostasis (Pesiridis et al. 2011). It 
could involve a mutation in a non-neuronal support cell, such as astrocytes or microglia, that 
create a stressed environment surrounding vulnerable MNs. It also might affect protein 
degradation pathways such as the ubiquitin-proteasome system or authophagy, both of which 
show evidence of dysfunction in certain forms of ALS (Lee et al. 2011).  With recovery of a 
motor phenotype in mice on a mixed genetic background, and potentially other modifications to 
diet or environment, this model will provide a very powerful tool in the study of TDP-43-
mediated neurodegeneration and hopefully aid in distinguishing between potential second “hits” 
that permit the manifestation of effects of TDP-43 mutation. 
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Figure 5.1: Model of TDP-43 Mislocalization and Aggregation 
Soluble TDP-43 binds to RNA (orange line). Likely one or more “hits” listed in the center tip the 
















Generation of mice and mouse genetics (Primarily the work of Dr. Aarti Sharma) 
All procedures were performed in accordance with the National Institutes of Health 
Guidelines on the Care and Use of Animals and approved by the Institutional Animal Care and 
Use Committee (IACUC) at Columbia University. 
The tOFFhTDP-43 mouse lines were generated using a vector modified from that designed 
to target the mouse MAPT (tau) genomic locus by homologous recombination (Hippenmayer et 
al. 2005). This targeting vector was modified to include a LoxP-flanked transcriptional “stop” 
sequence (poly-A3) followed by a myc-tagged human TDP-43 cDNA (hTDP-43WT or hTDP-
43M337V generously provided by Brian McCabe). 
To generate tOFFhTDP-43WT and tOFFhTDP-43M337V mouse lines the targeting constructs 
(described in Experimental Procedures) were electroporated into Ola/129 ES cells.  Homologous 
recombinants were detected in approximately 35% of G418 resistant ES cell clones by Southern 
analysis using a probe in the 5’ region, as described previously (Bibel & Barde 2000).  Positive 
ES cell clones were injected into mouse blastocysts to generate chimeras, which were then back-
crossed, save the small mixed background cohort, to the C57BL/6J strain for 6 generations to 
establish the τ OFF mouse lines. τON mice were generated by crossing τOFF and Protamine-Cre 
mouse lines. τMN mice were generated by crossing tOFF and ChAT-Cre mice.  
C57BL/6J (Stock # 000664), ChAT-Cre (Stock #018957), Protamine-Cre (Stock # 
003328) and Hb9::GFP (Stock # 005029) mouse lines were obtained from the Jackson 
Laboratory (Bar Harbor, Maine, United States).  ChAT-Cre and Protamine-Cre lines were back-
crossed to the C57BL/6J strain for 6 generations.  
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Tissue preparation for immunohistochemical analysis  
Animals were deeply anesthetized using ketamine (100mg/kg) and xylazine (10mg/kg) 
and transcardially perfused with 4% paraformaldehyde in 0.1M phosphate buffer, pH 7.4 (4% 
PFA). For muscle analysis, tibialis anterior (TA) and soleus (SO) muscles were dissected, post-
fixed for 2 hours by immersion in 4% PFA, and washed in 1x phosphate buffered saline, pH 7.4 
(PBS).  Muscles were then equilibrated in a gradient of sucrose (10%-20%-30% sucrose in 0.1M 
phosphate buffer, pH 7.4), embedded in O.C.T. compound (Sakura, Torrance, CA) and frozen at 
−20°C.  Consecutive sections (30-40µm thick) were cut using a freezing microtome (Leica CM 
3050S) and stored at −20°C. 
Spinal cords were isolated, immersion-fixed overnight in 4% PFA, and washed in 1x 
PBS.  Spinal cord segments were embedded in 4% low melting point agarose (Promega) and 
serial transverse sections (70µm) were cut using a vibratome (Leica VT 1000S) and processed 
free-floating.  
 
Muscle innervation analysis 
Cryosections of muscle (30-40µm) were stained with antibodies against synaptophysin 
(Syn) to identify the pre-synaptic terminal, and tetramethylrhodamine-conjugated α-
bungarotoxin (α-BTX, Invitrogen) to detect post-synaptic acetylcholine receptors (AChR).  
Images were acquired using Zeiss Pascal LSM 510 confocal microscope using a 10x objective.  
Percentage (%) neuromuscular junction (NMJ) innervation was determined by dividing the total 
number of areas of overlap between Syn and α-BTX signals (innervated endplates) by the 
number of areas α-BTX signal (all endplates). 
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Immunohistochemistry of spinal cord sections 
Free-floating spinal cord sections were blocked with 5% normal donkey serum diluted in 
Tris buffered saline (pH 7.4) with 0.2% Triton X-100 (TBS-T) and incubated in primary antisera 
(Supplemental Table 1) diluted in TBS-T with 5% normal donkey serum overnight at room 
temperature.  After washing with TBS-T, tissue sections were incubated for 4 hours at room 
temperature with species-specific secondary antibodies coupled to Alexa 405, 488, 555, 647 
(1:1,000; Life Technologies, Carlsbad, CA, USA), Cy3 or Cy5 (dilution 1:500; Jackson 
Immunoresearch Labs, West Grove, PA, USA).  After washing with TBS-T, stained tissue 
sections were mounted on microscope slides in Flouromount G (Southern Biotech) and imaged 
using an Olympus FV 1000 confocal microscope. 
 
Motor Neuron Counts 
The lateral motor column (LMC) of lumbar spinal segment L5 was imaged as a z-series 
of confocal optical sections at a 20x magnification (z-step of 1.5µm).  Motor neurons (MNs) 
labeled with an anti-choline acetyltransferase (ChAT) antibody were counted by outlining the 
cell body in the confocal plane of the nucleolus using ImageJ. 
 
Statistical Analysis 
For all statistical tests, Graph Pad Prism 6 software (La Jolla) was used. Statistical 
analysis of mean differences between groups was performed using either one- or two-way 
ANOVA, followed by a Bonferroni post hoc analysis or Fisher’s LSD test depending on the 
number of variables and time-points in each experiment. All error bars represent the standard 
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error of the mean (SEM) of n=3 biological replicates, unless otherwise indicated, and non-
significance was determined at a p-value cutoff of 0.05. 
 
Derivation of mouse ESCs 
ESC lines were derived as previously described with some variations (Digiorgio et al. 
2007).  Briefly, mice transgenic for Hb9::GFP (Jackson lab, Stock #005029) were mated with 
either τONhTDP-43WT or τONhTDP-43M337V mice. Females were checked daily for a vaginal plug 
indicating successful mating and killed 3 d after the vaginal plug appeared. Blastocysts were 
flushed from the uterine horn with kES cell medium (knockout-DMEM (GIBCO), 20% 
Knockout Serum Replacement (Life Technologies), 100 unit/ml penicillin and 0.1 mg/ml 
streptomycin (Life Technologies), 2mM Glutamax (Invitrogen),  
100 mM nonessential amino acids (Millipore), 55 mM 2-mercaptoethanol (Millipore), 1x 
Nucleosides (100x, Milipore) and 1,000 units/ml leukocyte inhibiting factor (Chemicon)) and 
squeezed out with forceps. Blastocysts were plated individually into one 10-mm well of a tissue 
culture dish containing mitotically inactivated mouse embryonic fibroblasts (Global Stem Cells) 
and kES medium supplemented with the MEK kinase inhibitor PD98059 (Cell Signaling). At 48 
h after plating, one half volume of fresh mES medium (same as kES except with 15% ES-FBS 
(Invitrogen) in place of Knockout Serum Replacement) was added to each culture well. Medium 
was changed on alternating days thereafter. At 7-10d after plating, inner cell mass-derived 
outgrowths were dislodged with a P20 pipette tip, and incubated for 6-7 minutes in a drop of 
0.25% trypsin at 37 °C. ESC clumps were transferred onto a fresh layer of fibroblasts and gently 
dissociated with a pulled capillary needle inserted into a P200 pipette tip. For routine culture, the 
mouse ESCs were generally split 1:4 with a solution of 0.05% trypsin (GIBCO) every 2–3 d. 
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Differentiation of mES cells into motor neurons  
Mouse ES cells were differentiated into motor neurons according to methods previously 
described (Wichterle et al. 2002; Biollee et al. 2006; Digiorgio et al. 2007). ES cells were 
cultured to 70–80% confluence in 24mm wells of 6 well culture dishes (Corning) in mES 
medium (see recipe above). To form embryoid bodies, cells were given fresh medium 2 hours 
prior to trypsinization, washed one time with PBS, and then incubated with 0.5 mL 0.05% 
trypsin (Life Technologies) for 3 minutes at 37 °C. Cells were then resuspended in 12 mL 
aDFNK medium (1:1 ratio of Advanced DMEM/F12 (Invitrogen):Neurobasal Medium (Life 
Technologies), 10% knockout serum replacement (Life Technologies), 100 unit/ml penicillin and 
0.1 mg/ml streptomycin (Life Technologies), 2mM Glutamax (Invitrogen),  
55 mM 2-mercaptoethanol (Millipore)), counted, and plated at a concentration of ∼800,000 
cells/mL in 10cm dishes (Corning).  
The next day (d1), cells were given fresh aDFNK medium. On d2, embryoid bodies were 
split from one dish into two Petri dishes (Fisher) containing aDFNK medium supplemented with 
100 nM retinoic acid (Sigma) and 500nM sonic hedgehog agonist (VWR). On d4, embryoid 
bodies were given fresh aDFNK containing 1 ng/mL GDNF (Peprotech). On d5, the embryoid 
bodies were dissociated into single-cell suspensions. The embryoid bodies were pelleted by 
gravity in a 15mL Falcon tube, washed one time with PBS containing 0.4% glucose (Sigma), and 
incubated with agitation in Earle’s balanced salt solution with 20 units papain and 1,000 units 
DNase I (Worthington Biochemical) for 5 minutes at 37 °C. Ovomucoid albumin inhibitor 
(Worthington Biochemical) was then added to quench the papain, cells were pelleted by gravity, 
the supernatant was aspirated and cells were resuspended in 2mL of GPBD (PBS for Cell 
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Culture (Lonza/VWR), 0.4% glucose (Sigma), 2.5% horse serum (Life Technologies), B-27 
Supplement (Life Technologies), 3mM MgCl2, DNAse (Sigma)). The mixture was then triturated 
with a P1000 pipette tip no more than 10 times. Additional GPBD was added to a final volume 
of 10mL, undissociated material was permitted to settle to the bottom of the tube and the cloudy 
supernatant was transferred to a clean 15mL tube. A 4% BSA cushion was then layered at the 
bottom of tube with a long glass pipette and the density gradient was centrifuged for 5 minutes at 
400 × g to pellet cells at the bottom of the tube and capture cellular debris at the BSA/GPBD 
interface. The resulting cell pellet was washed with GPBD and pelleted again for 5 minutes at 
400xg. Cells were then either resuspended directly in MN medium (Neurobasal medium (Life 
Technologies), with 2% horse serum and penicillin-streptomycin (Life Technologies), B-27 
supplement (Life Technologies), N2 supplement (Life Technologies)) with neurotrophic factors 
(glial cell line-derived neurotrophic factor (GDNF), ciliary neurotrophic factor (CNTF), 
neurotrophin-3 (NT3), and brain-derived neurotrophic factor (BDNF); 10 ng/mL, Peprotech) for 
plating, or in GPBD for sorting on a MoFlo XDP cell sorter from Beckman Coulter, and then in 
MN medium. 
The cells were counted and plated on 96 well plates (VWR, for live imaging) precoated 
with poly-L-ornithine (Sigma), Laminin (Sigma), and Fibronectin (Sigma), or 12-mm coverslips 
(for immunocytochemistry, BD Biosciences). For MN co-culture with glia, glia monolayers were 
obtained as described previously (Phatnani et al. 2013). Live imaging was conducted with the 
Trophos Plate Runner HD® every day for 5-7 days (Luminy Biotech Enterprises), and MN 
tracing and counting by Metamorph Software (Molecular Devices). Data represent at least three 
technical replicates for each experimental condition and n=3 different differentiation 
experiments. 
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Protein Extraction and Quantitation 
Whole spinal cords, brains, and ES-MNs were homogenized in lysis buffer (50mM Tris-
HCl, 1% NP-40, 0.25% sodium deoxycholate, 150mM NaCl, 1mM EDTA, pH 7.5) with protease 
and phosphatase inhibitors added fresh (Roche).  Protein extracts were quantified by BCA assay 
(Fisher Scientific).  Extracts (10-25µg) were mixed with 4x LDS Running Buffer and 10x 
Reducing Agent (Invitrogen) and run on a 4-12% Novex Bis-Tris gel and transferred onto an 
Immunoblot PVDF membrane (Bio-Rad) using an X-cell II Blot module transfer unit (Life 
Technologies).  Immunoblots were probed with primary antibodies (Table 6.1).  Bound antibody 
was detected by incubation with secondary antibodies conjugated to horseradish peroxidase 
(Jackson Immunoresearch) followed by chemiluminescence using a SuperSignal West Pico 
chemiluminescent substrate (Thermo Scientific). Signal was detected by autoradiography using 
Biomax MR Film (Fisher Scientific).  Relative protein levels were calculated using ImageJ.  
 
Immunoprecipitation  
To immunoprecipitate myc-hTDP-43, anti-myc tag antibody (Millipore) was crosslinked 
to protein G Dynabeads. Total spinal cords or uES-MNs were lysed in ice-cold lysis buffer 
(described above) for 15-30 minutes and pre-cleared by centrifugation.  Lysates were quantified 
using the Pierce™ 660 Protein Assay Kit (Thermo Scientific) and loaded at equal concentration 
onto antibody cross-linked beads at a ratio of 1.6ug of antibody (conjugated to 25uL of beads) 
per 1ug of total protein. Bound proteins were eluted either with 2.5mg/mL of myc peptide 
(Pierce) or LDS sample buffer and run on a 4-12% NuPage Novex Bis-Tris gel and, for Western 
blot, transferred to nitrocellulose and probed with antibodies as described above. 
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For co-immunoprecipitation experiments, proteins were visualized using either a silver 
stain kit (Biorad) or colloidal blue staining kit (Invitrogen). In the case of colloidal blue staining, 
samples were electrophoresed so that the leading edge of the sample lay at roughly 1/3 of the 
total gel length. Gel slices containing all co-immunoprecipitated species were cut, proteins 
extracted, and subjected to protease digestion and mass spectrometry analysis by the Columbia 
University Proteomics Core Facility. Proteins that interact with TDP-43 were identified by 
spectral counts from the mass spectrometry experiment. 
 
RNA Extraction and Quantitation 
Whole brains, whole spinal cord, and ES-MNs were collected and RNA was extracted 
with TRIzol reagent (Invitrogen) and purified according to the provided protocol, with slight 
modifications. Briefly, spinal cord samples were homogenized in 500uL of TRIzol reagent by 
passing 5x through serially smaller gauge syringes (18 guage, 20 gauge, and 23 gauge), followed 
by centrifugation to remove cellular debris. Tissue and cellular samples were then subjected to 
the same treatment, beginning with bromo-chloropropane phase separation. The RNA-containing 
aqueous phase was then mixed with 1 volume of 100% isopropanol and the RNA carrier 
glycoblue to precipitate RNA. RNA was then treated with Turbo DNAse (Ambion) for 30-45 
minutes at 37°C, extracted with phenol/chloroform (<company for acid phenol/chloroform>), 
and precipitated a second time with 1 volume of 100% isopropanol, ammonium acetate, and 
glycoblue. RNA samples were then either submitted for cDNA library preparation and RNA-
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Quantitative PCR Analysis of Spinal Cord and ES-MN RNA 
Prior to reverse transcription, RNA samples were quantified and assessed for purity using 
the Nanodrop spectrometer, and a small volume was subjected to RNA electrophoresis to assess 
integrity. RNA samples were reverse transcribed using the Superscript III Reverse Transcriptase 
kit (Invitrogen). For quantitative RT-qPCR analysis, each sample was measured in triplicate with 
a Mastercycler EP Realplex4 (Eppendorf) PCR system and VeriQuest Fast SYBR Green qPCR 
Master Mix with Fluorescein (Affymetrix).  RT-qPCR data was normalized to β-actin.  Primers 
used in this study are listed in Table 6.2. 
 
cDNA Library Preparation and RNA Sequencing Data Analysis 
Libraries were prepared from RNA using either standard protocols from Illumina or the 
Nextera transposase-mediated method (Gertz et al. 2012) and sequenced using the Illumina 
platform. Sequenced reads were mapped to the mouse genome sequence [University of 
California at Santa Cruz (UCSC) mm10] and also a library of known exon–exon junctions using 
bowtie (Langmead et al. 2009). Both aligned and junction reads were then annotated against the 
UCSC known gene set (Karolchik et al. 2014). Reads per kilobase per million mapped reads 
(RPKM) values of raw read counts were calculated using DESeq (Anders & Huber 2010). All 
these individual steps were carried out in an automated fashion using ExpressionPlot 
(Friedman&Maniatis 2011), which was also used to generate the two-way (comparing RPKM 
values) plots. Alternative splicing analysis was carried out using a junction read aligner, Olego 
(Wu et al. 2013), and Quantas, a platform to analyse splicing using RNA-seq data that was 
developed by Chaolin Zhang. Both of these tools are freely available at 
http://zhanglab.c2b2.columbia.edu/index.php/Resources. 
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HiTS-CLIP Library Preparation and Sequencing 
Two different CLIP protocols were used, summarized in Figure 6.1. Standard CLIP 
libraries were prepared from iMNs (Appendix 1) as described previously  (Darnell, 2010; 
Licatalosi et al., 2008; Moore et al., 2014), with a commercially available anti-TDP-43 antibody 
(Proteintech), and the linker and primer sequences listed in Table 6.3. HiTS-CLIP experiments 
were performed with whole spinal cord tissue as previously described (Weyn-Vanhentenryck et 
al. 2014), using and anti-myc tag antibody (Millipore) and oligos listed in Table 6.3. The 
resulting libraries prepared with both standard CLIP and BrdU-CLIP protocols were sequenced 
by Illumina Hi-Seq 2000. 
 
HiTS-CLIP Data Analysis 
HITS-CLIP data analysis was performed as described previously (Moore et al. 2014, 
Zhang&Darnell 2011, Weyn-Vanhentenryck et al. 2014), including the following steps: filtering 
out of low quality reads (mean quality score of the first 25 positions ≥20), removal and separate 
recording of index and barcode sequences, mapping to the mm10 reference genome using the 
novoalign program (http://www.novocraft.com) allowing for ≤2 mismatches (substitutions, 
insertions, or deletions) per read with a minimum matching length of 25nt, and removal of PCR 
duplicates with identical barcode sequences. 
CLIP tag clusters were identified by grouping overlapping CLIP tags (Moore et al., 
2014), and the statistical significance of CLIP tag cluster peak height was evaluated using scan 
statistics as described previously (Charizanis et al., 2012). Simultaneous CIMS analysis was 
conducted to map binding sites at single nucleotide resolution (Zhang et al. 2011), however, we 
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proceeded with our analysis using the defined CLIP clusters to facilitate comparison to published 
datasets. Binding sites were sorted by peak height and assigned a site ranking (SR) based on the 
sorted list order. Significance of quantitative peak height differences between WT and M337V 
samples was determined by a two-tailed t-test with Bonferroni correction for multiple 
comparisons. 
 
Functional Analyses  
To perform functional enrichment analysis, we used (i) Qiagen’s Ingenuity ® Pathway 
Analysis (IPA ®, QIAGEN Redwood City, www.qiagen.com/ingenuity) for comparative 
analyses of large gene lists, which assesses statistical significance using right-tailed Fisher exact 
test to calculate a P value determining the probability that each biological function and/or disease 
assigned to that dataset is caused by chance alone, and (ii) WebGestalt for single analysis of 
smaller gene lists (Zhang et al. 2005, Wang et al. 2013). 
 
Motif Identification 
 A version of the HOMER novel motif discovery algorithm specifically designed to 
identify RNA motifs, was used for serial motif analysis to assess the presence of motifs with 
increasing size in HiTS-CLIP data (Heinz et al. 2010). In order to map the location of UG-
hexamers within CLIP tags, we used the DMINDA motif identification webserver, removed 
overlapping hexamers, and summed the number of hexamers starting within the previous 10 
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Figure 6.1: Schematic of Standard compared to BrdU HiTS-CLIP  
(Weyn-Vanhentenryck et al. 2014) 
 
  
Figure 1. HITS-CLIP Maps Rbfox-RNA Interaction Sites in Mouse Brain on a Genome-wide Scale
(A) A schematic illustration of two HITS-CLIP protocols used to map Rbfox binding sites.
(B) A UCSC Genome Browser view of Rbfox1, 2, and 3 CLIP data in an alternatively spliced region of a 93 nt cassette exon in Rbfox1 is shown. Rbfox1, 2, and 3
CLIP data are shown in separate wiggle tracks above the coordinates of UGCAUG and GCAUG elements and the phyloP conservation score.
(legend continued on next page)
1140 Cell Reports 6, 1139–1152, March 27, 2014 ª2014 The Authors
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Table 6.1: Antibodies used in Western Blotting and Immunoflourescence 
Protein Host Source 
ChAT Goat Millpore AB144P 
myc-tag Mouse Millipore 05-724 
myc-tag Guinea pig Kind gift from Susan Morton /TMJ  
TDP-43 Rabbit Proteintech 10782-2-AP  
α tubulin Mouse Sigma-Aldrich T9026  
Synaptophysin Rabbit Invitrogen 18-0130  
Pol II Mouse Covance MMS-126R 
GAPDH Goat Abcam ab9483 
Dhx9 Rabbit Abcam ab26271 
Elav-L Mouse Santa Cruz sc-28299 
Matrin3 Rabbit Bethyl A300-591A 
IGF2BP3 Rabbit Abcam ab177477 
SQSTM1/p62 Rabbit Abcam ab91526 
SQSTM1/p62 Mouse Abcam ab56416 
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Table 6.2: Primers used for Genotyping and qPCR 
Primer Target Sequence Use 
τON/OFF hTDP-43_F hTDP-43  GCCGGATGGGAAACTGAGGCTCTCC  Genotyping  
τON hTDP-43_R hTDP-43  TGCTCCATGGTGAGGTCGCCCAAGC  Genotyping τON 
τOFF hTDP-43_R hTDP-43  GGGCTGCTAAAGCGCATGCTCCAG  Genotyping τOFF 
hTDP-43_F hTDP-43  AGGAATTCTGCATGCCCCAG Genotyping 
hTDP-43_R hTDP-43  CCTCTGCATGTTGCCTTG Genotyping 
myc-hTDP-43_F (4) hTDP-43 AAATGGAGAGCTTGGGCGA qPCR 
myc-hTDP-43_R (3) hTDP-43 GAAACTGGGCTGTAACCGTG qPCR 
TDP-43 3UTR_F (1) mTDP-43 TTTCCCCATCTTGAGGCACC  qPCR 
TDP-43 3UTR_R (2) mTDP-43 TTGGGCTCAGGGAAGTCAAC qPCR 
Cdr1_F Cdr1 ACGCCTTCCACAAATCTACATC qPCR 
Cdr1_R Cdr1 TGGAGATGCTGGAAGACTTGG qPCR 
Cybb_F5 Cybb TGCCTCCATTCTCAAGTCTGTC qPCR 
Cybb_R4 Cybb AATGTACTGTCCCACCTCCATC qPCR 
Lcn2_F5 Lcn2 ACCACGGACTACAACCAGTTC qPCR 
Lcn2_R5 Lcn2 GGGACAGCTCCTTGGTTCTTC qPCR 
Ltf_F Ltf TGTGACTGAGGCTAAGAACTGC qPCR 
Ltf_R Ltf CCTCTGTCCATTTCTCCCAAAC qPCR 
Luzp2_F Luzp2 TTAAGGAGCGTAGCACAGTCC qPCR 
Luzp2_R Luzp2 GCACATCGGTTTTGGAAGATTG qPCR 
Lyz2_F2 Lyz2 GTGGAGACCAAAGCACTGAC qPCR 
Lyz2_R2 Lyz2 CACCACCCTCTTTGCACATTG qPCR 
Ngp_F Ngp CCAGGAGAGACAGCCTAAAGAC qPCR 
Ngp_R Ngp AATCCCTGTCGCAGGTCAAG qPCR 
Nrros_F Nrros/Lrrc33 ACTTCTTGATTGTGGAATGGAGG qPCR 
Nrros_R Nrros/Lrrc33 TGAGAGGGTTAGCATCCAGAAT qPCR 
Pglryp1_qF Pglyrp1 GCCATCCGAGTGCTCTAGC qPCR 
Pglryp1_qR Pglyrp1 CTTGTGGTAATGCTGCACATTG qPCR 
Plin4-qF Plin4 GTGTCCACCAACTCACAGATG qPCR 
Plin4-qR Plin4 GGACCATTCCTTTTGCAGCAT qPCR 
Rac2_F2 Rac2 CGGATTGCCTCATCGAAGAC qPCR 
Rac2_R2 Rac2 GAAGCTGAAGGAGAAGAAGCTG qPCR 
Rin3-qF Rin3 CACCCTGCCGGTCCTATTC qPCR 
Rin3-qR Rin3 CCTGGCCTAGACCTAGCTG qPCR 
S100a8_F S100a8 AAATCACCATGCCCTCTACAAG qPCR 
S100a8_R S100a8 CCCACTTTTATCACCATCGCAA qPCR 
S100a9_F2 S100a9 GCACAGTTGGCAACCTTTATG qPCR 
S100a9_R2 S100a9 TGATTGTCCTGGTTTGTGTCC qPCR 
Zbtb16-qF Zbtb16/Plzf CTGCGGAAAACGGTTCCTG qPCR 
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Zbtb16-qR Zbtb16/Plzf GTGCCAGTATGGGTCTGTCT qPCR 
β-actin_F β-actin CATGGCATTGTTACCAACTGGGACG qPCR 
β-actin_R β-actin AGTCCATCACAATGCCTGTGGTACGACC qPCR 
 






Name Type Sequence Use
RL5D 5' RNA Linker AGGGAGGACGAUGCGG NNNNG Standard CLIP
L32 3' RNA Linker GUGUCAGUCACUUCCAGCGG-puromycin Standard CLIP
PreA-L32 3' RNA Linker 5rApp-GTGTCAGTCACTTCCAGCGG-3ddC BrdU-CLIP
SLL-RL5D-L32-CTAG RT Primer (WT_3) DDDNNNGCTAGCCGCATCGTCCTCCCT/idSp/CCGCTGGAAGTGACTGACAC BrdU-CLIP
SLL-RL5D-L32-GATC RT Primer (WT_4) DDDNNNGGATCCCGCATCGTCCTCCCT/idSP/CCGCTGGAAGTGACTGACAC BrdU-CLIP
SLL-RL5D-L32-TACG RT Primer (WT_2) DDDNNNGTACGCCGCATCGTCCTCCCT/idSp/CCGCTGGAAGTGACTGACAC BrdU-CLIP
SLL-RL5D-L32-CGTA RT Primer (M337V_1) DDDNNNGCGTACCGCATCGTCCTCCCT/idSp/CCGCTGGAAGTGACTGACAC BrdU-CLIP
SLL-RL5D-L32-GCAT RT Primer (M337V_2) DDDNNNGGCATCCGCATCGTCCTCCCT/idSp/CCGCTGGAAGTGACTGACAC BrdU-CLIP
SLL-RL5D-L32-ATGC RT Primer (M337V_3) DDDNNNGATGCCCGCATCGTCCTCCCT/idSp/CCGCTGGAAGTGACTGACAC BrdU-CLIP
DP5 CLIP PCR1 AGGGAGGACGATGCGG CLIP
DP3 CLIP PCR1 CCGCTGGAAGTGACTGACAC CLIP
SP5 Sequencing Primer AATGATACGGCGACCACCGACTATGGATACTTAGTC(DP5) CLIP
SP3 Sequencing Primer CAAGCAGAAGACGGCATACGA(DP3) CLIP
	  
	   142	  
STATEMENT OF RESPECTIVE CONTRIBUTIONS 
 
Mouse lines were generated, data on the mixed genetic background were analyzed, and 
mice were backcrossed to the pure C57/Bl6 genetic background, by Aarti Sharma in the Shneider 
Lab. I performed subsequent mouse breeding, phenotypic data collection and analysis. I 
generated the mouse embryonic stem cell lines used in these studies and collected and analyzed 
survival data, with training and guidance from Lei Lu. I collected and processed samples for 
HiTS-CLIP and guided data analysis with bioinformatic support from Sean O’Keeffe. Samples 
for RNA-Seq were collected and submitted for sequencing at Hudson Alpha in collaboration 
with Aarti Sharma and the Shneider Lab, and data were loaded into expression plot by Sean 
O’Keeffe. Sean O’Keeffe, Paolo Guarnieri, and I designed comparative analyses which they then 
carried out. I cultured and processed samples for mass spectrometry, submitted these samples to 
the CUMC Proteomics Core Facility, analyzed the data, and performed all validation 
experiments. Cell culture experiments described in the subsequent Appendix were performed in 
collaboration with Monica Carrasco, and HiTS-CLIP experiments were performed by me with 
training from Yuan Yuan in the Darnell Lab. Tom Maniatis and I designed the experiments and 
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Appendix: 
Characterizing hTDP-43WT and M337V RNA Binding in iPS-MNs	  
 
A.1 Introduction 
 Both in vitro and in vivo mouse models of human disease provide many advantages, such 
as timepoint and sample size flexibility, as well as short lifespan. Human embryonic stem cells 
(hESCs) provided a cell culture system in which to study human disease, however public opinion 
spurred the search for more ethical alternative. In a landmark experiment in 2007, researchers 
reprogrammed human fibroblasts to a pluripotent state to generate induced pluripotent stem cells 
(iPSCs), capable of differentiation into cell types from all three germ layers (Takahashi et al. 
2007). The subsequent generation of iPSC lines from patients with both sporadic and familial 
ALS has enhanced our understanding of the human disease, despite technical and biological 
shortcomings of iPSC research (reviewed by Richard & Maragakis 2014). A great strength of 
iPSC techniques is the ability to study the effects of a mutant protein expressed at endogenous 
levels under the control of its own promoter in the context of the genetic background that led to 
disease in a patient. Inherent in this strength, however, is the difficulty of obtaining a control cell 
line in which the signal of disease relevant effects overpowers the noise of benign genetic 
variability.  
In this Appendix, we differentiate iPSCs from an ALS patient harboring the TDP-43M337V 
mutation and an age and gender-matched control, into MNs (iMNs) that we maintain in 
sandwich culture with supportive astrocytes to facilitate downstream separation and analysis of 
human iMNs. We describe here our detection of genotype-specific changes in gene expression 
and RNA binding in iPSCs. 
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A.2 Results 
Binding of TDP-43 to RNAs in iPSC-derived MNs from an ALS patient  
We were interested in whether, in a human disease relevant context, we might detect 
alternations in binding of hTDP-43 to RNA. We used the standard HiTS-CLIP protocol to 
process two replicates of TDP-43M337V and one replicate of TDP-43WT iMNs cultured for 56 
days. We obtained over 745,000 unique tags for each sample. By pooling tags from all samples, 
we identified 19,567 binding sites in 5,205 genes. Similar to TDP-43 binding in the mouse brain 
and in cultured cell lines, >80% of TDP-43 CLIP peaks in iMNs fall within intronic regions, 
with the next greatest binding, both by peak percentage and tag density, in 3’UTRs. As in the τON 
spinal cord and human brain samples, TDP-43 in iMNs binds to lncRNAs, particularly to Malat1 
and Neat1 (Figure A1.1B-C). 
Tables 3.3-3.5 display enrichment analyses of TDP-43 binding datasets, including iMNs 
in Column 4. As in the other datasets, pathways involved in neuronal signaling and development, 
intra- and extracellular structure, inflammation, and CNS disease are enriched in genes bound by 
TDP-43 in all datasets and not enriched among genes specifically bound by TDP-43 in iMNs. 
This further supports our proposal that the set of 504 genes may represent a common set of TDP-
43 mRNA targets. 
In contrast to our findings in the τON spinal cord, a greater number of bindings sites for 
hTDP-43 were identified in samples from hTDP-43M337V/WT iMNs compared to hTDP-43WT/WT 
iMNs. Because our analysis contains only one replicate for WT/WT and two replicates for 
M337V/WT, we cannot draw conclusions about differential binding. We do, however, identify 
14% of binding site exclusively in M337V/WT samples, although these sites are contained 
within only 225 (5%) of bound genes (Figure A1.1A). As in the τON spinal cord, this difference 
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may result more from the difference in sample number and identified tags in each sample than an 
underlying biological difference. Genes bound exclusively in M337V/WT samples are enriched 
for ion channel activity (p<0.05), and very few other specific pathways. When correlated with 
deep sequencing data, qualitative changes in binding generally mirror changes in expression 
between the two samples.   
As in all datasets analyzed, hTDP-43 in ES-MNs also binds to TG or UG rich motif, 
identified in over 2800 of the top 5000 shared binding sites (Figure A1.1D). This motif is highly 
represented at the center of the binding site with minimal enrichment persisting to 200 
nucleotides upstream and downstream of the binding peak (Figure A1.1F). Unlike in the τON 
spinal cord, we do not see a drop in UG-richness just upstream of the binding site. In addition, 
both the top 5000 binding sites and the sites bound exclusively in hTDP-43M337V/WT samples 
show enrichment of an interrupted T-rich hexamer, a motif that has been identified in RNA 
bound by TDP-43 in the rat brain as well (Figure A1.1E, Colombrita et al. 2012). 
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A.3 Discussion 
 Although we were not able to obtain sufficient replicates of HiTS-CLIP experiments to 
robustly assess changes in binding in hTDP-43M337V/WT iMNs, we do see both similarities and 
differences in binding sites identified compared to the binding of hTDP-43 in τON mouse spinal 
cords. TDP-43 in iMNs binds to more intronic regions with a higher density of tags in intronic 
compared to 3’UTR regions. A greater number of tags in mutant samples likely lead to a high 
percentage of sites with exclusive binding in M337V samples, contrary to the great WT 
exclusive binding identified in τON spinal cords. In both systems, TDP-43 binds to its canonical 
UG rich motif, however the motif is more highly present at the precise location of iMN binding 
sites compared to spinal cord binding sites. We see very little overlap of differentially expressed 
genes in spinal cord samples, however overlap with differentially expressed genes after TDP-43 
knockdown points more toward an enhancement of TDP-43M337V function rather than a loss of 
function. Of course, both systems have limitations, such as pulling down both the WT and 
M337V proteins in patient iMN samples compared to specifically pulling down myc-hTDP-43, 
either mutant or WT, in τON spinal cords, versus expression of endogenous mouse TDP-43 in 
spinal cords that might compete with hTDP-43 binding. Once an ALS-like phenotype is 
recovered in the τON system, comparison to data from iMNs will provide insight into 
generalizable alterations caused by hTDP-43M337V expression. 
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Figure A.1: TDP-43 binding to RNA in TDP-43 patient iMNs compared to control 
(A) 85.9% of sites are bound by both hTDP-43WT and M337V, while 95.7% of genes show 
binding in both samples. (B) Distribution of CLIP tags and (C) peaks across genic regions shows 
predominance of intronic binding. (D) The canonical UG-rich and (E) non-canonical T-rich 
motif bound in both samples and in WT exclusive samples. (F) Distribution of motif identified in 




















































































-200 -100 0 100 200
0
500
1000
1500
2000
2500
Distance from Center
Fr
eq
ue
nc
y 
of
 U
G
U
G
U
G
Data 1
